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A B S T R A C T
Background
Long-acting beta2-agonists (LABA) in combination with inhaled corticosteroids (ICS) are increasingly prescribed for children with
asthma.
Objectives
To assess the safety and efficacy of adding a LABA to an ICS in children and adolescents with asthma. To determine whether the
benefit of LABA was influenced by baseline severity of airway obstruction, the dose of ICS to which it was added or with which it was
compared, the type of LABA used, the number of devices used to deliver combination therapy and trial duration.
Search methods
We searched the Cochrane Airways Group Asthma Trials Register until January 2015.
Selection criteria
We included randomised controlled trials testing the combination of LABA and ICS versus the same, or an increased, dose of ICS
for at least four weeks in children and adolescents with asthma. The main outcome was the rate of exacerbations requiring rescue oral
steroids. Secondary outcomes included markers of exacerbation, pulmonary function, symptoms, quality of life, adverse events and
withdrawals.
Data collection and analysis
Two review authors assessed studies independently for methodological quality and extracted data. We obtained confirmation from
trialists when possible.
1Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
We included in this review a total of 33 trials representing 39 control-intervention comparisons and randomly assigning 6381 children.
Most participants were inadequately controlled on their current ICS dose. We assessed the addition of LABA to ICS (1) versus the
same dose of ICS, and (2) versus an increased dose of ICS.
LABA added to ICS was compared with the same dose of ICS in 28 studies. Mean age of participants was 11 years, and males accounted
for 59% of the study population. Mean forced expiratory volume in one second (FEV1) at baseline was ≥ 80% of predicted in 18
studies, 61% to 79% of predicted in six studies and unreported in the remaining studies. Participants were inadequately controlled
before randomisation in all but four studies.
There was no significant group difference in exacerbations requiring oral steroids (risk ratio (RR) 0.95, 95% confidence interval (CI)
0.70 to 1.28, 12 studies, 1669 children; moderate-quality evidence) with addition of LABA to ICS compared with ICS alone. There
was no statistically significant group difference in hospital admissions (RR 1.74, 95% CI 0.90 to 3.36, seven studies, 1292 children;
moderate-quality evidence)nor in serious adverse events (RR 1.17, 95% CI 0.75 to 1.85, 17 studies, N = 4021; moderate-quality
evidence). Withdrawals occurred significantly less frequently with the addition of LABA (23 studies, 471 children, RR 0.80, 95% CI
0.67 to 0.94; low-quality evidence). Compared with ICS alone, addition of LABA led to significantly greater improvement in FEV1
(nine studies, 1942 children, inverse variance (IV) 0.08 L, 95% CI 0.06 to 0.10; mean difference (MD) 2.99%, 95% CI 0.86 to 5.11,
seven studies, 534 children; low-quality evidence), morning peak expiratory flow (PEF) (16 studies, 3934 children, IV 10.20 L/min,
95% CI 8.14 to 12.26), reduction in use of daytime rescue inhalations (MD -0.07 puffs/d, 95% CI -0.11 to -0.02, seven studies; 1798
children) and reduction in use of nighttime rescue inhalations (MD -0.08 puffs/d, 95% CI -0.13 to -0.03, three studies, 672 children).
No significant group difference was noted in exercise-induced % fall in FEV1, symptom-free days, asthma symptom score, quality of
life, use of reliever medication and adverse events.
A total of 11 studies assessed the addition of LABA to ICS therapy versus an increased dose of ICS with random assignment of 1628
children. Mean age of participants was 10 years, and 64% were male. Baseline mean FEV1 was ≥ 80% of predicted. All trials enrolled
participants who were inadequately controlled on a baseline inhaled steroid dose equivalent to 400 µg/d of beclomethasone equivalent
or less.
There was no significant group differences in risk of exacerbation requiring oral steroids with the combination of LABA and ICS versus
a double dose of ICS (RR 1.69, 95% CI 0.85 to 3.32, three studies, 581 children; moderate-quality evidence) nor in risk of hospital
admission (RR 1.90, 95% CI 0.65 to 5.54, four studies, 1008 children; moderate-quality evidence).
No statistical significant group difference was noted in serious adverse events (RR 1.54, 95% CI 0.81 to 2.94, seven studies, N = 1343;
moderate-quality evidence) and no statistically significant differences in overall risk of all-cause withdrawals (RR 0.96, 95% CI 0.67
to 1.37, eight studies, 1491 children; moderate-quality evidence). Compared with double the dose of ICS, use of LABA was associated
with significantly greater improvement inmorning PEF (MD8.73 L/min, 95%CI 5.15 to 12.31, five studies, 1283 children; moderate-
quality evidence), but data were insufficient to aggregate on other markers of asthma symptoms, rescue medication use and nighttime
awakening. There was no group difference in risk of overall adverse effects, A significant group difference was observed in linear growth
over 12 months, clearly indicating lower growth velocity in the higher ICS dose group (two studies: MD 1.21 cm/y, 95% CI 0.72 to
1.70).
Authors’ conclusions
In children with persistent asthma, the addition of LABA to ICS was not associated with a significant reduction in the rate of
exacerbations requiring systemic steroids, but it was superior for improving lung function compared with the same or higher doses of
ICS. No differences in adverse effects were apparent, with the exception of greater growth with the use of ICS and LABA compared
with a higher ICS dose. The trend towards increased risk of hospital admission with LABA, irrespective of the dose of ICS, is a matter
of concern and requires further monitoring.
P L A I N L A N G U A G E S U M M A R Y
Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Background
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Most consensus statements recommend use of long-acting beta2-agonists (LABA) as adjunct therapy to inhaled corticosteroids (ICS)
for poorly controlled asthma, despite the use of low-dose ICS.
Review question
What are the benefits and safety of the combination of LABA and ICS in children with persistent asthma when compared with the
same dose or a higher dose of ICS alone?
What evidence did we find?
From available evidence until January 2015, we found 39 eligible studies evaluating the combination of LABA and ICS in children
with persistent asthma. Of these, 28 studies compared LABA with the same dose of ICS, and the remaining studies compared LABA
with a larger dose of ICS.
The number of people who had an exacerbation (worsening of symptoms) that required treatment with oral steroids was not significantly
different. However, lung function improved in people taking LABA and steroids compared with the same dose of steroids only or larger
doses of steroids. No evidence suggested increased serious adverse events or adverse events (also known as side effects) with the addition
of LABA.
Compared with the same dose of ICS, people used less of their rescue/relief bronchodilator treatment. There was no benefit for control
of asthma symptoms when LABA added to ICS was compared with higher doses of ICS. The higher dose of ICS was associated with
1.2 cm per year lower growth than was observed with the combination of LABA and a lower dose of ICS.
Conclusion
In children with persistent asthma, the combination of LABA and ICS did not reduce the risk of exacerbations requiring steroid
treatment but did improve lung function when compared with the same, or a higher, dose of ICS. No differences in adverse effects
were apparent, with the exception of better growth with use of ICS and LABA compared with a higher ICS dose. The trend towards
increasing chances of hospital admission indicates the need for continuous monitoring and additional trials in children.
Quality of the evidence
Overall, we judged the quality of evidence to be moderate. Most outcomes showed wide confidence intervals, which led to downgrading
of the quality of evidence to moderate. In a few outcomes for which open-label studies contributed data, we further downgraded
evidence quality to low.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LABA + ICS compared with same dose of ICS for children with chronic asthma
Patient or population: children with chronic asthma
Settings: outpatients
Intervention: LABA + ICS
Comparison: same dose of ICS




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk


























Total number of with-
drawals






Change in FEV1 (L) at
endpoint
Baseline mean FEV1
ranged from 1.65 L to 1.9
L (baseline data reported
in 4 studies only)
Mean FEV1 change from
baselinewith LABA+ ICS
was 0.08 L higher (0.06
to 0.1 higher)




















































































































Change in morning PEF
(L/min) at endpoint
Illustrative post-treatment
PEFs range from 235 to
290 L/min (data from 3
recent studies)
Mean PEF change from
baselinewith LABA+ ICS
was 10.20 L/min higher
(8.14 to 12.26 higher)
3934 (16 studies) ⊕⊕⊕©
Moderatea
Total number of adverse
events




*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; FEV1: Forced expiratory volume in 1 second;ICS: Inhaled corticosteroids; LABA: Long-acting beta2-agonists; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aLarger sample size may change the outcome.



















































































































B A C K G R O U N D
Description of the condition
Inhaled corticosteroids (ICS) are the most effective treatment for
long-term control of asthma in children (Adams 2005; Manning
2008; Adams 2008a; Chauhan 2012). They are recommended as
first-line agents for the management of childhood asthma in all
national and international consensus statements (NAEPP 2011;
Lougheed 2012; BTS 2014; GINA 2015). When ICS alone are
insufficient to achieve asthma control, various options may be
considered, such as increasing the dose of ICS (Adams 2008b) or
adding a second drug such as a long-acting beta2-agonist (LABA)
or a leukotriene receptor antagonist (LTRA) (Chauhan 2014).
Description of the intervention
In adults with unsatisfactory asthma control, international guide-
lines clearly favour the addition of LABA to low or moderate doses
of ICS over other options such as increasing the dose of steroids
or adding other agents (NAEPP 2011; BTS 2014; GINA 2015).
In children five to 12 years of age with insufficient control on
ICS, however, recommendations regarding the preferred step 3
strategy and the dose of ICS to which LABA should be added
differ markedly across countries. The International Australian and
Canadian guidelines recommend increasing the dose of ICS to
medium dose (201 to 400 µg beclomethasone equivalent) rather
than adding LABA or LTRA to low-dose ICS in children six to
11 years of age (Lougheed 2012; NAC Guidelines 2014). British
Thoracic Society guidelines recommend combination therapy at
a low dose (200 to 400 µg/d beclomethasone equivalent) (BTS
2014). Global Initiative for Asthma (GINA) and Australian guide-
lines recommend increasing the dose of ICS over adding LABA to
a higher dose of ICS (400 µg/d) (NAC Guidelines 2014; GINA
2015). American guidelines reveal no clear preference for adding
LABA to a low dose of ICS or increasing the dose of ICS for chil-
dren five to 11 years of age with uncontrolled asthma and taking
a low dose of ICS (NAEPP 2011). No formal recommendation is
available for their use in preschool-age children.
How the intervention might work
Data from paediatric clinical trials have been included in few
previous meta-analyses assessing the efficacy and safety of LABA
in combination with ICS (Ducharme 2010; Ducharme 2010a).
However, Bisgaard 2003 cautioned against routine use of LABA
in children, as they did not offer protection against exacerbations
and led to increased risk of hospital admission. Other outcomes
such as adverse effects, lung function and symptoms were not ex-
amined.
Why it is important to do this review
Thewide divergence of recommendations likely stems from lack of
solid evidence in children to support international asthma guide-
lines and justifies a systematic review of the topic. In 2010, we
published a Cochrane review conducted to compare LABA added
to ICS of the same dose, or a higher dose, for adults and children
with chronic persistent asthma, which demonstrated that LABA
and ICS led to a significant reduction in risk of exacerbations re-
quiring oral steroids (Ducharme 2010; Ducharme 2010a). The
Cochrane Collaboration had published a separate paediatric sys-
tematic review on the same topic in the year 2009 (Ni Chroinin
2009). Since that time, additional published and unpublished pae-
diatric trials have become available, enabling us to update the re-
view to include newly available evidence and to shed more light
on the role of LABA as adjunct therapy to ICS for children with
partial control when taking ICS alone.
O B J E C T I V E S
To assess the safety and efficacy of adding a LABA to an ICS
in children and adolescents with asthma. To determine whether
the benefit of LABA was influenced by baseline severity of airway
obstruction, the dose of ICS to which it was added or with which
it was compared, the type of LABA used, the number of devices
used to deliver combination therapy and trial duration.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials conducted in children for whom a
LABA was added to an ICS were eligible.
Types of participants
Children and adolescents two to 18 years of age with persistent
asthma who had received daily ICS therapy for at least four weeks
before study entry.
Types of interventions
LABA (salmeterol or formoterol) versus placebo administered
daily for at least four weeks. LABA added to ICS was compared:
• with the same ICS dose; or
• with an increased dose of ICS.
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Studies in which maintenance ICS therapy was interrupted for
the purposes of run-in were not eligible for the review. Other co-
interventions such as xanthines, anticholinergics and other anti-
asthmatic medications were permitted, provided that the dose re-
mained unchanged throughout the study. Inhaled short-acting
beta2-agonists (SABA) and short courses of systemic steroids were
allowed as rescue medications.
Types of outcome measures
Primary outcomes
• Number of asthma exacerbations of moderate intensity, that
is, requiring a short course of systemic corticosteroids.
Secondary outcomes
• Admissions to hospital.
• Urgent care visits.
• Pulmonary function tests (morning and evening peak
expiratory flow (PEF) or forced expiratory flow rate in one
second (FEV1)).
• Symptoms.
• Quality of life scores.
• Use of rescue SABA.
• Nighttime awakening.
• Changes in measures of inflammation such as serum
eosinophil cationic protein and sputum eosinophils.
• Rates of clinical and biochemical adverse effects.
• Any adverse effects including growth suppression, adrenal
suppression, bone mineral loss and others. A suite of related
Cochrane reviews considered serious adverse effects related to
LABA (Cates 2008a; Cates 2009a; Cates 2009b).
Search methods for identification of studies
Electronic searches
We carried out an electronic literature search of the Cochrane
Airways Group Specialised Register of asthma trials, which is de-
rived from systematic searches of bibliographic databases including
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, EMBASE and the Cumulative Index to Nursing and
Allied Health Literature (CINAHL), and we handsearched respi-
ratory journals and meeting abstracts (see Appendix 1 for addi-
tional details). This Register also includes a variety of studies pub-
lished in foreign languages. We did not exclude trials on the basis
of language. In Appendix 2, we have detailed search methods used
in the previous version of this review. For this update, we searched
the Register from May 2008 to January 2015, using the strategy
presented in Appendix 3.
Searching other resources
We checked reference lists of all included studies and reviews to
identify potentially relevant citations.
We searched manufacturers’ and clinical trial websites (Glaxo
Smith Kline clinical trials website
; AstraZeneca clinical trials website; Novartis clinical trial results
website; Clinical Study Results) to identify other published or un-
published study data.
Data collection and analysis
Selection of studies
From the title, abstract or descriptors, two of three review authors
(BC, MNC, SM) independently reviewed the literature searches.
We excluded all studies that were not randomised controlled trials
or that clearly did not fit the inclusion criteria. Two review authors
independently reviewed all other citations in full text to assess
eligibility.
Data extraction and management
Two of four review authors (BC, MNC, CC, SM) independently
extracted data from included trials onto Excel spreadsheets and en-
tered data into the Cochrane software program, Review Manager
5.3 (Review Manager (RevMan)). When necessary, we expanded
graphic reproductions and estimations from other data presented
in the paper. We contacted primary authors or sponsors to request
confirmation of methods and data extraction and to ask for addi-
tional information, when needed.
We recorded the following as a ’User defined order’.
• Mean daily dose of ICS in trials in which both intervention
and control groups used the same dose of ICS.
• Dose difference between groups in studies that compared
LABA added to ICS with an increased dose of ICS. Researchers
reported both values in chlorofluorocarbon (CFC)-propelled
beclomethasone-equivalents, where 1 µg of beclomethasone
dipropionate equates to 1 µg of budesonide and 0.5 µg of
fluticasone propionate (NAEPP 2011), and all doses of inhaled
medications as ex-valve, rather than ex-inhaler, values.
Assessment of risk of bias in included studies
We assessed risk of bias according to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
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For each domain, we judged risk of bias as low, unclear or high, in
line with recommendations provided in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We judged
the study to have high methodological quality when reported ran-
domisation procedures and blinding were adequate and low and
balanced group attrition was noted, supporting low risk of bias.
Measures of treatment effect
We calculated treatment effects for dichotomous variables as
pooled risk ratios (RRs) with 95% confidence intervals (CI). For
continuous outcomes, such as pulmonary function tests, we cal-
culated pooled statistics as mean differences (MD) or standardised
mean differences (SMD) if results were reported on different scales
and were reported with 95% CIs. When standard deviations were
not presented but could be estimated from an effect estimate and
use of confidence intervals, standard error or P value, we com-
bined the MD with the generic inverse variance function (GIV)
in Review Manager.
Unit of analysis issues
We excluded cross-over studies from contributing data to dichoto-
mous measurements of exacerbations, as we used analyses that as-
sumed measurements were taken from independent samples.
Dealing with missing data
We directly contacted study investigators (or study sponsors when
trials had pharmaceutical company sponsorship) to request con-
firmation of methods and to ask for data missing from the original
trial report, if needed.
Assessment of heterogeneity
We examined homogeneity of effect sizes between pooled studies
by using the I2 statistic, with 50% or more as the cutoff for ex-
ploring possible causes of heterogeneity (Higgins 2003; Higgins
2011). In the absence of heterogeneity, we used the fixed-effect
model; otherwise, we applied theDersimonian and Laird random-
effects model (DerSimonian 1986) to the summary estimates. We
reported results of the fixed-effect model unless otherwise stated
in the text.
Assessment of reporting biases
We planned to use funnel plots to check for indications of possible
publication bias and small-study effects, if we had been able to
pool data from 10 or more studies.
Data synthesis
We performed meta-analyses using the Cochrane statistical pack-
age RevMan 5 (Review Manager (RevMan)) and assumed equiv-
alence if the risk ratio estimate and its confidence interval were
between 0.9 and 1.1.
We performed the analysis to examine two main comparisons,
namely, the combination of LABA and ICS versus:
• a similar dose of ICS with placebo, representing step 2 of
the BTS guidelines; or
• an increased dose of ICS with placebo, representing step 3
of the BTS guidelines.
When a trial included more than two arms, we considered ad-
ditional control-intervention group comparisons for this review.
If the same group was used twice as a comparator in a three-
arm study, we halved the number of participants in the group
used twice to avoid over-representation. For event rates, we halved
the denominator in the control group (Verberne 1998a; Verberne
1998b; Zimmerman 2004a; Zimmerman 2004b; Pohunek 2006a;
Pohunek 2006b; Morice 2008a; Morice 2008b; Eid 2010a; Eid
2010b; SAM40012a; SAM40012b).
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses to explore possible reasons for het-
erogeneity and, in the absence of heterogeneity, to identify po-
tential effect modifiers when the magnitude of benefit may vary
according to baseline characteristics. We examined the following
a priori defined subgroups.
• Magnitude of airway obstruction at baseline as determined
by the mean percent predicted FEV1: classified as mild (80% of
predicted or more), moderate (61% to 79% of predicted) or
severe (60% of predicted or less) (GINA 2015).
• Mean dose (ex-valve) of ICS in comparison 1 when LABA
+ ICS was compared with placebo + ICS, and the dose difference
in comparison 2 when LABA + ICS was compared with
increased doses of ICS, both reported in CFC-propelled
beclomethasone-equivalent doses (µg/d) and portrayed as the
user-defined number.
• Usual versus higher than usual dose (reported as ex-valve in
µg) of the LABA (salmeterol or formoterol).
• Type of LABA given (salmeterol vs formoterol).
• Use of one or two devices to deliver the combination of ICS
and LABA.
• Trial duration with trials ≤ 16 weeks compared with those
≥ 24 weeks.
Sensitivity analysis
We performed sensitivity analyses to assess whether results for our
primary outcome were sensitive to blinding, publication status
and funding.
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R E S U L T S
Description of studies
Results of the search
See Figure 1 for an overview of the literature search results, their
assessment and inclusion of studies in the review. Updated elec-
tronic and additional handsearches from May 2008 to January
2015 yielded 283 additional citations. We included eight new tri-
als, resulting in a total of 33 eligible trials representing 39 control-
intervention comparisons.
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Figure 1. Study flow diagram.
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Please note that some of the study names have changed since
the last published version to reflect the Cochrane study naming
convention: SAM104926, SFA 100314, SD 039 0719, SD 039
0725a, SD0390725b, and SFA100316 andwere replacedwithDe
Blic 2009; Pearlman2009; Berger 2010; Eid 2010a; Eid 2010band
Murray 2011, respectively.
Six trials generated an additional control-intervention compari-
son. Three trials (representing six control-intervention compar-
isons) assessed two forms of additive therapy (ICS and LABA via
one inhaler or via two inhaler devices against one dose of ICS):
Pohunek 2006a; Pohunek 2006b; Morice 2008a; Morice 2008b;
Eid 2010a; Eid 2010b. Three trials (representing six control-inter-
vention comparisons) assessed one form of ICS and LABA versus
two doses of ICS (Verberne 1998a; Verberne 1998b; Zimmerman
2004a; Zimmerman 2004b; SAM40012a; SAM40012b). The re-
view therefore lists 39 control-intervention comparisons.
Included studies
A total of 33 trials randomly assigned 6381 children. Twenty-seven
trials were available as full-text publications, and six trials were
published as abstracts or were presented in unpublished reports of
trials accessed through pharmaceutical company trial registries.
Most (69.7%) studieswere fundedby producers of both LABAand
ICS inhalers: 13 were supported by GSK; nine by AstraZeneca;
and one by Allen & Hanburys, a subsidiary of GSK in the United
Kingdom (Russell 1995). Two were supported by grant agen-
cies (Lemanske 2010; Lenney 2013), two were independently
supported by a charitable organization (Langton Hewer 1995;
Stelmach 2007) and five failed to identify the source of fund-
ing (Ortega-Cisneros 1998; Heuck 2000; Zimmerman 2004a;
Zimmerman 2004b; Teper 2005; Stelmach 2008).
We classified studies into one of two comparisons according to
the research question addressed. In accordance with therapeutic
management as recommended by GINA 2015 and BTS 2014,
we considered participants given low-dose ICS alone as receiv-
ing step 2 therapy. We referred to the comparison of LABA ver-
sus placebo added to the same ICS dose as step 3 versus step 2
comparison (28 control-intervention comparisons). Hereafter, we
refer to comparisons testing the combination of LABA and ICS
versus a double dose of ICS used before randomisation as a step 3
versus step 3 comparison (11 control-intervention comparisons).
Bisgaard 2006 examined LABA added to a lower dose of ICS (BDP
100 µg) than has been advocated by international guidelines as
step 3 and included this in the step 3/step 3 comparison.
We describe hereafter characteristics of studies that contributed
outcome data to one or more comparisons in the review. For a full
description of each eligible study, see Characteristics of included
studies.
LABA + ICS versus same dose of ICS as used before
randomisation (step 3 vs step 2)
Twenty-eight control-intervention comparisons randomly as-
signed 4753 children to assessLABA versus placebo added to the
same dose of ICS in both groups (Langton Hewer 1995; Meijer
1995; Russell 1995; Simons 1997; Verberne 1998a; Akpinarli
1999; Tal 2002; Zimmerman 2004a; Zimmerman 2004b;Malone
2005; Teper 2005; Pohunek 2006a; Pohunek 2006b; Stelmach
2007; Morice 2008a; Morice 2008b; Stelmach 2008; Pearlman
2009; Rutkowski 2009; Berger 2010; Carroll 2010; Eid 2010a;
Eid 2010b; Murray 2011; SAM40012a; Lenney 2013; SD 039
0714; SD 039 0718).
Participants
The mean age of participants was 11 years, and males accounted
for 59% of study populations. Mean FEV1 % predicted at base-
line was ≥ 80% in 19 control-intervention comparisons: Morice
2008a;Morice 2008b; LangtonHewer1995;Meijer 1995; Simons
1997; Verberne 1998a; Verberne 1998b; Malone 2005; Teper
2005; Pohunek 2006a; Pohunek 2006b; Stelmach 2007; Stelmach
2008; Pearlman 2009; Berger 2010; Carroll 2010; Murray 2011;
Lenney 2013; SD 039 0718); 61% to 79% of predicted in six con-
trol-intervention comparisons (Russell 1995; Akpinarli 1999; Tal
2002; Zimmerman 2004a; Zimmerman 2004b; SD 039 0714)
and unreported in the remaining studies. Participants were inade-
quately controlled before randomisation in all but four studies in
which theywere described as well controlled (Meijer 1995; Simons
1997; Pohunek 2006a; Pohunek 2006b), or when control was not
reported (Teper 2005; Stelmach 2008; Rutkowski 2009; Berger
2010; Eid 2010a; Eid 2010b).
Interventions
Salmeterol was assessed in 12, and formoterol in 16, control-in-
tervention comparisons. All but one comparison tested the usual
recommended dose of the LABA (i.e. salmeterol 50 µg twice daily,
formoterol 4.5, 6 or 12 µg twice daily); Langton Hewer 1995
used salmeterol 100 µg twice daily. The dose of ICS (beclometha-
sone-equivalent) was 200 µg/d in five studies (Stelmach 2007;
Stelmach 2008; Eid 2010a; Eid 2010b; SD 039 0718); 400 µg/
d in 13 control-intervention comparisons (Verberne 1998a; Tal
2002; Malone 2005; Pohunek 2006a; Pohunek 2006b; Morice
2008a; Morice 2008b; Pearlman 2009; Carroll 2010; Murray
2011; SAM40012a; Lenney 2013; SD 039 0714), 500 µg/d in
two studies (Meijer 1995; Teper 2005), 800 µg/d in two stud-
ies (Rutkowski 2009; Berger 2010) and unspecified or varied in
six studies (Langton Hewer 1995; Russell 1995; Simons 1997;
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Akpinarli 1999; Zimmerman 2004a; Zimmerman 2004b). Eigh-
teen (46%) control-intervention comparisons assessed the combi-
nation of LABA and ICS in a single device; the remainder assessed
the efficacy and safety of a LABA administered separately from an
ICS.
Trial duration ranged from eight weeks or less in nine studies
(Langton Hewer 1995; Simons 1997; Akpinarli 1999; Stelmach
2007; Stelmach 2008; Rutkowski 2009; Pearlman 2009; Carroll
2010; Murray 2011), to 12 to 16 weeks in 14 control-inter-
vention comparisons (Meijer 1995; Russell 1995; Tal 2002;
Zimmerman 2004a; Zimmerman 2004b;Malone 2005; Pohunek
2006a; Pohunek 2006b;Morice 2008a;Morice 2008b; Eid 2010a;
Eid 2010b; SD 039 0718; SD 039 0714), to 24 to 26 weeks in
two studies (Berger 2010; SAM40012a) to 48 to 52 weeks in three
studies (Verberne 1998a; Teper 2005; Lenney 2013).
Although co-intervention with other prophylactic medications
was permitted, trial protocols stipulated that their doses should
remain unchanged throughout. The proportion of participants
given additional therapy was not consistently reported. Permitted
drugs included systemic steroids, anticholinergics and xanthines
(Langton Hewer 1995), immunotherapy (Zimmerman 2004a;
Zimmerman 2004b) and unspecified agents (Russell 1995). Other
preventative medications were not permitted in the other studies
except for Teper 2005, in which this was unspecified. Rescue med-
ications such as inhaled SABA and systemic steroids were permit-
ted in all studies.
Outcomes
The primary outcome - the number of children with at least one
exacerbation requiring systemic steroids - was reported by 12 stud-
ies. When data were not reported, or were described only in a for-
mat we could not use directly, we asked study sponsors to provide
further information, if possible. Our requests for data on exacerba-
tions requiring rescue oral steroids for Pohunek 2006a; Pohunek
2006b; Stelmach 2007; Morice 2008a; Morice 2008b; SD 039
0718 and SD 039 0714 yielded no response.
Hospital admission data were available for seven studies. Measure-
ment of lung function was reported in most studies. Many studies
reported other secondary outcomes. Withdrawals were reported
in all but five studies (Meijer 1995; Akpinarli 1999; Teper 2005;
Stelmach 2008; Rutkowski 2009). Adverse events were reported in
all studies except Stelmach 2008; Rutkowski 2009; Berger 2010;
Carroll 2010; Lemanske 2010 and Lenney 2013.
LABA + ICS versus increased dose of ICS (step 3/step3)
A total of 11 studies, representing 1628 children, assessed the
addition of LABA versus placebo to ICS therapy with increased
dose of ICS in the control group (Ortega-Cisneros 1998; Verberne
1998b; Heuck 2000; Bisgaard 2006; De Blic 2009; Gappa
2009; Lemanske 2010; Murray 2010; Vaessen-Verberne 2010;
SAM40100; SAM40012b). Three studies did not contribute data
(Ortega-Cisneros 1998; Heuck 2000; Lemanske 2010).
Participants
The mean age of participants was 10 years and 64% were male.
Baseline airway obstruction was reported in seven of the 11 stud-
ies (Verberne 1998b; Heuck 2000; Bisgaard 2006: Gappa 2009;
Lemanske 2010; Murray 2010; Vaessen-Verberne 2010). Mean
FEV1 % predicted at baseline was ≥ 80% in five control-inter-
vention comparisons (Verberne 1998b; Gappa 2009; Lemanske
2010; Murray 2010; Vaessen-Verberne 2010).
Interventions
Salmeterol and formoterol were evaluated in eight and three stud-
ies, respectively. All comparisons tested the usual recommended
dose of the LABA (i.e. salmeterol 50 µg twice daily, formoterol 6
or 12 µg twice daily). Intervention groups in eight studies received
BDP equivalent doses of 400 µg/d (Verberne 1998b;DeBlic 2009;
Gappa 2009; Lemanske 2010; Murray 2010; Vaessen-Verberne
2010; SAM40100; SAM40012b). BDP at 100 µg/d was used in
Bisgaard 2006, and 200 µg/d was used in Heuck 2000. Respec-
tive control groups received twice the dose of ICS administered
to the intervention group. Four studies assessed LABA and ICS
as a single inhaler administration (Bisgaard 2006; De Blic 2009;
SAM40100; SAM40012b).
Study durationwas six to eightweeks in three studies (Gappa 2009;
Murray 2010; SAM40100), 12 to 16 weeks in four studies (Heuck
2000; Bisgaard 2006; De Blic 2009; Lemanske 2010), 26 weeks
in two comparisons (Vaessen-Verberne 2010; SAM40012b), and
one year in one study (Verberne 1998b).
All studies recruited children who were taking an ICS at baseline.
Rescue medications such as inhaled SABA and systemic steroids
were permitted in all trials.
Outcome data (obtaining data from trial authors)
Data on the primary outcome were available from three studies
(Verberne 1998b; De Blic 2009; Vaessen-Verberne 2010). When
data were not reported, or were described for an undefined exacer-
bation or composite of types of exacerbations, we requested study
sponsors to provide further information. Our requests for data
on exacerbations requiring rescue oral corticosteroids (OCS) from
study sponsors for Bisgaard 2006, SAM40012b and SAM40100
have not been successful.
Hospital admission datawere available for four studies. Lung func-
tion outcomes were available for all studies. Most studies provided
data on symptoms, SABA use, adverse events and withdrawals.
Two studies provided data on linear growth (Verberne 1998b;
Bisgaard 2006).
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Excluded studies
Details of 85 excluded studies, for which full-text articles were ex-
amined to judge eligibility, are listed in Characteristics of excluded
studies alongwith reasons for their exclusion (this number is drawn
from searches over all years January 2015 across this review).
Risk of bias in included studies
We have provided an overview of judgements on domains related
to risk of bias in Figure 2.We have summarised our findings below.
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Figure 2. Methodological quality summary: review authors’ judgments about each methodological quality
item for each included study.
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We verified with study authors study details for six control-in-
tervention comparisons (Russell 1995; Simons 1997; Verberne
1998a; Verberne 1998b; Pohunek 2006a; Pohunek 2006b). Infor-
mation on the design of GSK-sponsored studies was provided in
correspondence (Appendix 4). A total of 23 comparisons reported
the randomisation technique in adequate detail, and we assessed
remaining studies as unclear on the basis of inadequate reporting
of the randomisation technique.
Allocation
Seventeen studies reported adequate details on allocation conceal-
ment of intervention treatment, and 22 provided unclear infor-
mation.
Blinding
Double-dummy designs or use of identical inhaler devices in 37
comparisons maintained blinding of the intervention. Two studies
had an open-label design (Ortega-Cisneros 1998; Berger 2010).
Incomplete outcome data
Information on the definition of intention-to-treat principle used
across studies was insufficient. Our judgement of this aspect of
the studies reflects uncertainty over the reliability of stated meth-
ods. However, on the basis of our judgements, we designated 14
comparisons as high-quality trials reporting complete outcomes,
23 as unclear and two as having high risk of bias (Russell 1995;
Eid 2010a; Eid 2010b).
Selective reporting
We did not find major selective reporting bias in included stud-
ies. Availability of our prespecified primary outcome - partici-
pants with exacerbations requiring rescue systemic steroids - from
trial reports was limited. This can be explained in part by the
different definitions of exacerbation used by investigators across
studies. Despite extensive efforts to obtain data for our primary
outcome, we obtained a limited quantity of available data for
analysis. We remain uncertain as to whether data for this end-
point were collected in nine studies (Langton Hewer 1995;Meijer
1995; Ortega-Cisneros 1998; Tal 2002; Pohunek 2006a; Pohunek
2006b; Teper 2005; Stelmach 2007; SAM40100); 21 were at low
risk, 14 at unclear risk and four at high risk.
Other potential sources of bias
In all, 23 studies were at low risk and 16 were at unclear risk.
Effects of interventions
See: Summary of findings for the main comparison; Summary
of findings 2
LABA + ICS versus same dose of ICS (step 3 vs step 2)
Primary outcome: participants with at least one
exacerbation requiring systemic steroids
Investigators reported no statistically significant differences be-
tween treatments in the number of participants with exacerbations
requiring systemic corticosteroids (12 studies; RR 0.95, 95% CI
0.70 to 1.28, N = 1669; Analysis 1.1; Figure 3).
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Figure 3. Forest plot of comparison: 1 LABA versus placebo: both groups receiving similar dose ICS,
outcome: 1.1 # participants with exacerbations requiring systemic steroids.
Subgroup analysis
We performed subgroup analysis based on characteristics of par-
ticipants and interventions to evaluate their influence on the mag-
nitude of the primary outcome. Airway obstruction as determined
by baseline mean FEV1 (Analysis 1.1), dose of ICS (Analysis 3.1),
dose of LABA (Analysis 3.2), type of LABA (Analysis 3.3), use of
single versus separate inhaler(s) to deliver LABA and ICS (Analysis
3.4) and trial duration (Analysis 3.5) did not influence the mag-
nitude of response.
Sensitivity analysis
We performed a sensitivity analysis on the primary outcome. The
primary outcome was robust and was not influenced by the fund-
ing source (Analysis 3.6) or by publication status (Analysis 3.7).
All studies contributing data to the primary outcome were double-
blinded, thus preventing exclusion of unblinded trials.
Secondary outcomes
Hospital admission, urgent care visit, withdrawal
Researchers found no statistically significant differences in num-
bers of participants with exacerbations requiring hospital admis-
sion (seven studies, RR 1.74, 95% CI 0.90 to 3.36, N = 1292;
Analysis 1.2; Figure 4), numbers of participants with exacerba-
tions requiring urgent care visit (one study, RR 0.29, 95%CI 0.09
to 0.96, N = 186; Analysis 1.3), withdrawals due to poor asthma
control (14 studies, RR 0.81, 95% CI 0.57 to 1.16, N = 2255;
Analysis 1.6), withdrawals due to adverse events (18 studies, RR
0.79, 95%CI 0.52 to 1.21,N =4117; Analysis 1.7) or withdrawals
due to serious non-respiratory events (two studies, RR 4.66, 95%
CI 0.23 to 96.30; N = 318; Analysis 1.8). Withdrawals for any
reason were significantly fewer with LABA than with placebo (23
studies, RR 0.80, 95% CI 0.67 to 0.94, N = 4374; Analysis 1.5).
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Figure 4. Forest plot of comparison: 1 LABA versus placebo: both groups receiving similar dose ICS,
outcome: 1.2 # participants with exacerbations requiring hospitalisation.
Lung function
LABA added to ICS provided significantly greater improvement
in lung function from baseline compared with the same dose of
ICS. This was true, irrespective of whether group differences were
reported for FEV1 as change in litres (inverse variance (IV) 0.08 L,
95%CI0.06 to 0.10, nine studies,N= 1942; Analysis 1.9), change
in % predicted (MD 2.99%, 95% CI 0.86 to 5.11; seven studies,
N = 534; Analysis 1.10) or change in morning PEF (MD 10.20
L/min, 95% CI 8.14 to 12.26, 16 studies, N = 3934; Analysis
1.12; and one study, MD 3.77%, 95% CI 1.84 to 5.70, N = 286;
Analysis 1.13) or evening PEF (MD 9.30 L/min, 95% CI 6.96
to 11.65, 12 studies, N = 3140; Analysis 1.14; and MD 3.40%,
95% CI 1.54 to 5.26, one study, N = 286; Analysis 1.15). The
change in clinic PEF (Analysis 1.16) and the variability in PEF
(Analysis 1.17) could not be aggregated, as they were reported by
a single trial. Studies contributing data to lung function endpoints
recruited children with mild to moderate airway obstruction, with
a range of lung function at baseline; they examined the effects of
both salmeterol and formoterol, given in conjunction with a range
of doses of ICS. The % fall in FEV1 % predicted due to exercise
showed no significant group difference (three studies, MD 0.46%,
95% CI -1.00 to 1.93, N = 517; Analysis 1.11).
Symptoms, rescue SABA use and quality of life
LABA added to ICS resulted in significant group differences for
the following outcomes: change in daytime use of rescue SABA
(MD -0.07 puffs/d, 95% CI -0.11 to -0.02, seven studies, N =
1798; Analysis 1.23) and change in nighttime use of rescue SABA
(MD -0.08 puffs/d, 95% CI -0.13 to -0.03, three studies, N =
672; Analysis 1.24).
The addition of LABA did not result in significant group differ-
ences for the following outcomes: change inmean symptom scores
(SMD-0.07, 95%CI -0.17 to 0.04, six studies, N = 1653; Analysis
1.18), change in nighttime symptom scores (two studies, MD -
0.03, 95% CI -0.07 to 0.02, N = 534; Analysis 1.19), change in %
symptom-free days at endpoint (MD 0.96, 95% CI -1.91 to 3.84,
seven studies, N = 1831; Analysis 1.20 ), % symptom-free days
(MD -0.04, 95%CI -0.20 to 0.12, four studies, N = 623; Analysis
1.21), % symptom-free nights (MD 0.00, 95% CI -2.38 to 2.38,
one study, N = 82; Analysis 1.22 ), % days without bronchodilator
use (MD 2.07, 95% CI -1.03 to 5.16, seven studies, N = 1710,
random-effects model; Analysis 1.25), change in nighttime awak-
ening (number of nights) (MD 0.20, 95% CI -2.21 to 2.61, one
study, N = 286; Analysis 1.26), % nights with awakening (MD -
1.10, 95% CI -3.51 to 1.31, one study, N = 286; Analysis 1.27),
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% change in awakening-free nights (MD 0.60, 95% CI -1.05 to
2.26, N = 519; Analysis 1.28), change in rescue medication-free
days (two studies, MD -2.20, 95%CI -12.15 to 7.75, two studies,
N = 231; Analysis 1.29), % change in asthma control days (MD
4.30, 95% CI -5.56 to 9.16, two studies, N = 519; Analysis 1.30),
change in paediatric asthma quality of life (MD -0.02, 95% CI -
0.14 to 0.10, four studies, N = 668; Analysis 1.31), absolute pae-
diatric asthma quality of life (MD 0.03, 95% CI -0.04 to 0.11, 10
studies, N = 2333; Analysis 1.32) and change in paediatric asthma
caregiver quality of life (MD 0.07, 95% CI -0.05 to 0.18; four
studies, N = 669; Analysis 1.33).
Adverse events
There was no statistically significant differences in risk of overall
adverse effects (RR 1.04, 95% 0.98 to 1.10, 15 studies, N = 3284;
Analysis 1.34), reaching our a priori defined criterion for equiv-
alence. However, for specific adverse effects, confidence intervals
are wide, so we cannot rule out differences in any of these spe-
cific events. Specifically, there was no significant group differences
in risk of oral candidiasis (RR 3.41, 95% CI 0.73 to 15.87, six
studies, N = 1341; Analysis 1.35), tremor (RR 3.07, 95% CI 0.38
to 25.05, six studies, N = 1467; Analysis 1.36), palpitations (RR
0.44, 95% CI 0.08 to 2.31, six studies, N = 1238; Analysis 1.37),
headache (RR 1.10, 95% CI 0.90 to 1.33, 14 studies, N = 2966;
Analysis 1.38), vomiting (RR 0.74, 95% CI 0.34 to 1.62, three
studies, N = 707; Analysis 1.39), otitis media (RR 0.70, 95% CI
0.30 to 1.63, three studies, N = 707; Analysis 1.40), upper respira-
tory tract infection (RR 0.86, 95%CI 0.58 to 1.27, five studies, N
= 1186; Analysis 1.41), urticaria (RR 0.11, 95% CI 0.01 to 2.04,
one study, N = 248; Analysis 1.42), cardiovascular adverse events
(RR 0.31, 95% CI 0.01 to 7.49, two studies, N = 148; Analysis
1.43) and serious adverse events (RR 1.17, 95% CI 0.75 to 1.85,
17 studies, N = 4021; Analysis 1.4), Although effects on growth
could not be aggregated because only one study documented this
outcome (Verberne 1998a), data show no statistically significant
group differences in growth velocity over 52 weeks among pre-
pubertal children (mean age 10 to 11 years) when beclometha-
sone 400 µg with salmeterol was compared with beclomethasone
400 µg alone (5.1 cm vs 4.5 cm, respectively; Analysis 1.47). In
three studies that recorded mortality, no deaths were mentioned
(Analysis 1.44).
LABA and ICS versus increased dose of ICS (step 3 vs
step 3)
Eight studies on 1520 participants contributed data to outcomes
under this comparison (Verberne 1998b; Bisgaard 2006; De
Blic 2009; Gappa 2009; Vaessen-Verberne 2010; Murray 2010;
SAM40100; SAM40012b).
Primary outcome: participants with at least one
exacerbation requiring systemic steroids
Despite correspondence with study sponsors to obtain data on
exacerbations requiring rescue oral steroids, we obtained data
from only three studies (Verberne 1998b; De Blic 2009; Vaessen-
Verberne 2010). There was no significant group differences in the
number of participants with exacerbations requiring OCS (RR
1.69, 95% CI 0.85 to 3.32, three studies, N = 581; Analysis 2.1;
Figure 5). All trials contributing data to the primary outcome re-
cruited participants with mild airway obstruction (FEV1 % pre-
dicted ≥ 80%).
Figure 5. Forest plot of comparison: 2 LABA + ICS versus placebo + higher dose of ICS, outcome: 2.1 #
participants with exacerbations requiring oral steroids.
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Subgroup analysis
We performed subgroup analysis to evaluate the potential influ-
ence of characteristics of participants and interventions on the
magnitude of the primary outcome. Dose of ICS (Analysis 4.1),
dose of LABA (Analysis 4.2), type of LABA (Analysis 4.3), use of
single versus separate inhaler(s) to deliver LABA and ICS (Analysis
4.4) and trial duration (Analysis 4.5) did not influence the mag-
nitude of response.
Sensitivity analysis
We performed sensitivity analysis by including data from
Lemanske 2010, which was a cross-over study that reported data
on the number of participants with exacerbations requiring oral
corticosteroids and contributed the greatest weight by including
the largest number of participants. There was no significant group
difference in numbers of participants with exacerbations requir-
ing OCS (RR 0.93, 95% CI 0.64 to 1.33, four studies, N = 895;
Analysis 5.1). We were not able to perform the other sensitivity
analysis, as all trials contributing data on the primary outcome
were funded by producers of LABA and ICS, were published as
full-text articles and were double-blinded.
Secondary outcomes
Hospital admission, urgent care visit, withdrawal
There was no significant group difference in the number of partic-
ipants with exacerbations requiring hospital admission (RR 1.90,
95% CI 0.65 to 5.54, four studies, N = 1008; Analysis 2.2; Figure
6) or an urgent care visit (RR 5.13, 95% CI 0.25 to 105.10, one
study, N = 158; Analysis 2.3). Data also showed no statistically
significant group differences in overall risk of all-cause withdrawals
(RR 0.96, 95% CI 0.67 to 1.37, eight studies, N = 1491; Analysis
2.5), withdrawals due to poor asthma control (RR 0.34, 95% CI
0.05 to 2.13, four studies, N = 862; Analysis 2.6) and withdrawals
due to adverse events (RR 0.76, 95% CI 0.19 to 3.07, five studies,
N = 951; Analysis 2.7). Only one trial reported withdrawals due to
a serious non-respiratory event, none of which occurred (Analysis
2.8), thus preventing aggregation.
Figure 6. Forest plot of comparison: 2 LABA + ICS versus placebo + higher dose of ICS, outcome: 2.2 #
participants with exacerbations requiring hospitalisation.
Lung function
LABA added to ICS led to greater improvement from baseline in
the change in morning PEF (MD 8.73 L/min, 95% CI 5.15 to
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12.31, five studies, N = 1283; Analysis 2.11) and evening PEF
(MD 6.5 L/min, 95% CI 2.64 to 10.37, four studies, N = 1163;
Analysis 2.12). Similarly, data showed a significant group differ-
ence in change in PEF recorded at clinic visit at the end point
(MD 8.33 L/min, 95% CI 2.12 to 14.54, two studies, N = 637;
Analysis 2.13). Changes from baseline in FEV1 between treatment
options were not statistically significant (MD 0.01 L, 95% CI -
0.03 to 0.05, two trials, N = 526; Analysis 2.9; and MD 0.38%,
95% CI -0.39 to 1.15, two trials, N = 682; Analysis 2.10). Data
were insufficient for pooling of other lung function data.
Symptoms and SABA
There was no statistically significant group difference in change
in daytime asthma symptom score (MD 0.01 L, 95% CI -0.20 to
0.23, three studies, N = 329; Analysis 2.17) and change in night-
time asthma symptom score (MD 0.01 L, 95% CI -0.20 to 0.23,
three studies, N = 329; Analysis 2.18). Studies were insufficient
for aggregation of other data related to markers of symptoms and
use of rescue SABA.
Adverse events
There was no statistically significant difference in risk of overall
adverse effects (RR 1.01, 95% CI 0.92 to 1.10, seven studies, N
= 1254; Analysis 2.28), meeting our a priori criteria for equiva-
lence. However, the specific adverse events have wide confidence
intervals, so we cannot rule out a difference in any of these specific
events. Data show no significant group difference in risk of oral
candidiasis (RR 0.76, 95% CI 0.17 to 3.30, three studies, N =
182; Analysis 2.29), headache (RR 1.13, 95%CI 0.85 to 1.50, five
studies, N = 1230; Analysis 2.30) and serious adverse events (RR
1.54, 95%CI 0.81 to 2.94, seven studies, N = 1343; Analysis 2.4).
Other adverse events including vomiting, cold, upper respiratory
tract infection and death could not be aggregated because trials
reporting data are lacking. Two studies measured linear growth
over one year (Verberne 1998b; Bisgaard 2006); findings favoured
LABA treatment for children by an average of 1.21 cm/y (95% CI
0.72 to 1.7; Analysis 2.34).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
LABA + ICS compared with increased dose of ICS for children with chronic asthma
Patient or population: children with chronic asthma
Settings: outpatients
Intervention: LABA + ICS
Comparison: increased dose of ICS




Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk





41 per 1000 69 per 1000 RR 1.69
(0.85 to 3.32)

















Total number of with-
drawals






Change in FEV1 (L) at
endpoint
Mean baseline FEV1
ranged from 1.6 to 1.7 L
Mean FEV1: change from
baselinewith LABA+ ICS
was 0.01 L higher (-0.03
to 0.05 higher)





















































































































Change in morning PEF
(L/min) at endpoint
Mean change in end
of treatment PEF ranged
from 16.7 to 39.2 L/min
Mean PEF: change from
baselinewith LABA+ ICS
was 8.73 L/min higher (5.
15 to 12.31 higher)
1283 (5 studies) ⊕⊕⊕©
Moderatea
Total number of adverse
events




*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; FEV1: Forced expiratory volume in 1 second; ICS: Inhaled corticosteroids; LABA: Long-acting beta2-agonists; PEF: Peak expiratory flow; RR: Risk ratio.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.




















































































































D I S C U S S I O N
Summary of main results
Exacerbations requiring systemic steroids in school-aged children
with inadequately controlled asthma despite the use of daily low-
dose ICS were not significantly reduced by adding LABA to ICS
compared with using the same, or an increased, dose of ICS. A
priori defined subgroup analysis indicates that characteristics of
participants or of the intervention did not influence outcomes.
Although not statistically significant, a trend towards increased
risk of exacerbations requiring hospital admissions was noted in
children treated with combination therapy. This trend towards
increased risk of hospital admission with the addition of LABA
compared with the same dose of ICS (step 2) or an increased dose
of ICS (step 3) is a matter of concern, particularly as combination
therapy failed to show any benefit in reducing severity markers
including the primary outcome, that is, exacerbation requiring
systemic steroids.
With regard to secondary outcomes, lung function endpoints con-
sistently favoured the addition of LABA to ICS therapy, whether
compared with the same or an increased dose of ICS. A modest
reduction in the use of rescue SABA was evident with the addi-
tion of LABA to ICS when compared with the same dose of ICS;
however, data were insufficient to pool for comparison with an in-
creased ICS dose. In contrast, LABA added to ICS did not result in
significantly greater improvement in asthma symptoms compared
with the same or an increased dose of ICS. With the exception of
growth, data show no statistically significant group differences in
reported adverse events; overall adverse events met our definition
of equivalence. The combination of LABA and ICS led to greater
gain in linear growth than was seen with an increased dose of ICS;
this is consistent with recent findings of a dose-response effect of
ICS on growth in children (Pruteanu 2014).
In this paediatric review, LABA added to ICS did not result in
improvement in most other clinical indicators of asthma control
and future risk of exacerbations. We recognised that absence of a
significant group difference in other clinical indicators of asthma
control may be due to mild asthma severity among most partici-
pants. Yet, aggregation of the best available evidence to date pro-
vides little data to support the addition of LABA to ICS in chil-
dren insufficiently controlled by ICS monotherapy.
Overall completeness and applicability of
evidence
Although we identified several unpublished studies, we had only
limited success in obtaining useable data for our primary out-
come. We successfully obtained data for exacerbations requiring
rescue systemic steroids and for hospital admissions for a small
number of trials from a recent meta-analysis of GSK-sponsored
trials (Bateman 2008). Few data in study reports are available as
downloads from pharmaceutical company trial results registries.
Quality of the evidence
Overall we judged the quality of evidence to be moderate. Most
outcomes showed wide confidence intervals, which led to down-
grading of evidence quality to moderate. In a few outcomes for
which open-label studies contributed data, we further downgraded
evidence quality to low.
Potential biases in the review process
These findings are consistent with findings of Bisgaard 2003. Of
note, about half of the trials in our review were conducted in
school-aged children treated predominantly with ICS and LABA
delivered in separate (rather than single) devices. Although ad-
herence to ICS may have been suboptimal, we cannot speculate
whether different results would have been obtained if most trials
had used a single device to deliver LABA and ICS. Is it possible that
ongoing inflammation associated with use of a lower dose of ICS
or tachyphylaxis associated with prolonged use of LABA may be
associated with more severe exacerbations with combination ther-
apy. In light of the prevailing uncertainty and an FDA mandate, a
large six-month study, to evaluate safety and benefit of LABA and
ICS (salmeterol and fluticasone), is ongoing in children of four to
11 years of age. Outcomes of the study will shed more light on
the safety and benefits of this combination (NCT01462344).
Agreements and disagreements with other
studies or reviews
Our findings contrast with some of the estimates derived from the
systematic review of adult trials performing the same comparisons
(Ducharme 2010). Indeed, when compared with a similar dose
of ICS, LABA added to ICS reduces by 20% the risk for adults
with exacerbations requiring systemic steroids (RR 0.77, 95% CI
0.68 to 0.88; Ducharme 2010). This was accompanied by no-
tably greater improvement in lung function (170 mL in FEV1)
and symptom-free days (+ 17%) and a modest reduction in use
of rescue SABA (-0.7 puffs/d). Given the smaller lung volumes
in children, the observed 80 mL greater improvement in FEV1
associated with LABA added to ICS in children may be of clini-
cal importance. However, observed improvement in lung function
was expected, given that LABA is a bronchodilator, and children
were selected primarily on the basis of significant reversibility with
SABA to confirm the diagnosis of asthma. This apparent discor-
dance between outcomes may be due to a more rapid effect of
LABA on lung function, which is more easily detectable in studies
of short duration, whereas a longer period of follow-up may be
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required to detect an effect on exacerbations, particularly among
children with normal or near normal lung function.
With regard to the second comparison - LABA and ICS versus a
higher dose of ICS - findings also differ from aCochrane Review of
studies in adults (Ducharme 2010a), which demonstrates a signif-
icant reduction associated with LABA in the risk of patients with
exacerbations requiring rescue systemic steroids (RR 0.88, 95%
CI 0.78 to 0.98). Despite identification of 11 studies, only four
provided data for the primary outcome. A modest improvement
(< 9 L/min) in morning and evening PEF, but not in FEV1, was
associated with use of LABA compared with a higher ICS dose.
Insufficient reporting prevented aggregation of most outcomes.
However, the trend towards a higher proportion of exacerbations
requiring hospital admission and serious adverse events in children
using LABA in combination with ICS, compared with a high dose
of ICS, is a matter of concern. Findings are consistent with an
overview of Cochrane Reviews evaluating the safety of formoterol
or salmeterol in children with asthma (Cates 2012), in which re-
view authors reported an additional three children per 1000 who
suffered a non-fatal serious adverse event with combination ther-
apy in comparison with ICS over three months. Meanwhile, avail-
able data are also insufficient to allow firm recommendations re-
garding the preference of increasing the ICS dose versus adding
LABA to ICS as a step 3 strategy. One must weigh the greater lin-
ear growth (reported in only two trials with beclomethasone and
budesonide - molecules known to be associated with growth sup-
pression) (Skoner 2000; CAMP Research Group 2012) and the
improvement in PEF against the possible, but unproven, increased
risk of greater severity of exacerbations associated with combina-
tion therapy.
Data show no group differences in adverse effects or withdrawals
due to adverse effects when the combination of LABA and ICSwas
compared with the step 2 or step 3 strategy. Of note, side effects
were scarcely reported in short-term trials, and long-term studies
were lacking. Moreover, although an increased dose of ICS calls for
assessment of growth, adrenal function and bone mineralisation
in children, no trial reported data on adrenal function and bone
mineralisation that could be aggregated. Only two studies report-
ing the addition of LABA to 400 versus 800 µg of beclometha-
sone (Verberne 1998b) and to 100 versus 400 µg of budesonide
(Bisgaard 2006) examined growth, for a differential of 300 to 400
µg of BDP-equivalent. The observed reduction in growth averag-
ing 1.2 cm/y is consistent with the documented decrease in linear
growth associated with 400 µg/d of BDP (Sharek 1999; Pruteanu
2014) and the documented dose-response relationship between
growth impairment and ICS dose (Pruteanu 2014). Any apparent
benefit of doubling the dose of ICS should be weighed against
the possible impact on growth compared with other therapeutic
regimens; it deserves careful evaluation (Pruteanu 2014).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence is insufficient at present to firmly support use of LABA
as an adjunct therapy to ICS as a step 3 strategy to reduce risk of
asthma exacerbations requiring steroids, as compared with using
the usual dose of ICS (step 2) or an increased dose of ICS (step
3). The wide confidence intervals do not rule out a superior ef-
fect of either treatment. Stepping up therapy with the addition of
LABA to the usual dose of ICS improves lung function beyond
that observed when remaining on ICS as step 2 strategy, but with
no apparent benefits of asthma symptom control and use of rescue
SABA. Similarly, significant improvements in morning PEF ob-
served with the combination of LABA and usual ICS dose versus
an increased dose of ICS have not been associated with improve-
ment in other indicators of lung function and asthma control.
The apparent reduction in growth associated with use of 400 to
800 µg/d of BDP-equivalent raises concern when high-dose be-
clomethasone or budesonide is considered as increased ICS (step 3
therapy). Of note, the trend towards increased hospital admission
with LABA, irrespective of the dose of ICS, and toward serious
adverse health events compared with an increased dose of ICS is a
matter of some concern and calls for larger, longer-term trials in
children with substantial morbidity, to clarify this issue.
Implications for research
Future trials should have the following characteristics.
Population
A large study is urgently needed in children with moderate and
severe airway obstruction and with higher asthma morbidity (e.g.
prior hospital admission, requirement for OCS) at baseline than
those recruited to trials aggregated in this review. Stratification ac-
cording to degree of airway obstruction (i.e. baseline FEV1) and
inclusion of younger, preschool-aged children should feature in
the design of such trials. Use of diagnostic criteria for asthma that
do not require a positive bronchodilator response for enrolment
would allow the study to be more generalisable to the general pae-
diatric asthma population and would reduce the potential overes-
timation of effect on lung function (by preselecting responders to
SABA).
Interventions
Future interventions should test the combination therapy deliv-
ered by a single inhaler (combining LABA and ICS) to ensure no
use of LABA as monotherapy. Interventions may include head-to-
head comparisons of salmeterol versus formoterol, combined with
low or moderate doses of ICS. The control intervention should
24Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
focus on increased doses of ICS (step 3), so that two step 3 treat-
ment strategies are compared.
Design
• Double-blinding, adequate randomisation and complete
reporting of withdrawals and dropouts with an explicit definition
of the intention-to-treat population analysed.
• Intervention period of 24 to 52 weeks or longer, to properly
assess the impact on exacerbations requiring systemic
corticosteroids and those resulting in hospital admission, as well
as adverse health events (growth, adrenal function, bone
mineralisation, serious adverse health events).
• Clear reporting of the percentage of (and reasons for) non-
eligibility of approached participants and of those enrolled in the
run-in period is required, as inadequate reporting of the selected
population results in difficulty identifying to whom the results
can be generalised.
• Complete reporting of continuous (denominators, mean
change and mean standard deviation of change) and
dichotomous (denominators and rate) data in the units used in
this systematic review would allow aggregation of data.
Outcomes of particular importance to assess include the following.
• Exacerbations requiring rescue systemic corticosteroids.
• Asthma-related hospital admission or acute care visit.
• Compliance with either intervention both before (for ICS)
and after randomisation (for both ICS and combination
therapy). The impact of compliance with combination therapy
versus placebo and ICS on the magnitude of the effect size
should be examined.
• Cost-effectiveness of use of combination inhalers as
compared with ICS alone.
• Serious or overall adverse events associated with LABA or
ICS especially growth, adrenal function, bone mineralisation.
• Functional measures including quality of life.
An ongoing large six-month study on safety and benefit of LABA
and ICS (salmeterol and fluticasone) in children four to 11 years
of age may provide further evidence to support our preliminary
outcomes (NCT01462344).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akpinarli 1999
Methods Parallel-group multi-centre study
Participants Symptomatic asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 32 (ICS + F12 (twice daily): 16; ICS: 16)
WITHDRAWALS: not described
AGE, mean (range) or mean (SD): 6 to 14 years
GENDER (% male): 47
SEVERITY: not reported
BASELINE % PRED FEV1: not described
BASELINE DOSE OF ICS: 400 to 800 µg
ASTHMA DURATION: not described
ATOPY (%): 68
ELIGIBILITYCRITERIA:met ATS criteria for asthma;≥ 15% increase in FEV1 within
previous year
EXCLUSION CRITERIA: asthma exacerbation or respiratory infection within last
month
ELIGIBILITYCRITERIADURINGRUN-IN:Only participants requiring salbutamol
more than once a week were randomly assigned
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES reported at 6 weeks
RUN-IN PERIOD: 2 weeks with ICS 400 to 800 µg/d to document symptoms and
beta2-use
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 6 weeks
TEST GROUP: (ICS + F12) ICS 400 to 800 µg/d + F 12 µg twice daily
CONTROL GROUP: (ICS) ICS (400 to 800 µg/d) + placebo twice daily
DEVICE: MDI + large volume spacer (Volumatic)
NUMBER OF DEVICES: 2
COMPLIANCE: assessed by weighing canisters
CO-TREATMENT: SABA as needed
Outcomes PULMONARYFUNCTIONTEST: FEV1 predicted; amPEF; pmPEF; PEF variability
(%); PC 20
SYMPTOM SCORES: score of 0 to 3 (max 9); nighttime symptom score; symptom-
free days or nights
FUNCTIONAL STATUS: rescue medication use; exacerbations requiring systemic
steroids; exacerbations requiring admission
INFLAMMATORY MARKERS: not described
ADVERSE EFFECTS: described
WITHDRAWALS: not described
PRIMARY OUTCOME MEASURE; not reported
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Study author contacted and unable to confirm methods or data
User-defined number: 600 (mean ICS dose in LAB2 group in µg/d of BDP-equivalent:
400 to 800)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other information pre-
sented
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; identical placebo used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information available on statistical handling of
missing data
Selective reporting (reporting bias) Low risk Data on OCS-treated exacerbations available
Other bias Unclear risk No data provided on % participants meeting eligi-
bility criteria from screening nor on run-in popula-
tions
Berger 2010
Methods Randomised open-label tolerability study (SD-039-0719)
Participants Inadequately controlled on other asthma controller medication
% ELIGIBLE OF SCREENED POPULATION: 74
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 187 (ICS + F (twice daily): 124; ICS: 63)
WITHDRAWALS:
ICS + F: 13
ICS: 10
AGE, mean (SD): 9 (1.6) years
GENDER (% male): 64
SEVERITY: not reported
BASELINE % PRED FEV1: 83.5
BASELINE DOSE OF ICS, mean (SD) µg/d:
ICS + F: 306 (214.1)
ICS: 309 (212.6)
ASTHMA DURATION: not reported
ATOPY (%): not reported
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Berger 2010 (Continued)
ELIGIBILITY CRITERIA
• 6 to 11 years of age
• Documented diagnosis of asthma for 6 months, as defined by the American
Thoracic Society; 23 eligible to participate
• Must have received daily ICS treatment (as monotherapy or in combination with
other controller medications) at any consistent dose for 4 weeks before screening and to
have a forced expiratory volume in 1 second (FEV1) of 50% of predicted normal 6
hours after the last dose of a short-acting beta2-adrenergic agonist and 24 hours after
the last dose of LABA
• Documented history of reversibility of 12% in FEV1 or of 15% in PEF within 15
to 30 minutes after albuterol inhalation
EXCLUSION CRITERIA
• Required treatment with any non-inhaled corticosteroids within previous 4 weeks,
sensitivity to drugs specified in the protocol or need for treatment with beta-blockers
• Cancer in the previous 5 years or with significant disease.
ELIGIBILITY CRITERIA DURING RUN-IN
• Only participants not adequately controlled
on other asthma controller medication
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES reported at 12 weeks
RUN-IN PERIOD: 1 week with existing ICS to document inadequate asthma control
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 12 weeks
TEST GROUP: BUD 320 µg/d + F 9 µg twice daily
CONTROL GROUP: budesonide 400 µg/d
DEVICE: single device
• Test group: MDI
• Control: dry powder inhaler
COMPLIANCE: not reported.
CO-TREATMENT: Albuterol pMDI was permitted as rescue medication throughout
the study but was to be withheld for 6 hours before scheduled spirometry. If the par-
ticipant experienced uncontrolled asthma or increased symptoms after 2 weeks of ran-
domly assigned treatment, leukotriene receptor antagonists, inhaled non-steroidal anti-
inflammatory agents, methylxanthines and alternative SABA were permitted as needed.
OCS bursts were allowed for treatment of asthma exacerbations
Outcomes PULMONARY FUNCTION TEST: morning predose forced vital capacity (FVC [L]),
FEV1 (L) and forced expiratory flow expired during middle half of exhalation (FEF25-
75% [L/s])
SYMPTOM SCORES:
FUNCTIONAL STATUS: physician and caregiver global assessments, Quality of Life
Questionnaire (PAQLQ[S]) and caregiver quality of life
INFLAMMATORY MARKERS: not described
ADVERSE EFFECTS: adverse effects, clinical laboratory data (including serum glucose,
serum potassium and 24-hour urinary cortisol), vital signs, 12-lead ECGs and physical
examinations
WITHDRAWALS: described
Blood chemistry, haematology tests and urinary free cortisol were evaluated
Validated standardised paediatric asthma
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Berger 2010 (Continued)
PRIMARY OUTCOME MEASURE: Safety evaluation was the primary aim of the
study. However, specific primary outcome was not specified
Notes Full-text publication
Funded by AstraZeneca
Dose of ICS: Intervention: 800 µg/d of BDP-equivalent; control: 800 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated allocation schedule
was used
Allocation concealment (selection bias) Low risk Interactive voice response system was used
to assign randomisationnumbers and treat-
ment assignments to eligible
participants to avoid selection bias
Blinding (performance bias and detection
bias)
All outcomes
High risk Open-label study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawal rate is imbalance. Reasons for
withdrawals were reported
Selective reporting (reporting bias) Unclear risk Primary or secondary outcomes were not
distinguished. Not clear
Other bias Unclear risk Inadequate information was reported
Bisgaard 2006
Methods Parallel-group multi-centre study
Participants Steroid-using asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 223 (Bud/F: 117; Bud: 106)
WITHDRAWALS: not reported
AGE, mean (range): 8 (4 to 11) years
GENDER (% male): 68
ASTHMA SEVERITY: moderate
BASELINE % PRED FEV1 mean: 76
BASELINE DOSE OF ICS (start of run-in): 200 to 500 µg/d
ASTHMA DURATION: not reported
ATOPY (%): not reported
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Bisgaard 2006 (Continued)
ELIGIBILITY CRITERIA: ICS 200 to 500 µg BDP-equivalent (≥ 3 months before
run-in); FEV1 60% to 100% of predicted normal;≥ 1 severe exacerbation≤ 12 months
before run-in
EXCLUSION CRITERIA: not reported
CRITERIA FOR RANDOMISATION DURING RUN-IN: 8 puffs over last 10 days
of run-in
Interventions LABA + ICS vs INCREASED dose of ICS
OUTCOMES: reported at 12 months
RUN-IN PERIOD: 2 weeks to document stability
DOSE OF ICS DURING RUN-IN: not clear
DOSE OPTIMISATION PERIOD: none reported
INTERVENTION PERIOD: 12 months
TEST GROUP: combination F 4.5/BUD 80 µg qd
CONTROL GROUP: BUD 320 µg qd
DEVICE: Turbuhaler
NUMBER OF DEVICES: 1
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: recorded but not reported
SYMPTOM SCORES: recorded but not reported
FUNCTIONAL STATUS: night awakenings; rescue medication use; exacerbations*
(hospitalisation/need forOCS or othermedication, increase in ICS, PEF≤ 70%baseline
on 2 consecutive days)









Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated randomisation scheme
Allocation concealment (selection bias) Unclear risk Eligible patients were randomised in balanced
blocks by allocating patient numbers in consecutive
order
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; identical inhaler devices used.
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Bisgaard 2006 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ’All analyses were performed on an intention-to-
treat basis.’ Additional information on the compo-
sition of the ITT population was not provided
Selective reporting (reporting bias) Low risk Data on OCS-treated exacerbations reported as
composite with ED visits/hospitalisations, PEF falls
and requirement for medical intervention. Request
for separate data on OCS-treated exacerbations
from study sponsors has not been successful
Other bias Unclear risk No data provided on % participants meeting eligi-
bility criteria from screening or run-in populations
Carroll 2010
Methods Randomised double-blind placebo-controlled
Participants Children with persistent asthma symptoms despite treatment with low-dose ICS
% ELIGIBLE OF SCREENED POPULATION: 84







AGE, mean (range): 10.6 (7 to 18) years
GENDER (% male): 59
ASTHMA SEVERITY: not reported
BASELINE % PRED FEV1 mean: 95.8%
BASELINE DOSE OF ICS (start of run-in): 400 µg/d of BDP, BUD or 200 µg/d of
fluticasone propionate
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• Children between 7 and 18 years of age with physician-confirmed diagnosis of
asthma and persistent symptoms despite treatment with low-dose ICS
EXCLUSION CRITERIA:
• Unable to perform spirometry; unable to demonstrate satisfactory inhaler
technique
• Respiratory disorders other than asthma
CRITERIA FOR RANDOMISATION DURING RUN-IN: not adequately reported
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES: reported at 4 and 8 weeks
RUN-IN PERIOD: 4 weeks
DOSE OF ICS DURING RUN-IN: FP 100 µg twice daily
DOSE OPTIMISATION PERIOD: none reported
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Carroll 2010 (Continued)
INTERVENTION PERIOD: 8 weeks
TEST GROUP: combination fluticasone and salmeterol 100/50 twice daily
CONTROL GROUP: fluticasone 100 µg twice daily
DEVICE: Diskus inhaler
NUMBER OF DEVICES: 1
COMPLIANCE: estimated at each visit by reading the number of doses left in each
inhaler device
CO-TREATMENT: not reported
Outcomes PULMONARY FUNCTION TEST: changes in mean basal FEV1 (% predicted), fall
in mean basal FEV1 (% predicted) due to cold air*, salbutamol reversibility
SYMPTOM SCORES: reported
FUNCTIONAL STATUS: not reported






Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 400 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Trail was randomised but no information
was provided on how the randomisation
was generated
Allocation concealment (selection bias) Low risk Devices were masked to make them iden-
tical in external physical appearance
Blinding (performance bias and detection
bias)
All outcomes
Low risk Dobule-blind study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12% withdrawal from control vs no with-
drawal in the treatment group. Reasons for
withdrawals were mentioned
Selective reporting (reporting bias) Low risk Study protocol was not available. All out-
comes were presented
Other bias Low risk No apparent source of bias was noted.
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De Blic 2009
Methods Randomised double-blind double-dummy parallel-group non-inferiority study
(SAM104926)
Participants Not controlled asthmatic children
% ELIGIBLE OF SCREENED POPULATION: 55







AGE, mean (range): 8.1 (4 to 11) years
GENDER (% male): 65
ASTHMA SEVERITY: not reported
BASELINE % PRED FEV1 mean: not reported
BASELINE DOSE OF ICS (start of run-in): BDP 400 µg/d or equivalent
ASTHMA DURATION: not reported
ATOPY (%): 88
ELIGIBILITY CRITERIA:
• Children, 4 to 11 years of age with clinical history of asthma for ≥ 6 months,
documented reversibility in FEV1 or PEF of ‡15%, who were currently receiving ICS
(BDP, 400 µg/d or equivalent)
EXCLUSION CRITERIA:
• Respiratory tract infection or acute asthma exacerbation requiring emergency
room treatment within previous 4 weeks, or hospitalisation due to asthma or use of
systemic corticosteroids in previous 12 weeks
CRITERIA FORRANDOMISATIONDURINGRUN-IN: Asthma had been assessed
as ’Not controlled’ for ≥ 2 of the 4 weeks of the run-in period
Interventions LABA + ICS vs INCREASED dose of ICS
OUTCOMES: reported at 12 months
RUN-IN PERIOD: 4 weeks to document asthma control
DOSE OF ICS DURING RUN-IN: FP 100 µg twice daily
DOSE OPTIMISATION PERIOD: none reported
INTERVENTION PERIOD: 12 weeks
TEST GROUP: combination fluticasone and salmeterol 100/50 twice daily
CONTROL GROUP: fluticasone 200 µg twice daily
DEVICE: Diskus inhaler
NUMBER OF DEVICES: 1
COMPLIANCE: checked by counting the number of remaining doses in the Diskus
inhalers
CO-TREATMENT: not reported
Outcomes PULMONARY FUNCTION TEST: clinic morning PEF, home morning and evening,
before taking any study medication, FEV1, MEF50, reversibility in PEF/FEV1
SYMPTOM SCORES: symptoms, exacerbations* (deterioration in asthma requiring
administration of OCS and/or deterioration in asthma requiring emergency room visit
and/or admission to hospital); exacerbation requiring OCS
FUNCTIONAL STATUS: number of night-time awakenings, amount of rescue use,
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De Blic 2009 (Continued)
asthma control






Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 800 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was generated by cen-
tralised RANDALL system
Allocation concealment (selection bias) Low risk All study inhalers were identical in appear-
ance, and use of dummy inhalers ensured
that both participants and site personnel
remained blinded to an individual’s treat-
ment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Well-balanced withdrawal in both groups;
intention-to-treat analysis
Selective reporting (reporting bias) Low risk Study protocol is available, and primary
and secondary outcomes are predefined
Other bias Low risk No apparent source of bias was noted
Eid 2010a
Methods Parallel-group multi-centre study
Participants % ELIGIBLE OF SCREENED POPULATION: 35
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: 79
RANDOMLY ASSIGNED: 521 (BUD/F twice daily: 184; BUD/F QD: 168; BUD:
169)
WITHDRAWALS: BUD/F twice daily: 21; BUD/F QD: 37; BUD: 33
AGE, mean (range) or mean (SD): 10.3 (2.5) years
SEVERITY: not stated
BASELINE % PRED FEV1: 78.3 (8.56)
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BASELINE DOSE OF ICS: 245.3
ASTHMA DURATION: 6.8
ATOPY (%): not reported
ELIGIBILITY CRITERIA: 6 to 15 years; diagnosis of asthma for ≥ 6 months; main-
tenance ICS treatment for ≥ 4 weeks before screening; FEV1 predicted 60%-90% pre-
dicted; reversibility of FEV1 ≥ 12% and > 0.20 L from baseline; children > 11 years
were required to demonstrate reversibility > 12% only
EXCLUSION CRITERIA: not stated
ELIGIBILITY CRITERIA DURING RUN-IN: stable asthma symptoms
Interventions LABA and ICS vs SAME DOSE ICS
OUTCOMES: 12 weeks
RUN-IN PERIOD: 4 to 5 weeks
DOSE OPTIMISATION PERIOD: not reported
INTERVENTION PERIOD: 12 weeks
TEST GROUP: combination BUD and F 80/9 µg twice daily via MDI
CONTROL GROUP: BUD 160 µg QD via MDI
NUMBER OF DEVICES: 1
COMPLIANCE: not assessed
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1; am PEF; pm PEF*
SYMPTOM SCORES: day and nocturnal symptoms
FUNCTIONAL STATUS: AQLQ
INFLAMMATORY MARKERS: not reported
ADVERSE EFFECTS: reported
WITHDRAWALS: reported by treatment group
Notes Full-text article
Funding source: AZ
Confirmation of methods and data obtained from AZ in April 2008
Unpublished data downloaded from http://www.astrazenecaclinicaltrials.com
Dose of ICS: intervention: 200 µg/d of BDP-equivalent; control: 200 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other information pre-
sented. Age-based strata to ensure balance in ages
between groups (6-11 years & 12-15 years)
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double dummy
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Efficacy analysis does not explicitly describewhether
missing data imputed or drawn from follow-up:
’all randomised subjects who took at least 1 dose
of double-blind treatment, and who contributed at
least 1 evening PEF diary entry after receiving dou-
ble-blind medication, was used in the primary anal-
ysis.’
Selective reporting (reporting bias) High risk OCS-treated exacerbations were not reported in the
study publication. Data request has been made to
study sponsors for this information
Other bias Low risk 37% screening population eligible for randomisa-
tion
Eid 2010b
Methods See Eid 2010b
Participants See Eid 2010b
Interventions See Eid 2010b
TEST GROUP:
• Combination BUD and F 160/9 µg QD via MDI
Outcomes See Eid 2010b
Notes See Eid 2010b
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Efficacy analysis does not explicitly describe whether missing
data imputed or drawn from follow-up:
’all randomised subjects who took at least 1 dose of double-blind
treatment, and who contributed at least 1 evening PEF diary
entry after receiving double-blind medication, were used in the
primary analysis’
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Selective reporting (reporting bias) High risk OCS-treated exacerbations were not reported in the study pub-
lication. Data request has been made to study sponsors for this
information
Other bias Low risk 37% screening population eligible for randomisation
Gappa 2009
Methods Multi-center prospective randomised double-blind double-dummy parallel-group study
Participants Children with uncontrolled asthma
% ELIGIBLE OF SCREENED POPULATION: not reported







MEAN AGE, mean age (range): 9.5 (4 to 16) years
GENDER (% male): 81
SEVERITY: not reported.
BASELINE FEV1 % predicted: 91.6
BASELINE DOSE OF ICS: mean: (200 to 400 µg/d BDP-equivalent)
ASTHMA DURATION (range in years): not reported.
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• Children and adolescents 4 to 16 years of age with symptomatic persistent
seasonal or perennial asthma according to current guidelines and prior treatment with
ICS were eligible for the study. Participants were included if:
◦ continuous treatment with ICS (200 to 400 µg/d BDP-equivalent) during
at least the previous 4 weeks;
◦ consent to change ICS treatment to twice-daily inhalation of fluticasone 100
µg via a Diskus inhaler; or
◦ consent to not use SABA or anticholinergic drugs on a regular basis.
EXCLUSION CRITERIA: Participants were excluded if they had experienced 1 of
the following events during the 4 weeks preceding the study: pneumonia, bronchitis,
respiratory infection requiring antibiotic treatment or an asthma-related hospitalisation.
Asthma medications
during the 4 weeks before visit 1, which precluded the child from being admitted to the
trial, were oral or parenteral corticosteroids, and included oral or inhaled LABA
Interventions LABA + ICS vs increased dose of ICS
OUTCOMES: reported weekly
RUN-IN: none
DOSE OF ICS DURING RUN-IN: N/A
INTERVENTION PERIOD: 12 weeks
TEST GROUP: F 12 µg twice daily + BUD 100 twice daily
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CONTROL GROUP: placebo + ICS BUD 200 twice daily
DEVICE: Diskus inhalers
NUMBER OF DEVICES: 1
COMPLIANCE: not reported
CO-TREATMENT: Participants were not allowed to take any other drugs for the long-
term treatment of asthma. Medications for concomitant illnesses could be continued
during the study, if the dose was kept constant and the drug had no influence on asthma
Outcomes PULMONARY FUNCTION TEST: FVC, FEV1 and morning and evening PEF
SYMPTOM SCORE: asthma Symptom Score (ASS) on a scale of 0 to 4
FUNCTIONAL STATUS: number of days (24 hours) without asthma symptoms, use




PRIMARYOUTCOMEMEASURE: change inmean morning expiratory PEF (L/min)
Notes Full-text publication
Source of funding: GlaxoSmithKline
Confirmation of methods and data not obtained
Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 800 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated code produced in the
centralised facility
Allocation concealment (selection bias) Unclear risk Inadequate details were reported on alloca-
tion concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, double-dummy study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Well-balanced withdrawals in groups com-
pared; intention-to-treat analysis
Selective reporting (reporting bias) Low risk Study protocol is available. Primary and
secondary outcomes were prespecified
Other bias Low risk No apparent source of bias was noted
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Heuck 2000
Methods Cross-over study; single centre (outpatient referral centre)
Participants Asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 27
WITHDRAWALS: 2 participants were withdrawn during treatment with BUD alone;
1 withdrawal - unclear which period
AGE, mean (range): 9.6 (6.1 to 13.5) years
GENDER (% male): 52
SEVERITY: mild to moderate
BASELINE FEV1: not reported
BASELINE PEF L/min: 280 L/min
BASELINE DOSE OF ICS: mean - BUD 200 twice daily or equivalent
ASTHMA DURATION (range in years): 4.5 (1.4 to 9.5)
ATOPY (%): not reported
ELIGIBILITY CRITERIA: treatment with inhaled BUD 200µg twice daily (or equipo-
tent doses of other ICS) for 1 month before study entry; children were prepubertal
EXCLUSION CRITERIA: not described
Interventions LABA + ICS vs INCREASED DOSE ICS
OUTCOMES: reported weekly
RUN-IN: none
DOSE OF ICS DURING RUN-IN: N/A
INTERVENTION PERIOD: 12 weeks
TEST GROUP: F 12 µg twice daily + BUD 100 µg twice daily
CONTROL GROUP: placebo + ICS BUD 200 µg twice daily
DEVICE: Turbuhaler (ICS) and Aerolizer (F)
NUMBER OF DEVICES: 2
COMPLIANCE: Turbuhalers weighed and number of F capsules counted
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1; am PEF; pm PEF
SYMPTOM SCORE: daytime and nighttime score (score of 0 to 4)
FUNCTIONAL STATUS: exacerbations; rescue medication use; lower leg growth;
serum and urinary markers of type I and III collagen turnover
INFLAMMATORY MARKERS: inflammatory markers in serum
ADVERSE EFFECTS: reported
WITHDRAWALS: reported
PRIMARY OUTCOME MEASURES: not reported
Notes Full-text publication
Source of funding not stated
Confirmation of methods and data not obtained
User-defined number: 400
Risk of bias
Bias Authors’ judgement Support for judgement
50Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Heuck 2000 (Continued)
Random sequence generation (selection
bias)
Low risk ’Treatment order was allocated by a com-
puterised randomisation scheme prepared
in balanced blocks’
Allocation concealment (selection bias) Unclear risk Information on concealment of allocation
not provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information available
Selective reporting (reporting bias) Low risk Data on OCS-treated exacerbations avail-
able
Other bias Unclear risk No data provided on % participants meet-
ing eligibility criteria from screening or
run-in populations
Langton Hewer 1995
Methods Parallel-group single-centre double-blind placebo-controlled study
Participants Symptomatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
NUMBER RECRUITED NOT RANDOMLY ASSIGNED: not stated
RANDOMLY ASSIGNED: 23 (usual ICS + salmeterol 100 twice daily: 11; usual ICS:
12)
WITHDRAWALS: usual ICS + salmeterol: 0; usual ICS: 2
AGE, median (range): 15 (12 to 17) years
GENDER (% male): 70
SEVERITY: severe
BASELINE % PRED FEV1: 82
BASELINE DOSE OF ICS (start of run-in): 400
ASTHMA DURATION: 13 years
ATOPY (%): 100
ELIGIBILITYCRITERIA: severe asthma (not defined but severe enough to be attending
residential school for asthma and persistent symptoms)
EXCLUSION CRITERIA: already taking LABA
CRITERIA FOR RANDOMISATION DURING RUN-IN: none specified
Interventions LABA + ICS vs SAME DOSE (usual dose) of ICS
OUTCOMES reported at 8 and 10 weeks
RUN-IN PERIOD: 2 weeks
DOSE OF ICS DURING RUN-IN: same as during study
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DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 8 weeks
TEST GROUP: (usual ICS + salmeterol): salmeterol 100 µg twice daily
CONTROL GROUP: usual ICS and placebo twice daily
DEVICE: Diskhaler
NUMBER OF DEVICES: 2
COMPLIANCE: supervised in school taking medication by investigators
CO-TREATMENT OCS: methylxanthines and anticholinergics taken by 20% of par-
ticipants
Outcomes PULMONARY FUNCTION TEST: FEV1; am PEF; pm PEF
SYMPTOM SCORES: morning and evening symptom scores
FUNCTIONAL STATUS: SABA; symptom-free days/nights; exacerbation (requiring




PRIMARY OUTCOME MEASURES: not reported
Notes Full-text publication
Funded by Charity
Confirmation of methods and data pending
User-defined number: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation presented
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identical placebo
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data analysis described as intention to
treat; methods applied not elaborated
Selective reporting (reporting bias) Low risk Data on OCS-treated exacerbations avail-
able
Other bias Unclear risk No data provided on % participants meet-
ing eligibility criteria from screening or
run-in populations (niche population sam-
pled for residential school for children with
particularly difficult to treat asthma)
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Lemanske 2010
Methods Randomised double-blind 3-treatment 3-period cross-over trial
Participants Symptomatic asthmatic children despite low-dose ICS therapy
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: 38
RANDOMLY ASSIGNED: 182
WITHDRAWALS: 25
AGE, median ± SD years: 2 age strata
6 to 11 years (N = 126): 9.1 ± 1.5
12 to 17 years (N = 56): 14.7 ± 1.7
GENDER (% male): 65
SEVERITY: mild to moderate
BASELINE % PRED FEV1: 97
BASELINE DOSE OF ICS (start of run-in): 100 µg of fluticasone twice daily
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA: children 6 to 17 years of age with mild to moderate asthma
diagnosed by a physician on the basis of criteria recommended by the National Asthma
Education and Prevention Program; ability to perform reproducible spirometry; FEV1
≥ 60% before bronchodilation; increase in FEV1 ≥ 12% (bronchodilator reversibility)
or methacholine PC20 in FEV1 ≤ 12.5 mg/mL
EXCLUSION CRITERIA: not reported.
CRITERIA FOR RANDOMISATION DURING RUN-IN: after use of 100 µg of
fluticasone twice daily during run-in period, documentation of uncontrolled asthma,
which was defined as occurrence of ≥ 1 of the following more than 2 days per week on
average during a 2-week period: diary-reported symptoms (coughing rated as moderate
or severe, or wheezing rated as mild, moderate or severe); rescue use of an inhaled
bronchodilator with ≥ 2 puffs per day; or PEF < 80% of predetermined reference value
Interventions LABA + ICS vs INCREASED dose of ICS
OUTCOMES: reported at 16 weeks
RUN-IN PERIOD: 2 to 8 weeks
DOSE OF ICS DURING RUN-IN: 100 µg of fluticasone twice daily
INTERVENTION PERIOD: 16-weeks
TEST GROUP: 100 µg of fluticasone + 50 µg of long-acting beta-agonist salmeterol
(Advair Diskus, GlaxoSmithKline) twice daily
CONTROL GROUP: 250 µg of fluticasone (Flovent Diskus, GlaxoSmithKline) twice
daily
DEVICE: Diskus
NUMBER OF DEVICES: 1
COMPLIANCE: recorded
CO-TREATMENT: Participants received open-label metered-dose inhaler of albuterol
(Ventolin HFA, GlaxoSmithKline). Standardised course of prednisone treatment was
initiated for an asthma exacerbation if predetermined clinical criteria were met
Outcomes PULMONARY FUNCTION TEST: FEV1, PC20
SYMPTOM SCORES: symptom scores; symptom-free days
FUNCTIONAL STATUS: An asthma-control day, as documented in each participant’s
diary, was a day with no use of albuterol rescue (excluding use of albuterol as pre-exercise
treatment), no use of a non-study asthma medication, no daytime or nighttime asthma
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symptoms, no unscheduled visit to a healthcare provider for asthma and no PEF < 80%
of predetermined reference value




PRIMARY OUTCOME MEASURES: differential response to each of the 3 step-up
therapies on the basis of fixed threshold criteria for the following 3 asthma-control mea-
sures: need for treatment with oral prednisone for acute asthma exacerbations, number
of asthma-control days and FEV1
Notes Full-text publication
Funded by grant agencies but not by pharmaceutical companies
Confirmation of data and methods not obtained
Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 1000 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 3 × 3 cross-over design based on complete
set of orthogonal Latin squares; stratifica-
tion based on clinical sites
Allocation concealment (selection bias) Low risk Drug assignments were masked
with use of placebo tablets anddummydisk
devices that discharged powder without ac-
tive drug




Incomplete outcome data (attrition bias)
All outcomes
Low risk Few withdrawals; intention-to-treat analy-
sis
Selective reporting (reporting bias) Low risk Study protocol is available; primary and
secondary outcomes were prespecified
Other bias Low risk No apparent source of bias was noted
54Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lenney 2013
Methods Randomised double-blind placebo-controlled trial
Participants Children with uncontrolled asthma
% ELIGIBLE OF SCREENED POPULATION: 7







AGE, mean (range): 10.5 (6 to 14) years
GENDER (male%): 73
ASTHMA SEVERITY: not reported
BASELINE % PRED FEV1 mean: 88.5
BASELINE DOSE OF ICS (start of run-in): not reported
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• Physician-diagnosed asthma in individuals 6 years to 14 years 11 months of age
• Required frequent SABA relief therapy: ≥ 7 puffs in the past 7 days
• Symptoms of asthma (i.e. wheeze, shortness of breath but not cough alone) that
resulted in:
◦ nocturnal wakening in the last week; and/or
◦ interference with usual activities in the past week; and/or
◦ exacerbations, defined as short course of OCS, an unscheduled general
practitioner or accident and emergency (A&E) department visit or a hospital admission
within past 6 months
• Fully informed written (proxy) consent and assent, when appropriate
EXCLUSION CRITERIA:
• Received LABA, LTRA, regular theophylline therapy or high-dose ICS (> 1000
µg) and unlicensed BDP or equivalent (at the discretion of the investigator)
• Other respiratory diseases, cystic fibrosis, cardiac disease or immunological
disorders
CRITERIA FOR RANDOMISATION DURING RUN-IN: The following eligibility
criteria were considered before randomisation
INCLUSION CRITERIA:
• Asthma in individuals 6 years to 14 years 11 months of age
• Required frequent SABA relief therapy: ≥ 7 puffs in the past 7 days
• Symptoms of asthma (i.e. wheeze, shortness of breath but not cough alone)
resulting in:
◦ nocturnal wakening in the last week; and/or
◦ interference with usual activities in the past week.
• Continuing consent/assent (when appropriate)
EXCLUSION CRITERIA:
• Asthma controlled after 4-week run-in, in which control was defined as absence of
any symptoms of asthma (except cough alone) or cases in which symptoms of asthma
had not interfered with usual activities in the past week
• Receiving LABA, LTRA, regular theophylline therapy or high-dose ICS (> 1000
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µg) and unlicensed BDP or equivalent (at the discretion of the investigator)
• Other respiratory diseases, cystic fibrosis, cardiac disease or immunological
disorders
Interventions LABA + ICS vs same dose of ICS
OUTCOMES: reported at 48 weeks
RUN-IN PERIOD: 4 weeks
DOSE OF ICS DURING RUN-IN: usual maintenance dose
INTERVENTION PERIOD: 48 weeks
TESTGROUP: combination fluticasone propionate 100µg and salmeterol 50µg twice
daily
CONTROL GROUP: fluticasone propionate 100 µg twice daily
DEVICE: Accuhaler
NUMBER OF DEVICES: 1
COMPLIANCE: reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1, FVC
SYMPTOM SCORES: not reported
FUNCTIONAL STATUS: quality of life of children as measured by the Paediatric
Asthma Quality of Life Questionnaire, quality of life of caregivers as measured by the
Paediatric Asthma Caregiver’s Quality of Life Questionnaire, number of schooldays
missed because of respiratory problems, amount of rescue SABA therapy prescribed for
asthma symptoms, time from randomisation to treatment withdrawal (because of lack
of efficacy or side effects)
EXACERBATIONS: number of asthma exacerbations requiring treatment with OCS*;
time from randomisation to first exacerbation requiring treatment with a short course
of OCS; number of hospital admissions due to respiratory problems





Funded by the Health Technology Assessment programme (HTA) of the Department
of Health
Confirmation of data and methods not obtained
Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 400 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation with variable block
length, stratified by secondary care centre,
with allocation to 3 treatment arms in the
ratio of 1 : 1 : 1
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Allocation concealment (selection bias) Low risk Study drugs were identical in appearance
and were identically packaged, with all
participants, clinicians and trial personnel
blinded to treatment allocation throughout
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for withdrawals reported
Selective reporting (reporting bias) Low risk Full protocol is available. Primary and sec-
ondary outcomes were prespecified
Other bias Low risk Study was prematurely terminated due to
lack of funds. However, no apparent source
of bias was noticed
Malone 2005
Methods Parallel-group multi-centre (66 centres in North America)
Participants Steroid-using asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: 48
RANDOMLY ASSIGNED: 203 (fluticasone/salmeterol: 101; fluticasone: 102)
WITHDRAWALS: fluticasone/salmeterol: 19; fluticasone: 16
AGE, mean: 8 years
GENDER (male %): 64
ASTHMA SEVERITY: mild to moderate
BASELINE % PRED FEV1 mean: 80%
BASELINE DOSE OF ICS (start of run-in): 166 µg fluticasone
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA: 4 to 11 years of age; ATS defined asthma ≥ 2 months; ICS
therapy (BDP-equivalent 252 to 336 µg/d) for 1 month before entry; participants 6
to 11 years of age required to have FEV1% predicted; participants 4 to 5 years of age
required to have am PEF 50% to 95% of predicted; ≥ 12% response to beta2-agonist
at screening visit or within 1 year of screening visit
EXCLUSION CRITERIA: history of life-threatening asthma; hospitalisation with
asthma twice or more in previous year; significant concurrent disease; oral or parenteral
use of steroids during month before study entry
CRITERIA FOR RANDOMISATION DURING RUN-IN: am FEV1 50% to 95%
of predicted; daytime asthma (score ≥ 1); use of SABA on 3+ days of last 7 days of run-
in; ≥ 70% diary card entry
57Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Malone 2005 (Continued)
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES: reported at 3 months
RUN-IN PERIOD: 2 weeks
DOSE OF ICS DURING RUN-IN: usual maintenance dose
INTERVENTION PERIOD: 3 months
TEST GROUP: combination salmeterol 50/fluticasone 100 µg twice daily
CONTROL GROUP: fluticasone 100 µg twice daily
DEVICE: Diskus
NUMBER OF DEVICES: 1
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1; clinic PEF; am PEF; pm PEF
SYMPTOM SCORES: symptom scores; symptom-free days
FUNCTIONAL STATUS: OCS-treated exacerbations; hospitalisations; use of reliever
medication; SABA-free days
INFLAMMATORY MARKERS: not reported
ADVERSE EFFECTS: reported
WITHDRAWALS: stated




Confirmation of data and methods obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Appendix 4
Allocation concealment (selection bias) Low risk See Appendix 4
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; identical inhaler devices
Incomplete outcome data (attrition bias)
All outcomes
High risk ’For patients who withdrew from the study
prematurely, all available data up to the
time of discontinuation were included in
the intent-to-treat population’
Selective reporting (reporting bias) Low risk Full protocol is available. Primary and sec-
ondary outcomes were prespecified
58Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Malone 2005 (Continued)
Other bias Low risk Study was prematurely terminated due to
lack of funds. However, no apparent source
of bias was noticed
Meijer 1995
Methods Parallel-group single-centre study
Participants Asymptomatic asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 40 (salmeterol 50 µg twice daily + ICS: 20; ICS + placebo:
20)
WITHDRAWALS: salmeterol 50 µg twice daily + ICS: 0; ICS + placebo: 1 (5%)
AGE, mean (SD): 11.4 (2.6) years
GENDER (% male): 58
SEVERITY: mild
BASELINE % PRED FEV1: 94
BASELINE DOSE OF ICS: twice-daily 200 or 400 µg BDP rotadisk
ASTHMA DURATION: 8.4 years
ATOPY (%): 100
ELIGIBILITY CRITERIA: none reported
EXCLUSION CRITERIA: none reported
CRITERIA FOR RANDOMISATION DURING RUN-IN: N/A
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES: reported at 1, 8, 16 weeks
RUN-IN PERIOD: none
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 16 weeks
TEST GROUP: salmeterol 50 µg twice daily + BDP 250 µg twice daily
CONTROL GROUP: BDP 250 µg twice daily + placebo
DEVICE: dry powder inhaler (Diskhaler)
NUMBER OF DEVICES: 2
COMPLIANCE: returned powder disks counted
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1 predicted; PC20 doubling doses (DD);
circadian variation (day-night differences in FEV1)
SYMPTOM SCORES: only individual symptoms reported (yes/no)
FUNCTIONAL STATUS: rescue medication use
INFLAMMATORY MARKERS: not reported
ADVERSE EFFECTS: not reported
WITHDRAWALS: reported
PRIMARY OUTCOME MEASURE: not specified
Notes Full-text publication
Funded by Glaxo
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User-defined number: 500
Confirmation of data and methods not obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; noother informationpre-
sented
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not enough information presented to determine
this
Selective reporting (reporting bias) Unclear risk Unclear whether data on OCS-treated exacerba-
tions were collected in the study
Other bias Unclear risk No data presented on % screening population eli-
gible for randomisation
Morice 2008a
Methods Parallel-group multi-centre study (53 centres in South America, Europe, Hong Kong
and Taiwan)
Participants % ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: 77
RANDOMLYASSIGNED: 622 (BUD: 207; BUD/F (DPI): 203; BUD/F (MDI): 212)
WITHDRAWALS: BUD: 14 BUD/F (DPI): 11; BUD/F (MDI): 14
AGE, mean (range): 9 (6 to 11) years
GENDER (% male): 66
SEVERITY: not specified
BASELINE % PRED FEV1: 89
BASELINE DOSE OF ICS: (start of run-in): 470 µg
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA: age 6 to 11 years; diagnosis of asthma for ≥ 6 months; PEF
> 50% of predicted normal; history daily ICS use (stable dose of 375 to 1000 µg 30
days before enrolment); clinically important exercise-induced bronchoconstriction for 3
months before enrolment; ability to use DPI, pMDI and peak flow meter
EXCLUSION CRITERIA: not reported
CRITERIA FOR RANDOMISATION DURING RUN-IN: symptom score 1 to 4;
mean morning PEF 50% to 85% post SABA
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Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES: 12 weeks
RUN-IN PERIOD: 2 weeks
DOSE OF ICS DURING RUN-IN: 470
DOSE OPTIMISATION PERIOD: not reported
INTERVENTION PERIOD: 12 weeks
TESTGROUP: combination BUD and F (160/9µg) twice daily via dry powder inhaler
+ placebo metered-dose inhaler
CONTROL GROUP: BUD 200 µg twice daily
DEVICE: MDI and DPI
NUMBER OF DEVICES: 1
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: am PEF*; pm PEF; FEV1
SYMPTOM SCORES: day/night scores








Confirmation of data and methods not obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated schedule
Allocation concealment (selection bias) Unclear risk Information not provided
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ’...all randomised patients with post-ran-
domisation data’
Selective reporting (reporting bias) High risk Data on OCS-treated exacerbations were
not reported in the trial publication. Study
sponsors have indicated that the data from
this study are not available
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Morice 2008a (Continued)
Other bias Low risk 77% of screening population eligible for
randomisation
Morice 2008b
Methods See Morice 2008a
Participants See Morice 2008a
Interventions See Morice 2008a, except for:
TEST GROUP:
• Combination BUD and F (160/9 µg) twice daily via metered-dose inhaler +
placebo dry powder inhaler
Outcomes See Morice 2008a
Notes See Morice 2008a
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Morice 2008a
Allocation concealment (selection bias) Unclear risk See Morice 2008a
Blinding (performance bias and detection
bias)
All outcomes
Low risk See Morice 2008a
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See Morice 2008a
Selective reporting (reporting bias) High risk See Morice 2008a
Other bias Low risk See Morice 2008a
Murray 2010
Methods Two-centre randomised double-blind double-dummy study (SAM40100)
Participants Children with moderate/severe persistent asthma
% ELIGIBLE OF SCREENED POPULATION: 40
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AGE, mean (SD): 7.3 (2.2) years
GENDER (% male): 50
SEVERITY: moderate to severe
BASELINE % PRED FEV1 mean (SD): 84.5
ASTHMA DURATION: reported as strata of 1 to 5 years and > 5 years
ATOPY (%): not reported
ELIGIBILITY CRITERIA: children 4 to 11 years of age, physician-diagnosed asthma,
daily 200 to 800 µg BDP-equivalent ICS use
EXCLUSIONCRITERIA: participantswith oral, parenteral or nebulized corticosteroids
4 weeks before run-in; ≥ 3 courses of oral prednisolone in previous year; intensive care
admission in previous 3 months; regular use of SABA; use of LTRA; cromoglycates and/
or theophyllines; known serious, uncontrolled systemic disease and asthma exacerbation
requiring change of asthma medication during run-in
CRITERIA FOR RANDOMISATION DURING RUN-IN: Randomisation included
sRaw ≥ 1.3 kPa.s; correct completion of diary; symptom score ≥ 2 or required use of
salbutamol on ≥ 2 occasions per day for ≥ 3 days of previous 7 days of run-in period
Interventions LABA + ICS vs HIGH HIGH dose
ICS RUN-IN PERIOD: 2 weeks
OUTCOMES: reported at 6 weeks
DOSE OF ICS DURING RUN-IN: FP 100 µg twice daily
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 6 weeks
TEST GROUP: fluticasone 100 µg and salmeterol 50 µg twice daily
CONTROL GROUP: fluticasone 200 µg twice daily
DEVICE: Accuhaler/Diskus
NUMBER OF DEVICES: 1
COMPLIANCE: reported
CO-TREATMENT: albuterol as needed
Outcomes PULMONARY FUNCTION TEST: predose sRaw at end of 6 weeks of treatment*,
FEV1
SYMPTOM SCORES: symptom score recorded
FUNCTIONAL STATUS: salbutamol rescue use, percent of rescue-free days and nights,
percent of symptom-free days






Confirmation of methods and data not obtained
Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 800 µg/d of BDP-
equivalent
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Murray 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Insufficient information on sequence gen-
eration reported
Allocation concealment (selection bias) Unclear risk Insufficient information on allocation con-
cealment reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and balanced withdrawals. Intention
to treat analysis.
Selective reporting (reporting bias) Low risk Primary and secondary outcomes prespec-
ified. All outcomes were reported
Other bias Low risk No apparent source of bias was noticed.
Murray 2011
Methods Stratified multi-centre randomised double-blind parallel-group study (SFA100316)
Participants Children with persistent asthma treated with daily ICS for ≥ 4 weeks
% ELIGIBLE OF SCREENED POPULATION: 33







AGE, mean (range): 11.6 (4 to 17) years
GENDER (% male): 57
SEVERITY: not reported
BASELINE % PRED FEV1 mean (SD): 83.5
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• 4 to 17 years of age
• Diagnosis of persistent asthma treated with daily ICS for ≥ 4 weeks
• FEV1 of 70% to 95% of predicted based on Polgar predicted normal values [10]
• Decrease in FEV1 ≥ 15% after exercise challenge
EXCLUSION CRITERIA:
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Murray 2011 (Continued)
• History of life-threatening asthma; asthma hospitalisation within 6 months of
screening
• Significant concurrent disease, including recent respiratory tract infection (within
4 weeks before screening)
• Pregnancy and/or lactation
• Use of oral or parenteral corticosteroids within 4 weeks of screening or 2 courses
of oral or parenteral corticosteroids within 6 months of screening
• Use of the following medications within 2 weeks before screening and throughout
the study: inhaled cromolyn, nedocromil, leukotriene modifiers, LABA, theophylline
products and inhaled anticholinergics
CRITERIA FOR RANDOMISATION DURING RUN-IN:
• Participants had to maintain their FEV1 at 70% to 95%. To be randomly
assigned to treatment, participants were required to have documented albuterol use
and/or asthma symptoms during the 7 days immediately before the study visit, while
receiving FP 100 µg twice daily. A minimum 20% fall in baseline FEV1 following
exercise challenge was also required at the end of the run-in period
Interventions LABA + ICS vs SAME dose
ICS RUN-IN PERIOD: 2 to 5 weeks
OUTCOMES: reported at 4 weeks
DOSE OF ICS DURING RUN-IN: FP 100 µg twice daily (Flovent DISKUS, Glaxo-
SmithKline, Research Triangle Park, North Carolina)
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 4 weeks
TEST GROUP: fluticasone 100 µg and salmeterol 50 µg twice daily
CONTROL GROUP: fluticasone 100 µg twice daily
DEVICE: Diskus
NUMBER OF DEVICES: 1
COMPLIANCE: reported
CO-TREATMENT: albuterol as needed
Outcomes PULMONARY FUNCTION TEST: maximal percent fall in FEV1 following exercise
challenge*, 4-hour serial post-dose FEV1 AUC
on Treatment Day 1, morning PEF, evening PEF
FUNCTIONAL STATUS: percent of rescue-free days, percent of symptom free days






Confirmation of methods and data not obtained
Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 400 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
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Murray 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk Insufficient information on sequence gen-
eration reported.
Allocation concealment (selection bias) Unclear risk Insufficient information on allocation con-
cealment reported.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and balanced withdrawals. Intention
to treat analysis.
Selective reporting (reporting bias) Low risk Primary and secondary outcomes prespec-
ified. All outcomes were reported
Other bias Low risk No apparent source of bias was noticed.
Ortega-Cisneros 1998
Methods Parallel-group single-centre
Participants Symptomatic asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICAPNTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 20
• Salmeterol + BDP: 10
• BDP: 10
WITHDRAWALS: not described
AGE (range): 6 to 19 years
GENDER (% male): not described
SEVERITY: moderate
BASELINE % PRED FEV1 mean (SD): not reported
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA: still symptomatic despite maintenance treatment with 200
µg twice daily of BDP
EXCLUSION CRITERIA: not described
Interventions LABA + ICS vs INCREASED dose
ICS RUN-IN PERIOD: 2 weeks
OUTCOMES: reported at 8, 12 weeks
DOSE OF ICS DURING RUN-IN: BDP 200 µg twice daily
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 12 weeks
TEST GROUP: salmeterol 50 µg twice daily + BDP 200 µg twice daily
CONTROL GROUP: BDP 400 µg twice daily
DEVICE: not specified
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Ortega-Cisneros 1998 (Continued)
NUMBER OF DEVICES: 2
COMPLIANCE: not reported
CO-TREATMENT: not specified
Outcomes PULMONARY FUNCTION TEST: FEV1; PEF; FEF 25% to 75%
SYMPTOM SCORES: symptoms
FUNCTIONAL STATUS: not reported
INFLAMMATORY MARKERS: not reported




Confirmation of methods and data not obtained
User-defined number: 400
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other information presented
Allocation concealment (selection bias) Unclear risk Information not provided




Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided
Selective reporting (reporting bias) Unclear risk Unclear whether data on OCS-treated exacerbations were
collected in the study
Other bias Unclear risk No information provided
Pearlman 2009
Methods Multi-centre stratified randomised double-blind parallel-group study (Protocol
SFA100314)
Participants Children with persistent asthma with a minimum decrease in FEV1 of 15% after exercise
challenge
% ELIGIBLE OF SCREENED POPULATION: 31
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 248
• Fluticasone/salmeterol: 124
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AGE, mean (range) 11.1 (4 to 17) years
GENDER (male %): 60
ASTHMA SEVERITY: not reported
BASELINE % PRED FEV1 mean: 83.6
BASELINE DOSE OF ICS (start of run-in): 237 µg/d
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• Eligible participants had to demonstrate a minimum decrease in FEV1 of 15%
after exercise challenge at the
first visit, approximately 8 hours after taking their prestudy ICS
EXCLUSION CRITERIA:
POST-RUN-IN: Participants were required to have documented use of albuterol and/
or asthma symptoms in the 7 days immediately before randomisation. In addition, at
the end of the run-in period, each participant was required to demonstrate a ≥ 20%
decrease from baseline in FEV1 following the exercise challenge
Interventions LABA + ICS vs SAME dose ICS
OUTCOMES: 4 weeks
RUN-IN PERIOD: 1 to 2 weeks
DOSE OF ICS DURING RUN-IN: fluticasone 100 µg twice daily
INTERVENTION PERIOD: 4 weeks
TEST GROUP: combination fluticasone/salmeterol 100/50 µg twice daily
CONTROL GROUP: fluticasone 100 µg twice daily
DEVICE: Diskus
NUMBER OF DEVICES: 1
COMPLIANCE: reported
CO-TREATMENT: albuterol as needed
Outcomes PULMONARY FUNCTION TEST: maximal % fall in FEV1 following exercise chal-
lenge*, 4-hour serial post-dose FEV1 AUC on Treatment Day 1, FEV1 (L), am PEF (L/
min), pm PEF (L/min)
SYMPTOM SCORES: not reported
FUNCTIONAL STATUS: % symptom-free days, % albuterol-free days






Confirmation of methods and data not obtained
Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 400 µg/d of BDP-
equivalent
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Pearlman 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Assignment to blinded study drug was
stratified on the basis of age
Allocation concealment (selection bias) Unclear risk Inadequate informationwas reported on al-
location concealment
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Well-balanced withdrawals in comparison
groups; reasons for withdrawals were re-
ported; intention-to-treat analysis
Selective reporting (reporting bias) Low risk Study protocol is available; primary and
secondary outcomes were prespecified
Other bias Low risk No apparent source of bias was noted
Pohunek 2006a
Methods Parallel-group multi-centre study (80 centres in Europe); 3 treatment groups
Participants Steroid-using asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: 77
RANDOMLY ASSIGNED: 429 (BUD/F: 216; BUD: 213)
WITHDRAWALS: BUD/F: 14 BUD: 13
AGE, mean (range): 8 (4 to 11) years
GENDER (male %): 67
ASTHMA SEVERITY: mild to moderate
BASELINE % PRED FEV1 mean: 92
BASELINE DOSE OF ICS (start of run-in): 454 µg/d
ASTHMA DURATION: 3
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• 4 to 11 years of age
• Diagnosis of asthma (ATS) for ≥ 6 months
• Pre-SABA PEF ≥ 50% of predicted
• ICS treatment ≥ 12 weeks before entry into the study, at a constant dose of 375
to 1000 µg/d during the 30 days before enrolment
• History of an average of ≥1 clinically important exercise-induced
bronchoconstriction per week during 12 weeks leading up to the study
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Pohunek 2006a (Continued)
• Ability to use Turbuhaler device and peak flow meter
EXCLUSION CRITERIA:
• Oral, parenteral or rectal corticosteroids within 30 days
• Respiratory infection affecting asthma control within 30 days
• Any significant co-existing disease/disorder
• Known/suspected hypersensitivity to study medication or inhaled lactose
• Inhaled anticholinergics, beta-blockers (including eye drops), xanthines and other
anti-asthma agents not permitted during the study
POST-RUN-IN: total asthma symptom score≥ 1 on≥ 4 of last 7 days of run-in period;
during last 7 days of run-in, participants had to have a mean morning PEF of 50% to
85% of post-SABA PEF
Interventions LABA + ICS vs SAME dose ICS
OUTCOMES: 12 weeks
RUN-IN PERIOD: 10 to 14 days
DOSE OF ICS DURING RUN-IN: usual dose of ICS
INTERVENTION PERIOD: 12 weeks
TEST GROUP: combination BUD/F 200/6 µg twice daily
CONTROL GROUP: BUD 200 µg twice daily
DEVICE: Turbuhaler
NUMBER OF DEVICES: 1 (Symbicort; double-dummy)
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: am PEF; pm PEF; FEV1
SYMPTOM SCORES: not reported
FUNCTIONAL STATUS: not reported
INFLAMMATORY MARKERS: not reported
ADVERSE EFFECTS: reported
WITHDRAWALS: not reported
PRIMARY OUTCOME MEASURE: not reported
Notes Full-text publication
Funded by AstraZeneca
Confirmation of methods and data not obtained
User-defined number: 400
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Schedule generated using a computer pro-
gramme (AstraZeneca, UK)
Allocation concealment (selection bias) Low risk Person not involved in the study team gen-
erated the randomisation schedule
Blinding (performance bias and detection
bias)
Low risk Double-blind; double-dummy
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Pohunek 2006a (Continued)
All outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ’Intent to treat analysis was performed us-
ing data from all randomised patients’
No additional data were provided on the
composition of the ITT population
Selective reporting (reporting bias) Unclear risk Unclear whether OCS-treated exacerba-
tions were collected in the study; corre-
spondence with trialist has failed to clarify
this
Other bias Low risk 78% screening population eligible for ran-
domisation
Pohunek 2006b
Methods See Pohunek 2006a
Participants See Pohunek 2006a, except for
RANDOMLY ASSIGNED: 414 (F + BUD: 201; BUD: 213)
Interventions See Pohunek 2006a, except for
TEST GROUP: separate F 6 and BUD 200 µg twice daily
NUMBER OF DEVICES: 2
Outcomes See Pohunek 2006a
Notes See Pohunek 2006a
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Pohunek 2006a
Allocation concealment (selection bias) Low risk See Pohunek 2006a
Blinding (performance bias and detection
bias)
All outcomes
Low risk See Pohunek 2006a
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See Pohunek 2006a
Selective reporting (reporting bias) Unclear risk See Pohunek 2006a
Other bias Low risk See Pohunek 2006a
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Russell 1995
Methods Parallel-group multi-centre study (78 centres)
Participants Symptomatic asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 208 (salmeterol 50 + ICS: 99; placebo + ICS: 109)
WITHDRAWALS: salmeterol 50 + ICS: 22%; placebo + ICS: 16.8%
AGE, mean (SD): 10.2 (2.7) years
GENDER (% male): 60
SEVERITY: moderate
BASELINE MEAN % PRED FEV1: 78
BASELINE DOSE OF ICS: 750 µg
ASTHMA DURATION (%): < 1 year: 3; 1 to 5 years: 20; > 5 years: 77
ATOPY (%): 77
ELIGIBILITY CRITERIA DURING RUN-IN:
• Morning PEF-PP (percent predicted) ≤ 90 on ≥ 4 days of the last 10 days of the
baseline period
• Recorded symptoms on ≥ 7 of 14 days of the baseline period for which patients
used ≥ 1 salbutamol blister per episode
• Recorded diurnal variation in PEF ≥ 15% on ≥ 7 occasions during baseline
period
EXCLUSION CRITERIA: received a course of OCS; change in prophylactic therapy
during previous 2 weeks
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES: reported at 4, 8 and 12 weeks
RUN-IN PERIOD: 2 weeks
DOSE OF ICS DURING RUN-IN: continued on usual ICS of ≥ 400 µg/d BDP
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 12 weeks
TEST GROUP: (salmeterol 50 + ICS) salmeterol 50 µg twice daily + ICS 400 to 2400
µg/d
(average: 750 µg/d)
CONTROL GROUP: (placebo + ICS) placebo + ICS 400 to 2400 µg/d (average 750
µg/d)
DEVICE: Diskhaler
NUMBER OF DEVICES: 2
COMPLIANCE: evaluated using participant-kept record booklets
CO-TREATMENT: salbutamol as needed and any other prophylactic asthma medica-
tion via Diskhaler
Outcomes PULMONARY FUNCTION TEST: am PEF percent predicted*; pm PEF percent
predicted
SYMTPOM SCORES: Symptoms were recorded daily as present or absent wheeze or
cough during day or night
FUNCTIONAL STATUS: proportion symptom-free days; proportion symptom-free
nights; rescue medication use
INFLAMMATORY MARKERS: not described
ADVERSE EFFECTS: described
WITHDRAWALS: described
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Funded by Allen & Hanburys
Confirmation of methods and data obtained
User-defined number: 750 (750 µg/d)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Numbered coded envelopes supplied by
pharmacy
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; identical placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk ’Total population used, this comprised all
subjects who received at least one puff of
medication and recorded at least one day of
valid diary or clinic data during the treat-
ment period.Where a subject withdrew be-
fore completion of the study, data recorded
after this withdrawal data was excluded’
Selective reporting (reporting bias) Low risk OCS-treated exacerbation data available
Other bias Unclear risk Information on% screening population el-
igible not available
Rutkowski 2009
Methods Randomised double-blind placebo-controlled study
Participants Children with mild to moderate asthma
% ELIGIBLE OF SCREENED POPULATION: not reported







AGE (range): 10 to 18 years
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Rutkowski 2009 (Continued)
GENDER (male %): 45
ASTHMA SEVERITY: mild to moderate asthma
BASELINE % PRED FEV1 mean: not reported
BASELINE DOSE OF ICS (start of run-in): not reported
ASTHMA DURATION: 4.8 years
ATOPY (%): not reported
ELIGIBILITY CRITERIA: children with diagnosed mild to moderate asthma as per
GINA 2008, with FEV1 > 60% of predicted values, positive reversibility test to salbuta-
mol and no symptoms of respiratory tract infection
EXCLUSIONCRITERIA: childrenwith positive skin prick tests with common airborne
allergens (house dust mites, trees, grasses, weeds, cat, Alternaria, Cladosporium)
ELIGIBILITY CRITERIA DURING RUN-IN: not reported
Interventions ICS and LABA vs SAME dose ICS
OUTCOMES: 6 weeks
RUN-IN PERIOD: 1 week
DOSE OPTIMISATION PERIOD: NA
INTERVENTION PERIOD: 6 weeks
TEST GROUP: 400 µg BUD with 12 µg F fumarate twice daily
CONTROL GROUP: 400 µg BUD twice daily
NUMBER OF DEVICES: 2
COMPLIANCE: not reported
CO-TREATMENT: not reported
Outcomes PULMONARY FUNCTION TEST: FEV1 and FEF25% to 75%, adenosine provoca-
tive test
SYMPTOM SCORES: dyspnoea severity score
FUNCTIONAL STATUS: asthma exacerbation
INFLAMMATORY MARKERS: NA
ADVERSE EFFECTS: not reported
WITHDRAWALS: reported
Notes Full-text publication
Funded by: not reported
Confirmation of methods and data not obtained
Dose of ICS: intervention: 800 µg/d of BDP-equivalent; control: 800 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Inadequate information on randomisation
technique is reported
Allocation concealment (selection bias) Low risk Placebo capsules were identical in ap-
pearance, coded and inhaled via identical
aerosoliser
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Rutkowski 2009 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All data presented. No withdrawals in the
study.
Selective reporting (reporting bias) Unclear risk Primary and secondary outcomes were not
clearly defined. Study protocol is not avail-
able
Other bias Low risk No apparent source of bias was noticed.
SAM40012a
Methods Parallel-group multi-centre study in Europe and Middle East
Participants Steroid-using asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 362 (fluticasone/salmeterol: 181; fluticasone: 181)
WITHDRAWALS: fluticasone/salmeterol: 3; fluticasone: 10
AGE, mean: 8 years
GENDER (male %): 68
ASTHMA SEVERITY: moderate
BASELINE % PRED FEV1 mean: not reported
BASELINE DOSE OF ICS (start of run-in): not reported
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITYCRITERIA: 4 to 500µg BDP-equivalent; documented history of asthma
EXCLUSION CRITERIA: not reported
ELIGIBILITY CRITERIA DURING RUN-IN: symptom score ≥ 2 on 3 of last 7 days
of run-in
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES: reported at 6 months
RUN-IN PERIOD: 2 weeks
DOSE OF ICS DURING RUN-IN: not clear
DOSE OPTIMISATION PERIOD: none reported
INTERVENTION PERIOD: 6 months
TEST GROUP: combination salmeterol 50/fluticasone 100 µg twice daily
CONTROL GROUP: fluticasone 100 µg twice daily
DEVICE: Diskus
NUMBER OF DEVICES: 1
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
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SAM40012a (Continued)
Outcomes OUTCOMES: reported at 6 months
PULMONARY FUNCTION TEST: am PEF; pm PEF; FEV1
SYMPTOM SCORES: symptom-free days
FUNCTIONAL STATUS: use of reliever medication; exacerbations (undefined)




Notes Full unpublished data set available from http://www.ctr.gsk.co.uk
Source of funding: GSK
Confirmation of methods and data not obtained
User-defined number: 400
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Appendix 4
Allocation concealment (selection bias) Low risk See Appendix 4
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identical inhaler devices
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ’To be evaluable, subjects had to meet the
entry and randomisation criteria, receive at
least one dose of studymedication and have
completed at least one day’s post-randomi-
sation diary information.’
Selective reporting (reporting bias) Unclear risk Exacerbations described in trial report
available;OCS-treated exacerbations could
not be identified from the data available
Other bias Unclear risk Information not available
SAM40012b
Methods See SAM40012a
Participants See SAM40012a, except for
RANDOMLY ASSIGNED: fluticasone/salmeterol: 181; FP: 186
WITHDRAWALS: fluticasone/salmeterol: 3; FP: 5
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SAM40012b (Continued)





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Appendix 4
Allocation concealment (selection bias) Low risk See Appendix 4
Blinding (performance bias and detection
bias)
All outcomes
Low risk See SAM40012a
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See SAM40012a
Selective reporting (reporting bias) Unclear risk See SAM40012a
Other bias Unclear risk See SAM40012a
SAM40100
Methods Parallel-group multi-centre study
Participants % ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 24 (fluticasone/salmeterol: 12; FP: 12)
WITHDRAWALS: fluticasone/salmeterol: 1; FP: 1
AGE, mean: 7.3 years
SEVERITY: not stated.
BASELINE % PRED FEV1: not reported
BASELINE DOSE OF ICS: not stated
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• 4 to 8 years of age
• History of asthma ≥ 3 months
• Maintenance ICS dose of 200 to 800 µg/d BDP or equivalent for ≥ 4 weeks
• Sufficiently stable to receive FP 200 µg/d during 2-week run-in
• sRAW value of 1.3 kPa.s for entry into screening and treatment periods
EXCLUSION CRITERIA:
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SAM40100 (Continued)
• Use of systemic steroids in 4 weeks before study entry
• Required ≥ 3 courses of OCS in 12 months before study entry
• Admitted to intensive care for asthma within 3 months before study entry
ELIGIBILITY CRITERIA DURING RUN-IN: Participants who had a change in med-
ication following an exacerbation during run-in were excluded
Interventions LABA + ICS vs INCREASED DOSE ICS
OUTCOMES: 6 weeks
RUN-IN PERIOD: 2 weeks
DOSE OPTIMISATION PERIOD: 2 weeks
INTERVENTION PERIOD: 6 weeks
TEST GROUP: combination fluticasone and salmeterol 100/50 µg twice daily via DPI
CONTROL GROUP: fluticasone 200 µg twice daily via DPI
NUMBER OF DEVICES: 1
COMPLIANCE: not assessed
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1
SYMPTOM SCORES: day and nocturnal scores




Notes Unpublished data source from http://ctr.gsk.co.uk
Funding source: GSK
Confirmation of methods and data not obtained
User-defined number: 400
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Appendix 4
Allocation concealment (selection bias) Low risk See Appendix 4
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; identical devices used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No detailed information on how intention-to-treat
population was composed
Selective reporting (reporting bias) Unclear risk Unclearwhether data onOCS-treated exacerbations
were collected; request for data from study sponsors
has not been successful
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Other bias Unclear risk Information on % screening/run-in population eli-
gible not reported
SD 039 0714
Methods Parallel-group multi-centre study
Participants Steroid-using symptomatic asthmatic adolescents
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: 60
RANDOMLY ASSIGNED: 271 (F6/Bud 200 µg twice daily: 136; Bud 200 µg twice
daily: 135)
WITHDRAWALS: F/BUD 200 µg twice daily: 25; BUD 200 µg twice daily: 27
AGE, mean (range): 14 (11 to 17) years
GENDER (male %): 42
ASTHMA SEVERITY: moderate
BASELINE % PRED FEV1 mean: 75
BASELINE DOSE OF ICS (start of run-in): not reported
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA: ICS 375 to 1000 µg BDP equivalent; FEV1 40% to 90%
of predicted normal; ≥ 12% improvement following inhalation of 1 mg of terbutaline
EXCLUSION CRITERIA: not reported
CRITERIA FOR RANDOMISATION DURING RUN-IN: symptomatic
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES: reported at 1, 2 and 3 months
RUN-IN PERIOD: 2 weeks to document stability
DOSE OF ICS DURING RUN-IN: not clear
DOSE OPTIMISATION PERIOD: none reported
INTERVENTION PERIOD: 3 months
TEST GROUP: combination BUD and F 200/6 µg twice daily
CONTROL GROUP: BUD 200 µg twice daily
DEVICE: Turbuhaler
NUMBER OF DEVICES: 1
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1; am PEF*; pm PEF
SYMPTOM SCORES: recorded but not reported
FUNCTIONALSTATUS: rescuemedication use (recorded but not reported); nocturnal
awakening (recorded but not reported); episode-free days (recorded but not reported)
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Notes Unpublished data downloaded from AZ website (www.astrazenecaclinicaltrials.com)
Funded by AstraZeneca
Confirmation of data and methods obtained
User-defined number: 400
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Information not available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No detailed information on how intention-to-treat
population was composed
Selective reporting (reporting bias) Unclear risk OCS-treated exacerbations were not reported in the
study publication; data request was made to study
sponsors to ask for this information
Other bias Low risk 59% run-in population eligible
SD 039 0718
Methods Parallel-group multi-centre study (52 centres in USA)
Participants % ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: 60
RANDOMLY ASSIGNED: 273 (BUD/F: 128; BUD: 145)
WITHDRAWALS: BUD/F: 36; BUD: 51
AGE, mean (range) or mean (SD): 10.4 (2.6) years
SEVERITY: not stated
BASELINE % PRED FEV1: 82
BASELINE DOSE OF ICS: 235 µg/d
ASTHMA DURATION: 7 years
ATOPY (%): not stated
ELIGIBILITY CRITERIA: 6 to 15 years; low to medium dose of ICS; FEV1 predicted
> 50%; reversibility criteria age dependent: > 12 years 14% and 0.2 L; < 12 years: 12%
EXCLUSION CRITERIA: not reported
ELIGIBILITY CRITERIA DURING RUN-IN: symptoms and lung function not oth-
erwise described
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Interventions LABA + ICS vs SAME DOSE ICS
OUTCOMES: 12 weeks
RUN-IN PERIOD: 1 to 2 weeks
DOSE OPTIMISATION PERIOD: not applicable
INTERVENTION PERIOD: 12 weeks
TEST GROUP: combination BUD/F (100/9 µg) twice daily via metered-dose inhaler
CONTROL GROUP: BUD 100 µg twice daily via metered-dose inhaler
NUMBER OF DEVICES: 1
COMPLIANCE: not assessed
CO-TREATMENT: SABA as needed






Notes Unpublished data from AZ clinical trials website
Funded by AstraZeneca
Confirmation of data and methods obtained
User-defined number: 200
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation presented
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ’The efficacy analysis set (EAS) was defined
as all randomised subjects who took at least
1 dose of studymedication and contributed
at least 1 PEF value to the primary end-
point’
No information given on whether EAS
population included last observation
Selective reporting (reporting bias) Unclear risk OCS-treated exacerbations were not re-
ported in the study publication. Data re-
quest has been made to study sponsors for
this information
81Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SD 039 0718 (Continued)
Other bias Low risk 59% screening population eligible
Simons 1997
Methods Randomised double-blind cross-over single-centre study
Participants Asymptomatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 16
WITHDRAWALS: 2 (13%)
AGE, mean (range): 13.1 (12 to 16) years
GENDER (% male): 44
SEVERITY: not described
BASELINE % PRED FEV1: 93.4
BASELINE DOSE OF ICS: 100 to 200 µg BDP twice daily
ASTHMA DURATION: 5.9 ± 3.4 years
ATOPY (%): 100
ELIGIBILITY CRITERIA:
• 12 to 18 years old
• Well-controlled chronic asthma; diagnosed according to American Thoracic
Society criteria
• Able to perform treadmill running tests
• Perform pulmonary function tests satisfactorily
• Use a Nebulizer Chronolog correctly
EXCLUSION CRITERIA:
• Any significant medical conditions other than mild asthma, allergic rhinitis or
eczema
• Respiratory tract infection, or an acute asthma exacerbation within the previous
month
• Prednisone treatment and emergency department visit or hospitalisations within 3
months
• Life-threatening asthma episode or an adverse reaction to any beta2-adrenergic
agonist, or used salmeterol previously
CRITERIA FOR RANDOMISATION DURING RUN-IN: N/A
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES measured at: days 1 and 28
RUN-IN PERIOD: not specified
DOSE OF ICS DURING RUN-IN: not reported
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 28 days
WASHOUT PERIOD: 14 days
TEST GROUP: salmeterol 50 µg once daily + BDP 100 to 200 µg twice daily
CONTROL GROUP: BDP 100 to 200 µg twice daily + placebo
DEVICE: metered-dose inhaler and Nebulizer Chronolog device
NUMBER OF DEVICES: 2
COMPLIANCE: medication usage recorded in participant diary. Device inserted into
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MDI recorded date, hour and minute of each inhalation
CO-TREATMENT: SABA as needed (200 µg up to 3 times daily), except that albuterol
was not permitted 8 hours before each exercise test. If participants had allergic rhinitis,
they were permitted to use pseudoephedrine (Sudafed) 1 to 3 times daily as needed,
except on the days when exercise tests were scheduled
Outcomes PULMONARY FUNCTION TEST: exercise challenge (max % fall in FEV1 from pre-
exercise baseline)
SYMPTOM SCORES: symptoms
FUNCTIONAL STATUS: rescue medication use; exacerbations requiring systemic
steroids
INFLAMMATORY MARKERS: not reported
ADVERSE EFFECTS: reported
WITHDRAWALS: described
PRIMARY OUTCOME MEASURE: not specified
Notes Full-text publication
Funded by GSK
Confirmation of data and methods obtained
User-defined number: 300 (1/2 with BDP 100 twice daily; 1/2 with BDP 200 twice
daily)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study
Selective reporting (reporting bias) Low risk Data on OCS-treated exacerbations avail-
able
Other bias Unclear risk Information on% screening population el-
igible not available
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Methods Parallel-group single-centre study in Poland
Participants % ELIGIBLE OF SCREENED POPULATION: 97
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 58 (BUD/F: 29; BUD: 29)
WITHDRAWALS: 0
AGE, mean (range) or mean (SD): 10 years
SEVERITY: moderate
BASELINE % PRED FEV1: 94
BASELINE DOSE OF ICS: 400 µg/d BDP-equivalent
ASTHMA DURATION: 4 years
ATOPY (%): 100
ELIGIBILITY CRITERIA: 6 to 18 years; history of asthma requiring treatment with
ICS
EXCLUSION CRITERIA: upper RTI in previous 3 weeks; sinus disease requiring an-
tibiotics within 4 weeks; oral steroids within 4 weeks of study entry; immunotherapy
ELIGIBILITY CRITERIA DURING RUN-IN: not reported
Interventions ICS and LABA vs SAME DOSE ICS
OUTCOMES: 8 weeks
RUN-IN PERIOD: 4 weeks
DOSE OPTIMISATION PERIOD:
INTERVENTION PERIOD: 8 weeks
TEST GROUP: BUD 200 µg + F 9 µg via Turbuhaler
CONTROL GROUP: BUD 200 µg/d via Turbuhaler
NUMBER OF DEVICES: 2
COMPLIANCE: not assessed
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1 predicted; FEF25% to 75%; SRaw
SYMPTOM SCORES: not reported
FUNCTIONAL STATUS: not reported
INFLAMMATORY MARKERS: not reported
ADVERSE EFFECTS: not reported
WITHDRAWALS: reported
Notes Full-text article
Funded by grant from Lodz University, Poland
Confirmation of data and methods not obtained
User-defined number: 200
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
schedule
Allocation concealment (selection bias) Unclear risk Information not available
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Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double dummy
Incomplete outcome data (attrition bias)
All outcomes
Low risk All completed
Selective reporting (reporting bias) Unclear risk Unclear whether data on OCS-treated ex-
acerbations were collected. Request for this
information from study investigator has
not been successful
Other bias Low risk 97% screening population eligible for
study
Stelmach 2008
Methods Randomised double-blind placebo-controlled study
Participants Children with atopic asthma with confirmed fall ≥ 20% in FEV1 post exercise
% ELIGIBLE OF SCREENED POPULATION: 67







AGE, mean: 11.6 years
GENDER (% male): not reported
SEVERITY: not reported
BASELINE % PRED FEV1: 91.7
BASELINE DOSE OF ICS: not reported
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA: Male and female outpatients 6 to 18 years of age with a
clinical diagnosis of bronchial asthma lasting ≥ 6 months before the first visit were
enrolled. To be included in the study, participants had to have a resting FEV1 ≥ 70%
and a documented decrease in FEV1 ≥ 20% after a standard exercise challenge test
EXCLUSIONCRITERIA: Participants were excluded if they had an active upper respi-
ratory tract infection within 3 weeks before the study and acute sinus disease requiring
antibiotic treatment within 1 month before the study, previous intubation or asthma
hospitalisation during the 3 months before the prestudy visit. Additional criteria were
other clinically significant pulmonary, haematological, hepatic, gastrointestinal, renal,
endocrine, neurological, cardiovascular and/or psychiatric disease or malignancy that put
the patient at risk when participating in the study or could influence study results or
the patient’s ability to participate in the study as judged by the investigator. Medications
that resulted in patient exclusion
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included beta-blockers (eye drops included) or OCS within 1 month before the first
visit. Participants receiving immunotherapy were also excluded
CRITERIA FORRANDOMISATIONDURING RUN-IN: ICS (BUD; average dose,
400 µg/d) and montelukast sodium (5 mg or 10 mg, according to age) or LABA
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES measured at: 4 weeks
RUN-IN PERIOD: 4 weeks
DOSE OF ICS DURING RUN-IN: not applicable.
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 4 weeks
TEST GROUP: F 4.5 µg + BUD 100 µg twice daily
CONTROL GROUP: BDP 100 µg twice daily and placebo
DEVICE: Turbuhaler
NUMBER OF DEVICES: 2
COMPLIANCE: not reported
CO-TREATMENT: inhaled SABA as needed.
Outcomes PULMONARY FUNCTION TEST: exercise-induced bronchoconstriction (AUC0-
20min (% of predicted 3 minutes); maximum % fall in FEV1)
SYMPTOM SCORES: not reported
FUNCTIONAL STATUS: not reported
INFLAMMATORY MARKERS: not reported
ADVERSE EFFECTS: Standing height and weight were recorded
WITHDRAWALS: described
Notes Full-text publication
Source of funding: not reported
Confirmation of data and methods not obtained
Dose of ICS: intervention: 200 µg/d of BDP-equivalent; control: 200 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated allocation schedule
was used.
Allocation concealment (selection bias) Low risk Centralized hospital pharmacy prepared
the drugs and placebos by breaking formu-
lations open. The part of the turbuhaler
containing a reservoir of powderwith active
ingredient was replaced with inert placebo
powder
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind study.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Withdrawals were reported with reasons.
All data presented.
Selective reporting (reporting bias) Low risk Although, the study protocol was not avail-
able, no selective reporting was noted
Other bias Low risk No apparent source of bias was noticed.
Tal 2002
Methods Parallel-group multi-centre study (48 centres in 7 countries)
Participants Asymptomatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 286 (F + BDP: 148; BDP: 138)
WITHDRAWALS: F/BDP: 9; BDP: 9
AGE, mean (range): 11 (4 to 17) years
GENDER (% male): 62
SEVERITY: mild
BASELINE % PRED FEV1: 75
BASELINE DOSE OF ICS: 548
ASTHMA DURATION: 6.8 years
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• 4 to 17 years old
• Asthma diagnosed minimum 6 months
• FEV1 40% to 90% of predicted and > 15% reversibility in FEV1 within 15
minutes of bronchodilator
• Constant dose ICS for prior 6 weeks (> 400 µg BUD turbuhaler, > 600 µg BUD
via MDI, > 375 µg fluticasone propionate or > 600 µg CFC BDP)
EXCLUSION CRITERIA:
• Unstable asthma (defined as use of oral, parenteral or rectal corticosteroids within
30 days of study commencement)
• Respiratory tract infection within previous 4 weeks
• Known hypersensitivity to study medications or inhaled lactose
• Use of ICS other than study medication not allowed
CRITERIA FOR RANDOMISATION DURING RUN-IN: no other additional cri-
teria
Interventions LABA + ICS vs SAME dose of ICS
OUTCOMES measured at: 4, 8 and 12 weeks
RUN-IN PERIOD: 2 to 4 weeks
DOSE OF ICS DURING RUN-IN: BUD 200 twice daily
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 12 weeks
TEST GROUP: F 12 µg twice daily + BDP 200 µg twice daily
CONTROL GROUP: BDP 200 µg twice daily and placebo
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DEVICE: Turbuhaler
NUMBER OF DEVICES: 2
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed. If participants had allergic rhinitis, they were
permitted to use nasal corticosteroids; treatment with other asthma medication not
permitted
Outcomes PULMONARY FUNCTION TEST: am PEF*; pm PEF; FEV1 predicted
SYMPTOM SCORES: daily and nocturnal on 4-point scale
FUNCTIONAL STATUS: rescue medication use; nighttime awakening; symptom-free
days





Source of funding: AstraZeneca
Confirmation of data and methods obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk ’Individual treatment code envelopes were
provided for each subject’
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Explicit description of how ITT popula-
tion was composed was not presented:
’An intention-to-treat analysis was used
with all available data’
Selective reporting (reporting bias) Unclear risk Unclear whether data on OCS-treated ex-
acerbationswere collected in the study; cor-
respondence with study investigators has
not clarified this
Other bias Unclear risk No information available on % screening/
run-in populations eligible for the study
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Methods Parallel-group single-centre study
Participants Children with mild to moderate asthma
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 82 (fluticasone/salmeterol: 43; FP: 39)
WITHDRAWALS: not reported
AGE, mean: 10 years
GENDER (male %): 59
ASTHMA SEVERITY: mild to moderate
BASELINE % PRED FEV1: 95
BASELINE DOSE OF ICS (start of run-in): not reported
ASTHMA DURATION: not reported
ATOPY (%): not reported
ELIGIBILITY CRITERIA: ATS diagnosed mild or moderate asthma; age 6 to 14 years
of participants; FEV1 > 70% of predicted; methacholine PC20 < 2 µg/mL
EXCLUSION CRITERIA: not reported
CRITERIA FOR RANDOMISATION DURING RUN-IN: not reported
Interventions LABA + ICS vs SAME dose ICS
OUTCOMES: 12 months
RUN-IN PERIOD: unclear
DOSE OF ICS DURING RUN-IN: not reported
DOSE OPTIMISATION PERIOD: none reported
INTERVENTION PERIOD: 12 months
TEST GROUP: combination fluticasone and salmeterol 125/25 twice daily
CONTROL GROUP: fluticasone 125 µg twice daily
DEVICE: MDI (with aerochamber)
NUMBER OF DEVICES: 1
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1 % predicted
SYMPTOM SCORES: % symptom-free days; % symptom-free nights




PRIMARY OUTCOME MEASURES: not clear
Notes Unpublished conference abstract
Source of funding: not reported
Confirmation of data and methods not obtained
User-defined number: 500
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other information
available
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; means by which assignment to treat-
ment group is masked is not available
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information provided on ITT population
Selective reporting (reporting bias) Unclear risk Unclear whether data on OCS-treated exacerba-
tions were collected
Other bias Unclear risk No information available on % screening/run-in
populations eligible for the study
Vaessen-Verberne 2010
Methods Multi-centre randomised parallel-group double-blind study
Participants Children with moderate asthma
% ELIGIBLE OF SCREENED POPULATION: 62







AGE, mean: 9.4 years
GENDER (male %): 58
ASTHMA SEVERITY: moderate
BASELINE % PRED FEV1: 100
BASELINEDOSEOF ICS (start of run-in): maximum 250µg fluticasone or equivalent
ASTHMA DURATION: 5.6 years
ATOPY (%): 59
ELIGIBILITY CRITERIA: all children with moderate asthma; history of bronchial
hyperresponsiveness; used ICS (maximum 250 µg fluticasone or equivalent)
EXCLUSION CRITERIA: not reported
CRITERIAFORRANDOMISATIONDURINGRUN-IN: children still symptomatic
despite regular use of FP, 100 µg twice a day
Interventions LABA + ICS vs INCREASED dose ICS
OUTCOMES: evaluated at 1, 6, 16 and 26 weeks
RUN-IN PERIOD: 4 weeks
DOSE OF ICS DURING RUN-IN:
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INTERVENTION PERIOD: 26 weeks
DOSE OPTIMISATION PERIOD: none
Test group: salmeterol/fluticasone 50/100 µg twice a day
Control group: fluticasone 200 µg twice a day
DEVICE: Diskhaler
NUMBER OF DEVICES: 1
COMPLIANCE: reported
CO-TREATMENT: salbutamol 200 µg Diskus
Outcomes PULMONARY FUNCTION TEST: FEV1, FVC, FEV1/FVC, MEF50 and PEF rate,
PD20 methacholine test
SYMPTOM SCORES: symptom-free days after 26 weeks*
FUNCTIONAL STATUS: oropharyngeal examination, height by stadiometry (includ-
ing height history), 12-hour urine cortisol, weekly % of participants with ‘good con-
trolled weeks’, ‘maximal controlled weeks’, cumulative number of symptom-free weeks
until end of treatment, time to asthma control defined as time to first ‘good controlled
week’ or ‘maximum controlled week’
INFLAMMATORY MARKERS: exhaled nitric oxide (in selected centres)





Confirmation of methods and data not obtained
Dose of ICS: intervention: 400 µg/d of BDP-equivalent; control: 400 µg/d of BDP-
equivalent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported the technique of randomisa-
tion.
Allocation concealment (selection bias) Unclear risk Not reported the allocation technique.




Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention to treat analysis. All outcomes
were reported. Imbalancedwithdrawals but
reasons for withdrawals clearly reported
Selective reporting (reporting bias) Low risk Primary and secondary outcomes were re-
ported.
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Other bias Low risk No apparent bias was noticed.
Verberne 1998a
Methods Parallel-group multi-centre study (9 centres); 3 groups, of which 2 are considered in this
review
Participants Asthmatic children
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: not reported
RANDOMLY ASSIGNED: 117 (BDP 400 + salmeterol: 60; BDP 400: 57)
WITHDRAWALS: BDP 400 + salmeterol: 5; BDP 400: 4
AGE, mean (SD): 11 (2.6) years
GENDER (% male): 65
SEVERITY: mild
BASELINE % PRED FEV1: 88
BASELINE DOSE OF ICS (SD): 489 (153)
ASTHMA DURATION mean (SD): 8.1 (3.2)
ATOPY (%): 88
ELIGIBILITY CRITERIA:
• FEV1 between 55% and 90% of predicted or FEV1/FVC ratio of 50% to 75%
• ≥ 10% improvement in FEV1 after inhalation of salbutamol
• Airway hyper-responsiveness to methacholine (PD20)
• Ability to reproduce lung function test
• History of stable asthma ≥ 1 month without exacerbation or respiratory tract
infection
• Use of ICS between 200 and 800 µg/d for ≥ 3 months before the beginning of
the study
EXCLUSION CRITERIA:
• Operations for congenital heart disease, oesophageal atresia, congenital or





• Other serious conditions that may influence the possibility of continuation of the
study
• Using OCS continuously or ICS at a dose > 800 µg daily
• Using beta-blocking agents or used cromoglycate or nedocromil sodium within
previous 2 weeks
• Allergic to SABA, pregnant or lactating or females of childbearing age who in the
opinion of the supervising physician were not taking adequate contraceptive
precautions
• Ongoing hyposensitising programme
• Inability to follow therapy instructions, inability to inhale medications adequately
or inability to use peak flow meter
• During study: non-compliance with respect to study medication, completing
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diary cards, clinic visits; withdrawal at own or investigator’s discretion; total number of
courses of OCS more than allowed in the study
CRITERIA FOR RANDOMISATION DURING RUN-IN: no additional criteria
Interventions LABA + ICS vs SAME dose ICS
OUTCOMES: reported at 6, 12, 18, 24,
30, 36, 42, 48 and 54 weeks
RUN-IN PERIOD: 6 weeks
DOSE OF ICS DURING RUN-IN: BDP 200 µg twice daily
INTERVENTION PERIOD: 54 weeks
DOSE OPTIMISATION PERIOD: none
TEST GROUP: (salmeterol 50 µg + BDP 200 µg) salmeterol 50 µg twice daily and
BDP 200 µg twice daily
CONTROL GROUP: (BDP 200 + placebo) BDP 200 µg twice daily + placebo
DEVICE: Rotadisks in combination with a Diskhaler
NUMBER OF DEVICES: 2
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1; am PEF; pm PEF; FVC
SYMPTOM SCORES: Asthma symptoms like wheezing, dyspnoea, exercise-induced
asthma and cough were scored in the morning and evening on a scale from 1 to 3
FUNCTIONAL STATUS: Rescue medication use; exacerbation (requiring systemic
steroids); height, body weight, heart rate and systolic and diastolic blood pressures were
measured
INFLAMMATORY MARKERS: total IgE
ADVERSE EFFECTS: reported
WITHDRAWALS: reported




Confirmation of methods and data obtained
User-defined number: 400
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers
Allocation concealment (selection bias) Low risk Telephone notification of assignment by
coordinating centre
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; identical placebo used
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not clear howpopulationwas identified for
primary outcome
Incomplete diary card data not included in
analysis:
’Where patients failed to complete their
daily record cards for more than 7 d in
any 14-d period such assessments were not
included in the analysis. Otherwise, when
there were missing days in the record, pro
rata adjustment was made to give a 2-wk
assessment’
Selective reporting (reporting bias) Low risk OCS-treated exacerbation data available
Other bias Unclear risk No information available on % screening/
run-in populations eligible for the study
Verberne 1998b
Methods See Verberne 1998a
Participants As for Verberne 1998a, except for
RANDOMLY ASSIGNED: 120
WITHDRAWALS: BDP 400 + salmeterol: 5; BDP 800: 6
Interventions LABA + ICS vs INCREASED dose ICS
OUTCOMES: reported at 6, 12, 18, 24, 30, 36, 42, 48 and 54
RUN-IN PERIOD: 6 weeks
DOSE OF ICS DURING RUN-IN: BDP 200 twice daily
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 54 weeks
TEST GROUP: (salmeterol 50 + BDP200): salmeterol 50 µg twice daily + BDP 200
µg twice daily
CONTROL GROUP: (BDP 400 + placebo): BDP 400 µg/d + placebo
DEVICE: Rotadisks in combination with a Diskhaler
NUMBER OF DEVICES: 2
COMPLIANCE: not reported
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: FEV1; am PEF; pm PEF; FVC
SYMPTOM SCORES: Asthma symptoms like wheezing, dyspnoea, exercise-induced
asthma and cough were scored in the morning and evening on a scale from 1 to 3
FUNCTIONAL STATUS: Rescue medication use; exacerbation (requiring systemic
steroids); height, body weight, heart rate and systolic and diastolic blood pressures were
measured
INFLAMMATORY MARKERS: total IgE
ADVERSE EFFECTS: reported
WITHDRAWALS: reported
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Confirmation of methods and data obtained
User-defined number: 400
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See Verberne 1998a
Allocation concealment (selection bias) Low risk See Verberne 1998a
Blinding (performance bias and detection
bias)
All outcomes
Low risk See Verberne 1998a
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See Verberne 1998a
Selective reporting (reporting bias) Low risk See Verberne 1998a
Other bias Unclear risk See Verberne 1998a
Zimmerman 2004a
Methods Parallel-group multi-centre study (27 centres in Canada). Three treatment arms com-
paring LABA/ICS with 2 doses of LABA and ICS alone. Two groups will be considered
here, and as the same control group is used for both comparisons, half the control group
will be applied to each
Participants Children ≥ 6 to 11 years of age
% ELIGIBLE OF SCREENED POPULATION: not reported
% RUN-IN PARTICIPANTS RANDOMLY ASSIGNED: 68
RANDOMLY ASSIGNED: 196 (F + usual ICS twice daily: 95; usual ICS: 101)
WITHDRAWALS: F + usual ICS: 7; usual ICS: 16
AGE, mean (range): 9 (6 to 11) years
GENDER (% male): 63
SEVERITY: moderate
BASELINE FEV1 % Pred: 77.4
BASELINE DOSE OF ICS: 445
ASTHMA DURATION (years): 5.7
ATOPY (%): not reported
ELIGIBILITY CRITERIA:
• ≥ 12 years of age
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Zimmerman 2004a (Continued)
• Clinical diagnosis of asthma according to ATS criteria for ≥ 12 months
• Treated with ICS for ≥ 3 months before entry
• FEV1 between 50% and 90% of predicted normal
• ≥ 15% reversibility after bronchodilator
• Asthma symptoms suggestive that additional therapy might be needed
• Able to use peak flow meter and Turbuhaler, answer questions from the Paediatric
Asthma Quality of Life Questionnaire and parent or guardian had to complete a daily
diary card
EXCLUSION CRITERIA:
• Systemic corticosteroids or anti-leukotrienes within 30 days of study entry,
astemizole within 120 days, sodium cromoglycate or ketotifen within 7 days,
salmeterol or F within 72 hours or xanthines or antihistamines within 48 hours
• Nasal corticosteroids and immunotherapy permitted provided dose had been
constant ≥ 30 days and 90 days, respectively, before study entry
• Smoking history
RANDOMISATION CRITERIA FOLLOWING RUN-IN:
• Postbronchodilator reversibility ≥ 12% of prebronchodilator value or ≥ 9% of
predicted normal or diurnal variability or ≥ 15% on any 5 of the last 10 days of run-in
• 75% to 124% compliance with prescribed dose as assessed by diary card
• Symptoms during past 10 days of run-in (defined as having ≥ 1 of the following:
≥ 4 inhalations of rescue medication; daytime symptoms ≥ 4 days or night time
awakening ≥ 1 night)
Interventions LABA + ICS vs usual dose of ICS
OUTCOMES: measured at trial entry and after 4, 8 and 12 weeks
RUN-IN PERIOD: 2 weeks
DOSE OF ICS DURING RUN-IN: usual ICS
DOSE OPTIMISATION PERIOD: none
INTERVENTION PERIOD: 12 weeks
TEST GROUP: usual dose ICS + F 4.5 µg twice daily
CONTROL GROUP: usual dose ICS + placebo twice daily
DEVICE: Turbuhaler
NUMBER OF DEVICES: 2
COMPLIANCE: measured during run-in
CO-TREATMENT: SABA as needed
Outcomes PULMONARY FUNCTION TEST: am PEF*; pm PEF; FEV1 (Note: Mean value
during treatment for 12 weeks reported rather than value at endpoint)
SYMPTOM SCORES: total asthma symptom score
FUNCTIONAL STATUS: rescue medication use; paediatric asthma quality of life score





Supported by: not stated
Confirmation of methods and data not obtained
User-defined number (mean ICS dose in LABA group in µg/d of BDP-equivalent): 444
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Zimmerman 2004a (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as randomised; no other infor-
mation presented
Allocation concealment (selection bias) Unclear risk Information not available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind; double-dummy
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Intention-to-treat population presented in
study publication, but handling of missing
data not described
Selective reporting (reporting bias) Low risk Exacerbations described as those requir-
ingOCS-treatment and those requiring in-
creased ICS. Separate OCS-treated exacer-
bation data could not be extracted
Other bias Low risk 68% of screening population randomised
Zimmerman 2004b
Methods See Zimmerman 2004a
Participants See Zimmerman 2004a, except for
TEST GROUP: usual dose ICS + F 9 µg twice daily
CONTROL GROUP: usual dose ICS + placebo twice daily
RANDOMLY ASSIGNED: 196 (F + usual ICS: 95; usual ICS: 101)
WITHDRAWALS: F + usual ICS: 7; usual ICS: 16
Interventions As for Zimmerman 2004a, except for:
TEST GROUP: usual dose ICS + F 6 µg twice daily
Outcomes See Zimmerman 2004a
Notes See Zimmerman 2004a
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk See Zimmerman 2004a
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Zimmerman 2004b (Continued)
Allocation concealment (selection bias) Unclear risk See Zimmerman 2004a
Blinding (performance bias and detection
bias)
All outcomes
Low risk See Zimmerman 2004a
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See Zimmerman 2004a
Selective reporting (reporting bias) Low risk See Zimmerman 2004a
Other bias Low risk See Zimmerman 2004a
AQLQ: Asthma Quality of Life Questionnaire; AUC: Area under the curve; BDP: Beclomethasone dipropionate; BUD: Budesonide;
BUD/F: Budesonide and formoterol; DPI: Dry powder inhaler; F: Formoterol; FEF: Forced expiratory flow; FeNO: Exhaled nitric
oxide; FEV1: Forced expiratory volume in one second; FP: Fluticasone; FVC: Forced vital capacity; GINA: Global Initiative for
Asthma; ICS: Inhaled corticosteroid; IgE: Immunoglobulin E; ITT: Intention-to-treat; LABA: Long-acting beta2-agonist (salmeterol
or formoterol); LTRA: Leukotriene receptor antagonist; MDI: Metered-dose inhaler; MEF50: Maximal expiratory flow at 50%
vital capacity; OCS: Oral corticosteroids; PAQLQ: Paediatric Quality of Life Questionnaire; PC20: Provocative concentrations that
caused a 20% fall in FEV1; PEF: Peak expiratory flow; QD: Once per day; RTI: Respiratory tract infection; SABA: Short-acting
beta2-agonist; sRAW: Specific airway resistance; SD: Standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aldington 2006 Inadequate duration
Aubier 1999 Study conducted in adults
Bateman 2008 Jul Dose of ICS was not stable (dose tapering study)
Bergmann 2004 Not exclusively children
Bernstein 2011 Control was not ICS
Borker 2005 No LABA alone
Boulet 2003 Adult study
Bousquet 2005 No LABA alone
Bracamonte 2005 Comparison of devices
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(Continued)
Bruce 2005 Review article
Bruggenjurgen 2005 Not exclusively paediatric
Buchvald 2002 No ICS alone
Buhl 2004 Adjustable dosing in adults
Caffey 2005 No LABA alone
Chen 2010 Not an RCT
Chopra 2005 No ICS alone
Chuchalin 2005 No ICS alone
Corren 2013 Adult study
Covar 2008 Oct Duplication of Sorkness 2007
Cowan 2004 Not an RCT
Daviskas 2005 No ICS alone
Delaronde 2005 No assessment of asthma control
Drummond 2011 Duplication of LOCCS study
Dubus 2003 No LABA
Emeryk 2003 Comparison of devices
Everden 2004 Not placebo-controlled
Fardon 2005 No LABA
Grady 1995 Not exclusively children
Holgate 2004 Study of Xolair
Holt 2005 Not exclusively children
Ilowite 2004 Adult study
Jenkins 2005 Adult study
Karaman 2007 No prior ICS exposure
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Katial 2011 Mar Adult study
Kerwin 2008 Apr Adult study
Lara-Perez 2005 No ICS alone
Levy 2005 Co-treatment with ICS in only 3/4 participants. Study primarily interested in efficacy of formoterol on top
of usual therapy. ICS dosing not standardised
Li 2010 No asthma control
Lipworth 2013 Control group was not given ICS
LOCCS Adult study
Lundbäck 2009 Mar Adult study
Makela 2012 Steroid-naive patients enrolled in the study
Matthys 2004 Open study
Miraglia 2007 No prior exposure to ICS
Mitchell 2005 No LABA
Mitra 2003 No concurrent ICS
Morice 2005 Not exclusively children
Morice 2005a Not exclusively children
Morice 2008 Compared the same medication
Murray 2004 Not exclusively children
Nathan 2005 Not exclusively children
Nelson 2006 Not exclusively children
Nguyen 2005 Not an RCT
Noyes 2013 Not an RCT
O’Byrne 2001 Adolescents and adults
Pearlman 2004 Study in adults
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(Continued)
Peroni 2005 No ICS alone
Peters 2008 Sep-Oct Adult study
Pijnenburg 2005 No LABA
Prates 2009 Not an RCT
Price 2011 May Adult study
Prieto 2005 Not exclusively children
Quirce 2011 Oct Adult study
Reddel 2010 Aug Adult study
Renzi 2005 Not exclusively children
Renzi 2010 Apr Steroid-naive patients enrolled in the study
SAM30002 Not exclusively children
SAM40101 Inadequate duration
SAS30021 Steroid-naive children
Schauer 2003 No ICS alone
Scicchitano 2004a Study in adults
Selroos 2004 No LABA
SFCF3001 Different devices used
SFCF3002 Different devices used
Sienra-Monge 2004 Not an RCT
Soes-Petersen 2011 Jul Adult study
Sorkness 2007 Mixed population at baseline
Spector 2012 Adult study
Stelmach 2008a Steroids were stopped for 4 weeks before study visit
Storms 2004 Study in adults
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(Continued)
van den Toorn 2005 No ICS alone
Vogelmeier 2005 No ICS alone
Von Berg 2003 No concurrent ICS
Weiler 2005 Study in adults
You-Ning 2005 Study in adults; no ICS alone
EIB: Exercise-induced bronchoconstriction; ICS: Inhaled corticosteroid; LABA: Long-acting beta2-agonist; RCT: Randomised con-
trolled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. LABA versus placebo: both groups receiving similar dose of ICS




participants Statistical method Effect size
1 # participants with exacerbations
requiring systemic steroids
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
1.1 Mean baseline FEV1 ≥
80% of predicted
9 1399 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.69, 1.37]
1.2 Mean baseline FEV1
61%-79% of predicted
2 230 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.48, 1.64]
1.3 Mean baseline FEV1 not
reported
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 # participants with exacerbations
requiring hospitalisation
7 1292 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [0.90, 3.36]
2.1 Mean baseline FEV1 ≥
80% of predicted
3 165 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.36, 6.14]
2.2 Mean baseline FEV1
61%-79% of predicted
3 772 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [0.86, 3.82]
2.3 Mean baseline FEV1 not
reported
1 355 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 # participants with exacerbations
requiring urgent care visit
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Mean baseline FEV1 ≥
80% of predicted
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Serious adverse events 17 4021 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.75, 1.85]
4.1 Mean baseline FEV1 ≥
80% of predicted
13 2897 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.53, 1.92]
4.2 Mean baseline FEV1
61%-79% of predicted
3 762 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.68, 2.59]
4.3 Mean baseline FEV1 not
reported
1 362 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.18, 21.86]
5 Total # withdrawals 23 4374 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.67, 0.94]
5.1 Mean baseline FEV1 ≥
80% of predicted
17 3205 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.66, 0.96]
5.2 Mean baseline FEV1
61%-79% of predicted
4 794 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.63, 1.32]
5.3 Mean baseline FEV1 not
reported
2 375 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.12, 1.11]
6 # withdrawals due to poor
asthma control or exacerbation
14 2255 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.57, 1.16]
6.1 Mean baseline FEV1 ≥
80% of predicted
10 1461 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.55, 1.21]
6.2 Mean baseline FEV1
61%-79% of predicted
4 794 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.34, 1.81]
7 # withdrawals due to adverse
events
18 4117 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.52, 1.21]
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7.1 Mean baseline FEV1 ≥
80% of predicted
13 3053 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.42, 1.13]
7.2 Mean baseline FEV1
61%-79% of predicted
5 1064 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.51, 2.44]
8 # withdrawals due to serious
non-respiratory event
2 318 Risk Ratio (M-H, Random, 95% CI) 4.66 [0.23, 96.30]
8.1 Mean baseline FEV1
61%-79% of predicted
2 318 Risk Ratio (M-H, Random, 95% CI) 4.66 [0.23, 96.30]
9 Change in FEV1 (L) at endpoint 9 1942 Litres (Fixed, 95% CI) 0.08 [0.06, 0.10]
9.1 Mean baseline FEV1 ≥
80% of predicted
7 1515 Litres (Fixed, 95% CI) 0.08 [0.05, 0.10]
9.2 Mean baseline FEV1
61%-79% of predicted
2 427 Litres (Fixed, 95% CI) 0.12 [0.04, 0.19]
10 Change in FEV1 at endpoint
(% predicted) stratifying on
baseline FEV1
7 534 Mean Difference (IV, Fixed, 95% CI) 2.99 [0.86, 5.11]
10.1 Mean baseline FEV1 ≥
80% of predicted
4 214 Mean Difference (IV, Fixed, 95% CI) 4.06 [1.32, 6.80]
10.2 Mean baseline FEV1
61%-79% of predicted
2 238 Mean Difference (IV, Fixed, 95% CI) 3.35 [-1.50, 8.20]
10.3 Mean baseline FEV1 not
reported
1 82 Mean Difference (IV, Fixed, 95% CI) -0.40 [-5.03, 4.23]
11 % fall in FEV1 % predicted
due to exercise
3 517 Mean Difference (IV, Fixed, 95% CI) 0.46 [1.00, 1.93]
11.1 Mean baseline FEV1 ≥
80% of predicted
3 517 Mean Difference (IV, Fixed, 95% CI) 0.46 [1.00, 1.93]
12 Change in morning PEF
(L/min) at endpoint
16 3934 L/min (Fixed, 95% CI) 10.20 [8.14, 12.26]
12.1 Mean baseline FEV1 ≥
80% of predicted
12 2870 L/min (Fixed, 95% CI) 10.79 [8.43, 13.16]
12.2 Mean baseline FEV1
61%-79% of predicted
3 713 L/min (Fixed, 95% CI) 9.26 [4.42, 14.10]
12.3 Mean baseline FEV1 not
reported
1 351 L/min (Fixed, 95% CI) 5.7 [-2.62, 14.02]
13 Change in morning PEF (%
predicted)
1 % (Fixed, 95% CI) Totals not selected
13.1 Mean baseline FEV1
61%-79% of predicted
1 % (Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Change in evening PEF
(L/min) at endpoint
12 3140 L/min (Fixed, 95% CI) 9.30 [6.96, 11.65]
14.1 Mean baseline FEV1 ≥
80% of predicted
10 2503 L/min (Fixed, 95% CI) 9.31 [6.67, 11.94]
14.2 Mean baseline FEV1
61%-79% of predicted
1 286 L/min (Fixed, 95% CI) 11.7 [5.29, 18.11]
14.3 Mean baseline FEV1 not
reported
1 351 L/min (Fixed, 95% CI) 5.0 [-3.58, 13.58]
15 Change in evening PEF (% of
predicted)
1 % (Fixed, 95% CI) Totals not selected
15.1 Mean baseline FEV1
61%-79% of predicted
1 % (Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Change in clinic PEF (L/min) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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16.1 Mean baseline FEV1 not
reported
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Change in PEF variability at
endpoint
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
17.1 Mean baseline FEV1
61%-79% of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Mean change in asthma
symptom score
6 1653 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.17, 0.04]
18.1 Mean baseline FEV1 ≥
80% of predicted
6 1653 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.17, 0.04]
19 Change in nighttime symptom
score
2 534 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.07, 0.02]
19.1 Mean baseline FEV1 ≥
80% of predicted
2 534 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.07, 0.02]
20 Change in % symptom-free
days at endpoint
7 1831 Mean Difference (IV, Fixed, 95% CI) 0.96 [-1.91, 3.84]
20.1 Mean baseline FEV1 ≥
80% of predicted
7 1831 Mean Difference (IV, Fixed, 95% CI) 0.96 [-1.91, 3.84]
21 % symptom-free days 4 623 Std. Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.20, 0.12]
21.1 Mean baseline FEV1 ≥
80% of predicted
1 231 Std. Mean Difference (IV, Fixed, 95% CI) -0.21 [-0.47, 0.05]
21.2 Mean baseline FEV1
61%-79% of predicted
1 286 Std. Mean Difference (IV, Fixed, 95% CI) 0.12 [-0.11, 0.35]
21.3 Unclear baseline FEV1 2 106 Std. Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.56, 0.31]
22 % symptom-free nights at 52 ±
4 weeks
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
22.1 Mean baseline FEV1 not
reported
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Change in # daytime rescue
inhalations (puffs per day) at
endpoint
7 1798 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.11, -0.02]
23.1 Mean baseline FEV1
61%-79% of predicted
7 1798 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.11, -0.02]
24 Change in # nighttime rescue
inhalations at endpoint
3 672 Mean Difference (IV, Random, 95% CI) -0.08 [-0.13, -0.03]
24.1 Mean baseline FEV1
61%-79% of predicted
3 672 Mean Difference (IV, Random, 95% CI) -0.08 [-0.13, -0.03]
25 % days without bronchodilator
usage
7 1710 Mean Difference (IV, Random, 95% CI) 2.07 [-1.03, 5.16]
25.1 Mean baseline FEV1 ≥
80% of predicted
6 1628 Mean Difference (IV, Random, 95% CI) 2.87 [-0.44, 6.18]
25.2 Mean baseline FEV1 not
reported
1 82 Mean Difference (IV, Random, 95% CI) -1.0 [-4.04, 2.04]
26 Change in nighttime awakening
(number of nights) at endpoint
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
26.1 Mean baseline FEV1
61%-79% of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27 % nights with awakening 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
27.1 Mean baseline FEV1
61%-79% of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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28 % change in awakening-free
nights
2 519 Mean Difference (IV, Fixed, 95% CI) 0.60 [-1.05, 2.26]
28.1 Mean baseline FEV1 ≥
80% of predicted
2 519 Mean Difference (IV, Fixed, 95% CI) 0.60 [-1.05, 2.26]
29 Change in rescue-free days (%) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
29.1 Mean baseline FEV1 ≥
80% of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
30 Change in % asthma-control
days at endpoint
2 519 Mean Difference (IV, Fixed, 95% CI) 4.30 [-0.56, 9.16]
30.1 Mean baseline FEV1 ≥
80% of predicted
2 519 Mean Difference (IV, Fixed, 95% CI) 4.30 [-0.56, 9.16]
31 Change in quality of life
(P-AQLQ)
4 668 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.14, 0.10]
31.1 Mean baseline FEV1 ≥
80% of predicted
4 668 Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.14, 0.10]
32 Quality of life (P-AQLQ) 10 2333 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.04, 0.11]
32.1 Mean baseline FEV1 ≥
80% of predicted
6 1586 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.01, 0.16]
32.2 Mean baseline FEV1
61%-79% of predicted
4 747 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.28, 0.03]
33 Change in paediatric asthma
caregiver quality of life
(P-AQLQ)
4 669 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.05, 0.18]
33.1 Mean baseline FEV1 ≥
80% of predicted
4 669 Mean Difference (IV, Fixed, 95% CI) 0.07 [-0.05, 0.18]
34 Total # adverse events 15 3284 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.98, 1.10]
34.1 Mean baseline FEV1 ≥
80% of predicted
11 2424 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [1.00, 1.16]
34.2 Mean baseline FEV1
61%-79% of predicted
2 474 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.86, 1.09]
34.3 Mean baseline FEV1 not
reported
2 386 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.78, 1.09]
35 # participants with oral
candidiasis
6 1341 Risk Ratio (M-H, Fixed, 95% CI) 3.41 [0.73, 15.87]
35.1 FEV1 ≥ 80% of
predicted
5 1135 Risk Ratio (M-H, Fixed, 95% CI) 3.46 [0.60, 19.99]
35.2 Mean baseline FEV1
61%-79% of predicted
1 206 Risk Ratio (M-H, Fixed, 95% CI) 3.24 [0.13, 78.62]
36 # participants with tremor 6 1467 Risk Ratio (M-H, Fixed, 95% CI) 3.07 [0.38, 25.05]
36.1 Mean baseline FEV1 ≥
80% of predicted
3 959 Risk Ratio (M-H, Fixed, 95% CI) 5.30 [0.26, 109.66]
36.2 Mean baseline FEV1
61%-79% of predicted
3 508 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.06, 35.18]
37 # participants with tachycardia
or palpitations
6 1238 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.08, 2.31]
37.1 Mean baseline FEV1 ≥
80% of predicted
3 731 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.05, 3.33]
37.2 Mean baseline FEV1
61%-79% of predicted
3 507 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.03, 7.61]
38 # participants with headache 14 2966 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.90, 1.33]
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38.1 Mean baseline FEV1 ≥
80% of predicted
8 1779 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.79, 1.26]
38.2 Mean baseline FEV1
61%-79% of predicted
5 825 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.88, 2.04]
38.3 Mean baseline FEV1 not
reported
1 362 Risk Ratio (M-H, Fixed, 95% CI) 1.4 [0.64, 3.07]
39 # participants with vomiting 3 707 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.34, 1.62]
39.1 Mean baseline FEV1 ≥
80% of predicted
3 707 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.34, 1.62]
40 # participants with otitis media 3 707 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.30, 1.63]
40.1 Mean baseline FEV1 ≥
80% of predicted
3 707 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.30, 1.63]
41 # participants with upper
respiratory tract infection
5 1186 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.58, 1.27]
41.1 Mean baseline FEV1 ≥
80% of predicted
5 1186 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.58, 1.27]
42 # participants with urticaria 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
42.1 Mean baseline FEV1 ≥
80% of predicted
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
43 # participants with adverse
cardiovascular events
2 148 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.49]
43.1 Mean baseline FEV1 ≥
80% of predicted
1 116 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.49]
43.2 Mean baseline FEV1
61%-79% of predicted
1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
44 Deaths 3 690 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.01, 0.01]
44.1 Baseline FEV1 ≥ 80%
of predicted
3 690 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.01, 0.01]
45 # participants with
exacerbations requiring
hospitalisation
7 1292 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [0.90, 3.36]
45.1 Mean baseline FEV1 ≥
80% of predicted
3 165 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.36, 6.14]
45.2 Mean baseline FEV1
61%-79% of predicted
3 772 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [0.86, 3.82]
45.3 Mean baseline FEV1 not
reported
1 355 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
46 Change in height (cm) as SD
scores at 24 ± 4 weeks
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
46.1 Mean baseline FEV1 ≥
80% of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
47 Change in height at 1 year 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Comparison 2. LABA + ICS versus placebo + higher dose of ICS




participants Statistical method Effect size
1 # participants with exacerbations
requiring oral steroids
3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
1.1 Baseline FEV1 ≥ 80% of
predicted
3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
2 # participants with exacerbations
requiring hospitalisation
4 1008 Risk Ratio (M-H, Fixed, 95% CI) 1.90 [0.65, 5.54]
2.1 Baseline FEV1 ≥ 80% of
predicted
2 423 Risk Ratio (M-H, Fixed, 95% CI) 1.68 [0.22, 12.66]
2.2 Baseline FEV1 61%-79%
of predicted
1 225 Risk Ratio (M-H, Fixed, 95% CI) 3.17 [0.67, 14.95]
2.3 Mean baseline FEV1 not
reported
1 360 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 8.13]
3 # participants with exacerbations
requiring urgent care visit
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Baseline FEV1 ≥ 80% of
predicted
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Serious adverse events 7 1343 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.81, 2.94]
4.1 Baseline FEV1 ≥ 80%
predicted
4 729 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.42, 3.16]
4.2 Baseline FEV1 61%-79%
of predicted
1 223 Risk Ratio (M-H, Random, 95% CI) 2.90 [1.10, 7.64]
4.3 Mean baseline FEV1 not
reported
2 391 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.10, 2.77]
5 Total # withdrawals 8 1491 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.67, 1.37]
5.1 Baseline FEV1 ≥ 80% of
predicted
5 888 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.75, 1.78]
5.2 Baseline FEV1 61%-79%
of predicted
1 223 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.30, 1.39]
5.3 Mean baseline FEV1 not
reported
2 380 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.20, 2.36]
6 # withdrawals due to poor
asthma control or exacerbation
4 862 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.05, 2.13]
6.1 Baseline FEV1 ≥ 80% of
predicted
4 862 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.05, 2.13]
7 # withdrawals due to adverse
events
5 951 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.19, 3.07]
7.1 Baseline FEV1 ≥ 80% of
predicted
4 728 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.14, 3.63]
7.2 Baseline FEV1 61%-79%
of predicted
1 223 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.06, 14.30]
8 # withdrawals due to serious
non-respiratory event
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
8.1 Mean baseline FEV1 ≥
80% of predicted
1 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
9 Change in FEV1 (L) at endpoint 2 526 Mean Difference (Fixed, 95% CI) 0.01 [-0.03, 0.05]
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9.1 Baseline FEV1 ≥ 80% of
predicted
1 303 Mean Difference (Fixed, 95% CI) 0.0 [-0.05, 0.05]
9.2 Baseline FEV1 61%-79%
of predicted
1 223 Mean Difference (Fixed, 95% CI) 0.04 [-0.06, 0.14]
10 Change in FEV1 % predicted
at endpoint
2 % (Random, 95% CI) 0.38 [-0.39, 1.15]
10.1 Baseline FEV1 ≥ 80%
of predicted
2 % (Random, 95% CI) 0.38 [-0.39, 1.15]
11 Change in morning PEF
(L/min) at endpoint
5 1283 Mean Difference (IV, Fixed, 95% CI) 8.73 [5.15, 12.31]
11.1 Baseline FEV1 ≥ 80%
of predicted
3 704 Mean Difference (IV, Fixed, 95% CI) 9.50 [5.07, 13.93]
11.2 Baseline FEV1
61%-79% of predicted
1 223 Mean Difference (IV, Fixed, 95% CI) 9.0 [-0.07, 18.07]
11.3 Baseline FEV1 not
reported
1 356 Mean Difference (IV, Fixed, 95% CI) 5.90 [-2.28, 14.08]
12 Change in evening PEF
(L/min) at endpoint
4 1163 Mean Difference (Fixed, 95% CI) 6.50 [2.64, 10.37]
12.1 Baseline FEV1 predicted
≥ 80%
2 584 Mean Difference (Fixed, 95% CI) 7.08 [2.13, 12.02]
12.2 Baseline FEV1
61%-79% of predicted
1 223 Mean Difference (Fixed, 95% CI) 7.0 [-2.07, 16.07]
12.3 Baseline FEV1 not
reported
1 356 Mean Difference (Fixed, 95% CI) 4.4 [-4.05, 12.85]
13 Change in clinic PEF (L/min) 2 637 Mean Difference (IV, Fixed, 95% CI) 8.33 [2.12, 14.54]
13.1 Baseline FEV1 ≥ 80%
of predicted
1 281 Mean Difference (IV, Fixed, 95% CI) 11.3 [3.84, 18.76]
13.2 Baseline FEV1 not
reported
1 356 Mean Difference (IV, Fixed, 95% CI) 1.60 [-9.63, 12.83]
14 Change in morning PEF (%
predicted) at endpoint
1 Mean Difference (IV, Random, 95% CI) Totals not selected
14.1 Baseline FEV1 ≥ 80%
of predicted
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
15 Change in evening PEF (%
predicted) at endpoint
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
15.1 Baseline FEV1 ≥ 80%
of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Change in % of days with a
peak flow variability ≥ 20%
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
16.1 Baseline FEV1 ≥ 80%
of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17 Change in daytime asthma
symptom score (mean over
study period)
3 329 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.20, 0.23]
17.1 Baseline FEV1 ≥ 80%
of predicted
2 305 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.21, 0.24]
17.2 Baseline FEV1 not
reported
1 24 Std. Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.77, 0.84]
18 Change in nighttime asthma
symptom score (mean over
study period)
3 329 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.20, 0.23]
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18.1 Baseline FEV1 ≥ 80%
of predicted
2 305 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.21, 0.24]
18.2 Baseline FEV1 not
reported
1 24 Std. Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.80, 0.80]
19 Change in % of days without
asthma symptoms
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
19.1 Baseline FEV1 ≥ 80%
of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 # daytime rescue inhalations
(puffs per day; mean over study
period)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
20.1 Baseline FEV1 not
reported
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 # nighttime rescue inhalations
(puffs per day; mean over study
period)
1 Mean Difference (IV, Random, 95% CI) Totals not selected
21.1 Baseline FEV1 not
reported
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
22 # daytime rescue inhalations at
endpoint
1 puffs/d (Fixed, 95% CI) Totals not selected
22.1 Baseline FEV1
61%-79% of predicted
1 puffs/d (Fixed, 95% CI) 0.0 [0.0, 0.0]
23 Change in daytime rescue
inhalations (puffs per day)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
23.1 Baseline FEV1 ≥ 80%
of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
24 Change in nighttime rescue
inhalations (puffs per day)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
24.1 Baseline FEV1 ≥ 80%
of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
25 Change in number of weeks
with successful asthma control
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
25.1 Baseline FEV1 ≥ 80%
of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
26 Change in % of days without
salbutamol
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
26.1 Baseline FEV1 ≥ 80%
of predicted
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
27 Number of nighttime
awakenings
1 Awakenings/yr (Fixed, 95% CI) Totals not selected
27.1 Baseline FEV1
61%-79% of predicted
1 Awakenings/yr (Fixed, 95% CI) 0.0 [0.0, 0.0]
28 Total # adverse events 6 1254 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.92, 1.10]
28.1 Baseline FEV1 ≥ 80%
of predicted
4 863 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.94, 1.15]
28.2 Mean baseline FEV1 not
reported
2 391 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.79, 1.11]
29 # participants with oral
candidiasis
2 182 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.15, 6.85]
29.1 Mean baseline FEV1 ≥
80% of predicted
2 182 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.15, 6.85]
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30 # participants with headache 5 1230 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.85, 1.50]
30.1 Baseline FEV1 ≥ 80%
of predicted
4 863 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.80, 1.46]
30.2 Mean baseline FEV1 not
reported
1 367 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [0.66, 3.16]
31 # participants with vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
31.1 Baseline FEV1 ≥ 80%
of predicted
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
32 # participants with cold 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
32.1 Mean baseline FEV1 ≥
80% of predicted
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
33 # participants with upper
respiratory tract infection
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
33.1 Baseline FEV1 ≥ 80%
of predicted
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
34 Linear growth 2 Mean Difference (Fixed, 95% CI) 1.21 [0.72, 1.70]
35 Deaths 1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
35.1 Baseline FEV1 ≥ 80%
of predicted
1 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)




participants Statistical method Effect size
1 # participants with exacerbations
requiring oral steroids by dose
of ICS in both groups
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
1.1 Low dose of ICS (≤ 400
µg/d of BDP-eq)
8 1376 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.67, 1.37]
1.2 Moderate dose of ICS
(401 to 800 µg/d of BDP-eq)
3 270 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.48, 1.64]
1.3 High dose of ICS (> 800
µg/d of BDP-eq)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Unspecified dose of ICS or
range of dose only mentioned
1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.28, 4.32]
2 # participants with exacerbations
requiring oral steroids by
whether LABA dose is usual or
higher than usual
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
2.1 LABA at usual dose 11 1646 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.69, 1.28]
2.2 LABA at higher than usual
dose
1 23 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.28, 4.32]
3 # participants with exacerbations
requiring oral steroids by type
of LABA
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
3.1 Formoterol 4 591 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.58, 1.39]
3.2 Salmeterol 8 1078 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.66, 1.51]
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4 # participants with exacerbations
requiring oral steroids by single
inhaler or separate inhalers for
LABA and ICS
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
4.1 Single inhaler 6 1227 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.66, 1.47]
4.2 Separate inhaler 6 442 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.57, 1.42]
5 # participants with exacerbations
requiring oral steroids by trial
duration
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
5.1 ≤ 16 weeks 10 1526 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.65, 1.25]
5.2 ≥ 24 weeks 2 143 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.59, 2.52]
6 # participants with exacerbations
requiring oral steroids by
whether funded by producers
of LABA
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
6.1 Charity/grant agency
funded
2 49 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.60, 5.56]
6.2 Funded by manufacturers
of LABA
9 1580 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.66, 1.23]
6.3 Unknown funding source 1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 # participants with exacerbations
requiring systemic steroids by
publication status
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
7.1 Published as full-text
papers
10 1439 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.69, 1.37]
7.2 Not published as full-text
papers
2 230 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.48, 1.64]
8 # participants with exacerbations
requiring systemic steroids by
blinding of study
12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
8.1 Double-blinded studies 12 1669 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.70, 1.28]
8.2 Open-label studies 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS)




participants Statistical method Effect size
1 # participants with exacerbations
requiring oral steroids by dose
of ICS in control groups
3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
1.1 Low dose of ICS (≤ 400
µg/d of BDP-eq)
3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
1.2 Moderate dose of ICS
(401 to 800 µg/d of BDP-eq)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 High dose of ICS (> 800
µg/d of BDP-eq)
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Unspecified dose of ICS or
range of dose only mentioned
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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2 # participants with exacerbations
requiring oral steroids by
whether LABA dose is usual or
higher than usual
3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
2.1 LABA at usual dose 3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
2.2 LABA at higher than usual
dose
0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 # participants with exacerbations
requiring oral steroids by type
of LABA
3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
3.1 Formoterol 2 461 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [0.72, 5.82]
3.2 Salmeterol 1 120 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.58, 3.50]
4 # participants with exacerbations
requiring oral steroids by single
inhaler or separate inhalers for
LABA and ICS
3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
4.1 Combination inhaler 2 461 Risk Ratio (M-H, Fixed, 95% CI) 2.05 [0.72, 5.82]
4.2 Separate inhaler 1 120 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [0.58, 3.50]
4.3 Not reported 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 # participants with exacerbations
requiring oral steroids by trial
duration
3 581 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.85, 3.32]
5.1 ≤ 16 weeks 1 303 Risk Ratio (M-H, Fixed, 95% CI) 2.04 [0.19, 22.26]
5.2 ≥ 24 weeks 2 278 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.81, 3.36]
Comparison 5. Sensitivity analysis: LABA + ICS versus placebo + higher dose of ICS




participants Statistical method Effect size
1 # participants with exacerbations
requiring oral steroids
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Baseline FEV1 ≥ 80% of
predicted
4 895 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.64, 1.33]
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Analysis 1.1. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 1 #
participants with exacerbations requiring systemic steroids.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 1 # participants with exacerbations requiring systemic steroids
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
Subtotal (95% CI) 791 608 75.6 % 0.97 [ 0.69, 1.37 ]
Total events: 71 (LABA + ICS), 46 (ICS alone)
Heterogeneity: Chi2 = 6.44, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Mean baseline FEV1 61%-79% of predicted
Akpinarli 1999 0/16 0/16 Not estimable
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Subtotal (95% CI) 115 115 24.4 % 0.89 [ 0.48, 1.64 ]
Total events: 16 (LABA + ICS), 18 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
3 Mean baseline FEV1 not reported
Rutkowski 2009 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.2. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 2 #
participants with exacerbations requiring hospitalisation.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 2 # participants with exacerbations requiring hospitalisation
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Langton Hewer 1995 1/11 0/12 3.6 % 3.25 [ 0.15, 72.36 ]
Verberne 1998a 1/60 2/56 15.5 % 0.47 [ 0.04, 5.01 ]
Lenney 2013 2/15 0/11 4.3 % 3.75 [ 0.20, 71.12 ]
Subtotal (95% CI) 86 79 23.4 % 1.50 [ 0.36, 6.14 ]
Total events: 4 (LABA + ICS), 2 (ICS alone)
Heterogeneity: Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
2 Mean baseline FEV1 61%-79% of predicted
SD 039 0714 4/136 1/134 7.6 % 3.94 [ 0.45, 34.80 ]
Tal 2002 5/158 0/138 4.0 % 9.62 [ 0.54, 172.36 ]
Russell 1995 9/99 9/107 65.0 % 1.08 [ 0.45, 2.61 ]
Subtotal (95% CI) 393 379 76.6 % 1.81 [ 0.86, 3.82 ]
Total events: 18 (LABA + ICS), 10 (ICS alone)
Heterogeneity: Chi2 = 3.09, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.56 (P = 0.12)
3 Mean baseline FEV1 not reported
SAM40012a 0/180 0/175 Not estimable
Subtotal (95% CI) 180 175 Not estimable
Total events: 0 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 659 633 100.0 % 1.74 [ 0.90, 3.36 ]
Total events: 22 (LABA + ICS), 12 (ICS alone)
Heterogeneity: Chi2 = 4.60, df = 5 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 1.3. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 3 #
participants with exacerbations requiring urgent care visit.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 3 # participants with exacerbations requiring urgent care visit
Study or subgroup LABA + ICS ICS alone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 4/123 7/63 0.29 [ 0.09, 0.96 ]
0.005 0.1 1 10 200
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Analysis 1.4. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 4
Serious adverse events.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 4 Serious adverse events
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010a 2/184 1/85 4.2 % 0.92 [ 0.08, 10.05 ]
Eid 2010b 3/168 0/84 2.0 % 3.52 [ 0.18, 67.38 ]
Langton Hewer 1995 1/11 0/12 1.5 % 3.25 [ 0.15, 72.36 ]
Lenney 2013 3/23 2/19 6.7 % 1.24 [ 0.23, 6.67 ]
Malone 2005 0/101 0/102 Not estimable
Morice 2008a 2/212 2/104 8.2 % 0.49 [ 0.07, 3.43 ]
Morice 2008b 0/203 1/103 6.1 % 0.17 [ 0.01, 4.14 ]
Murray 2011 0/113 0/118 Not estimable
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(. . . Continued)
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pearlman 2009 0/124 0/124 Not estimable
Pohunek 2006a 3/216 2/101 8.4 % 0.70 [ 0.12, 4.13 ]
Pohunek 2006b 5/201 1/100 4.1 % 2.49 [ 0.29, 21.01 ]
SD 039 0718 0/128 0/145 Not estimable
Verberne 1998a 3/60 4/56 12.7 % 0.70 [ 0.16, 2.99 ]
Subtotal (95% CI) 1744 1153 53.9 % 1.01 [ 0.53, 1.92 ]
Total events: 22 (LABA + ICS), 13 (ICS alone)
Heterogeneity: Chi2 = 4.11, df = 8 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
2 Mean baseline FEV1 61%-79% of predicted
Russell 1995 10/99 13/107 38.3 % 0.83 [ 0.38, 1.81 ]
SD 039 0714 1/136 1/134 3.1 % 0.99 [ 0.06, 15.59 ]
Tal 2002 7/148 0/138 1.6 % 13.99 [ 0.81, 242.73 ]
Subtotal (95% CI) 383 379 43.0 % 1.33 [ 0.68, 2.59 ]
Total events: 18 (LABA + ICS), 14 (ICS alone)
Heterogeneity: Chi2 = 4.05, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.83 (P = 0.41)
3 Mean baseline FEV1 not reported
SAM40012a 2/181 1/181 3.1 % 2.00 [ 0.18, 21.86 ]
Subtotal (95% CI) 181 181 3.1 % 2.00 [ 0.18, 21.86 ]
Total events: 2 (LABA + ICS), 1 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 2308 1713 100.0 % 1.17 [ 0.75, 1.85 ]
Total events: 42 (LABA + ICS), 28 (ICS alone)
Heterogeneity: Chi2 = 8.32, df = 12 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 0.54, df = 2 (P = 0.76), I2 =0.0%
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Analysis 1.5. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 5
Total # withdrawals.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 5 Total # withdrawals
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 12/124 10/63 5.2 % 0.61 [ 0.28, 1.33 ]
Carroll 2010 0/21 2/16 1.1 % 0.15 [ 0.01, 3.01 ]
Eid 2010a 37/168 16/85 8.3 % 1.17 [ 0.69, 1.98 ]
Eid 2010b 21/184 16/84 8.6 % 0.60 [ 0.33, 1.09 ]
Langton Hewer 1995 0/11 2/12 0.9 % 0.22 [ 0.01, 4.07 ]
Lenney 2013 6/23 3/19 1.3 % 1.65 [ 0.48, 5.74 ]
Malone 2005 19/101 16/102 6.2 % 1.20 [ 0.65, 2.20 ]
Meijer 1995 0/20 1/20 0.6 % 0.33 [ 0.01, 7.72 ]
Morice 2008a 2/212 5/104 2.6 % 0.20 [ 0.04, 0.99 ]
Morice 2008b 4/203 4/103 2.1 % 0.51 [ 0.13, 1.99 ]
Murray 2011 7/113 10/118 3.8 % 0.73 [ 0.29, 1.85 ]
Pearlman 2009 13/124 22/124 8.6 % 0.59 [ 0.31, 1.12 ]
Pohunek 2006a 14/216 6/106 3.1 % 1.15 [ 0.45, 2.90 ]
Pohunek 2006b 11/201 7/107 3.6 % 0.84 [ 0.33, 2.10 ]
SD 039 0718 36/128 51/145 18.6 % 0.80 [ 0.56, 1.14 ]
Simons 1997 0/16 2/16 1.0 % 0.20 [ 0.01, 3.86 ]
Verberne 1998a 5/60 4/56 1.6 % 1.17 [ 0.33, 4.13 ]
Subtotal (95% CI) 1925 1280 77.1 % 0.79 [ 0.66, 0.96 ]
Total events: 187 (LABA + ICS), 177 (ICS alone)
Heterogeneity: Chi2 = 14.63, df = 16 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.015)
2 Mean baseline FEV1 61%-79% of predicted
Russell 1995 22/99 18/107 6.7 % 1.32 [ 0.75, 2.31 ]
Tal 2002 9/148 9/138 3.6 % 0.93 [ 0.38, 2.28 ]
Zimmerman 2004a 7/106 8/51 4.2 % 0.42 [ 0.16, 1.10 ]
Zimmerman 2004b 11/95 8/50 4.1 % 0.72 [ 0.31, 1.68 ]
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Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 448 346 18.7 % 0.91 [ 0.63, 1.32 ]
Total events: 49 (LABA + ICS), 43 (ICS alone)
Heterogeneity: Chi2 = 4.48, df = 3 (P = 0.21); I2 =33%
Test for overall effect: Z = 0.49 (P = 0.63)
3 Mean baseline FEV1 not reported
SAM40012a 3/176 10/175 3.9 % 0.30 [ 0.08, 1.07 ]
SAM40100 1/12 1/12 0.4 % 1.00 [ 0.07, 14.21 ]
Subtotal (95% CI) 188 187 4.3 % 0.36 [ 0.12, 1.11 ]
Total events: 4 (LABA + ICS), 11 (ICS alone)
Heterogeneity: Chi2 = 0.65, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
Total (95% CI) 2561 1813 100.0 % 0.80 [ 0.67, 0.94 ]
Total events: 240 (LABA + ICS), 231 (ICS alone)
Heterogeneity: Chi2 = 21.95, df = 22 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0071)
Test for subgroup differences: Chi2 = 2.40, df = 2 (P = 0.30), I2 =17%
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Analysis 1.6. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 6 #
withdrawals due to poor asthma control or exacerbation.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 6 # withdrawals due to poor asthma control or exacerbation
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Langton Hewer 1995 0/11 0/12 Not estimable
Malone 2005 3/101 5/102 8.5 % 0.61 [ 0.15, 2.47 ]
Verberne 1998a 0/60 1/56 2.6 % 0.31 [ 0.01, 7.49 ]
Carroll 2010 1/21 0/16 1.0 % 2.32 [ 0.10, 53.42 ]
Lenney 2013 0/23 1/19 2.8 % 0.28 [ 0.01, 6.45 ]
Pearlman 2009 2/124 2/124 3.4 % 1.00 [ 0.14, 6.99 ]
Stelmach 2008 2/20 0/20 0.9 % 5.00 [ 0.26, 98.00 ]
Murray 2011 2/113 1/118 1.7 % 2.09 [ 0.19, 22.71 ]
Eid 2010a 13/184 13/85 30.3 % 0.46 [ 0.22, 0.95 ]
Eid 2010b 28/168 13/84 29.5 % 1.08 [ 0.59, 1.97 ]
Subtotal (95% CI) 825 636 80.5 % 0.82 [ 0.55, 1.21 ]
Total events: 51 (LABA + ICS), 36 (ICS alone)
Heterogeneity: Chi2 = 6.65, df = 8 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
2 Mean baseline FEV1 61%-79% of predicted
Tal 2002 5/148 6/138 10.6 % 0.78 [ 0.24, 2.49 ]
Zimmerman 2004a 0/106 1/51 3.4 % 0.16 [ 0.01, 3.91 ]
Zimmerman 2004b 1/95 1/50 2.2 % 0.53 [ 0.03, 8.24 ]
Russell 1995 3/99 2/107 3.3 % 1.62 [ 0.28, 9.50 ]
Subtotal (95% CI) 448 346 19.5 % 0.78 [ 0.34, 1.81 ]
Total events: 9 (LABA + ICS), 10 (ICS alone)
Heterogeneity: Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 1273 982 100.0 % 0.81 [ 0.57, 1.16 ]
Total events: 60 (LABA + ICS), 46 (ICS alone)
Heterogeneity: Chi2 = 8.31, df = 12 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.92), I2 =0.0%
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Analysis 1.7. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 7 #
withdrawals due to adverse events.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 7 # withdrawals due to adverse events
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010b 4/168 1/85 2.8 % 2.02 [ 0.23, 17.83 ]
Eid 2010a 3/184 0/84 1.4 % 3.22 [ 0.17, 61.57 ]
SD 039 0718 4/128 10/145 19.7 % 0.45 [ 0.15, 1.41 ]
Morice 2008a 1/212 4/104 11.3 % 0.12 [ 0.01, 1.08 ]
Morice 2008b 3/203 3/103 8.4 % 0.51 [ 0.10, 2.47 ]
Langton Hewer 1995 0/11 0/11 Not estimable
Pohunek 2006b 2/201 1/107 2.7 % 1.06 [ 0.10, 11.61 ]
Verberne 1998a 2/60 0/56 1.1 % 4.67 [ 0.23, 95.24 ]
Pohunek 2006a 0/216 1/106 4.2 % 0.16 [ 0.01, 4.00 ]
Malone 2005 3/101 0/102 1.0 % 7.07 [ 0.37, 135.12 ]
Berger 2010 3/124 2/63 5.6 % 0.76 [ 0.13, 4.44 ]
Pearlman 2009 2/124 7/124 14.7 % 0.29 [ 0.06, 1.35 ]
Murray 2011 1/113 1/118 2.1 % 1.04 [ 0.07, 16.50 ]
Subtotal (95% CI) 1845 1208 75.1 % 0.69 [ 0.42, 1.13 ]
Total events: 28 (LABA + ICS), 30 (ICS alone)
Heterogeneity: Chi2 = 11.24, df = 11 (P = 0.42); I2 =2%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Mean baseline FEV1 61%-79% of predicted
SD 039 0714 4/136 8/134 17.0 % 0.49 [ 0.15, 1.60 ]
Tal 2002 2/148 0/138 1.1 % 4.66 [ 0.23, 96.30 ]
Zimmerman 2004b 1/95 0/50 1.4 % 1.59 [ 0.07, 38.42 ]
Zimmerman 2004a 2/106 0/51 1.4 % 2.43 [ 0.12, 49.70 ]
Russell 1995 4/99 2/107 4.0 % 2.16 [ 0.40, 11.54 ]
Subtotal (95% CI) 584 480 24.9 % 1.12 [ 0.51, 2.44 ]
Total events: 13 (LABA + ICS), 10 (ICS alone)
Heterogeneity: Chi2 = 3.62, df = 4 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
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Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total (95% CI) 2429 1688 100.0 % 0.79 [ 0.52, 1.21 ]
Total events: 41 (LABA + ICS), 40 (ICS alone)
Heterogeneity: Chi2 = 15.81, df = 16 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Chi2 = 1.06, df = 1 (P = 0.30), I2 =6%
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Analysis 1.8. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 8 #
withdrawals due to serious non-respiratory event.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 8 # withdrawals due to serious non-respiratory event








1 Mean baseline FEV1 61%-79% of predicted
Akpinarli 1999 0/16 0/16 Not estimable
Tal 2002 2/148 0/138 100.0 % 4.66 [ 0.23, 96.30 ]
Total (95% CI) 164 154 100.0 % 4.66 [ 0.23, 96.30 ]
Total events: 2 (Favours LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 9
Change in FEV1 (L) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 9 Change in FEV1 (L) at endpoint
Study or subgroup LABA + ICS ICS alone Litres (SE) Litres Weight Litres
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 123 63 0.08 (0.03) 14.3 % 0.08 [ 0.02, 0.14 ]
Eid 2010a 184 85 0.07 (0.0255) 19.8 % 0.07 [ 0.02, 0.12 ]
Eid 2010b 168 84 0.08 (0.0255) 19.8 % 0.08 [ 0.03, 0.13 ]
Langton Hewer 1995 11 10 0.42 (0.107) 1.1 % 0.42 [ 0.21, 0.63 ]
Malone 2005 79 81 0.06 (0.0408) 7.7 % 0.06 [ -0.02, 0.14 ]
Pohunek 2006a 213 106 0.07 (0.0306) 13.7 % 0.07 [ 0.01, 0.13 ]
Pohunek 2006b 201 107 0.07 (0.0306) 13.7 % 0.07 [ 0.01, 0.13 ]
Subtotal (95% CI) 979 536 90.2 % 0.08 [ 0.05, 0.10 ]
Heterogeneity: Chi2 = 10.65, df = 6 (P = 0.10); I2 =44%
Test for overall effect: Z = 6.47 (P < 0.00001)
2 Mean baseline FEV1 61%-79% of predicted
Russell 1995 76 87 0.09 (0.061) 3.5 % 0.09 [ -0.03, 0.21 ]
SD 039 0714 133 131 0.13 (0.045) 6.4 % 0.13 [ 0.04, 0.22 ]
Subtotal (95% CI) 209 218 9.8 % 0.12 [ 0.04, 0.19 ]
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 3.20 (P = 0.0014)
Total (95% CI) 1188 754 100.0 % 0.08 [ 0.06, 0.10 ]
Heterogeneity: Chi2 = 11.96, df = 8 (P = 0.15); I2 =33%
Test for overall effect: Z = 7.15 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.03, df = 1 (P = 0.31), I2 =3%
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Analysis 1.10. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 10
Change in FEV1 at endpoint (% predicted) stratifying on baseline FEV1.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 10 Change in FEV1 at endpoint (% predicted) stratifying on baseline FEV1





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Verberne 1998a 60 4.36 (10.53) 57 1.28 (9.13) 35.4 % 3.08 [ -0.49, 6.65 ]
Carroll 2010 21 6.4 (9.6) 16 1.2 (9.6) 11.6 % 5.20 [ -1.04, 11.44 ]
Lenney 2013 13 15.54 (19.77) 8 0.12 (12.74) 2.3 % 15.42 [ 1.51, 29.33 ]
Meijer 1995 20 5.8 (11.6) 19 2.2 (9.15) 10.5 % 3.60 [ -2.94, 10.14 ]
Subtotal (95% CI) 114 100 59.8 % 4.06 [ 1.32, 6.80 ]
Heterogeneity: Chi2 = 3.00, df = 3 (P = 0.39); I2 =0%
Test for overall effect: Z = 2.90 (P = 0.0037)
2 Mean baseline FEV1 61%-79% of predicted
Akpinarli 1999 16 3 (42.84) 16 1 (31.64) 0.7 % 2.00 [ -24.10, 28.10 ]
Russell 1995 99 5.2 (20) 107 1.8 (15.7) 18.5 % 3.40 [ -1.54, 8.34 ]
Subtotal (95% CI) 115 123 19.1 % 3.35 [ -1.50, 8.20 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
3 Mean baseline FEV1 not reported
Teper 2005 43 6.9 (13) 39 7.3 (8) 21.0 % -0.40 [ -5.03, 4.23 ]
Subtotal (95% CI) 43 39 21.0 % -0.40 [ -5.03, 4.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
Total (95% CI) 272 262 100.0 % 2.99 [ 0.86, 5.11 ]
Heterogeneity: Chi2 = 5.68, df = 6 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0058)
Test for subgroup differences: Chi2 = 2.67, df = 2 (P = 0.26), I2 =25%
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Analysis 1.11. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 11
% fall in FEV1 % predicted due to exercise.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 11 % fall in FEV1 % predicted due to exercise





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Pearlman 2009 124 -9.5 (9.24) 124 -12.7 (11.8) 30.7 % 3.20 [ 0.56, 5.84 ]
Murray 2011 113 -9.9 (10.7) 118 -11.1 (11.1) 27.1 % 1.20 [ -1.61, 4.01 ]
Stelmach 2008 18 -18.9 (2.75) 20 -16.9 (4.24) 42.2 % -2.00 [ -4.25, 0.25 ]
Total (95% CI) 255 262 100.0 % 0.46 [ -1.00, 1.93 ]
Heterogeneity: Chi2 = 9.00, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 12
Change in morning PEF (L/min) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 12 Change in morning PEF (L/min) at endpoint
Study or subgroup ICS + LABA ICS alone L/min (SE) L/min Weight L/min
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010a 184 85 12.25 (3.3571) 9.8 % 12.25 [ 5.67, 18.83 ]
Eid 2010b 168 84 8.95 (3.6122) 8.5 % 8.95 [ 1.87, 16.03 ]
Langton Hewer 1995 11 10 61 (24.8) 0.2 % 61.00 [ 12.39, 109.61 ]
Malone 2005 101 102 4.6 (4) 6.9 % 4.60 [ -3.24, 12.44 ]
Morice 2008a 212 104 10.3 (3.3418) 9.9 % 10.30 [ 3.75, 16.85 ]
Morice 2008b 207 103 9.5 (3.3163) 10.0 % 9.50 [ 3.00, 16.00 ]
Murray 2011 231 0 9.5 (6) 3.1 % 9.50 [ -2.26, 21.26 ]
Pearlman 2009 248 0 7.2 (4.9) 4.6 % 7.20 [ -2.40, 16.80 ]
Pohunek 2006a 216 106 10.9 (4.0408) 6.8 % 10.90 [ 2.98, 18.82 ]
Pohunek 2006b 201 107 15 (4.408) 5.7 % 15.00 [ 6.36, 23.64 ]
SD 039 0718 128 145 15.61 (3.663) 8.2 % 15.61 [ 8.43, 22.79 ]
Verberne 1998a 60 57 15.03 (7.158) 2.2 % 15.03 [ 1.00, 29.06 ]
Subtotal (95% CI) 1967 903 75.8 % 10.79 [ 8.43, 13.16 ]
Heterogeneity: Chi2 = 10.69, df = 11 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 8.94 (P < 0.00001)
2 Mean baseline FEV1 61%-79% of predicted
Russell 1995 75 88 8.5 (6.16) 2.9 % 8.50 [ -3.57, 20.57 ]
SD 039 0714 133 131 4.8 (4.49) 5.5 % 4.80 [ -4.00, 13.60 ]
Tal 2002 148 138 12 (3.37) 9.7 % 12.00 [ 5.39, 18.61 ]
Subtotal (95% CI) 356 357 18.1 % 9.26 [ 4.42, 14.10 ]
Heterogeneity: Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00018)
3 Mean baseline FEV1 not reported
SAM40012a 176 175 5.7 (4.244) 6.1 % 5.70 [ -2.62, 14.02 ]
Subtotal (95% CI) 176 175 6.1 % 5.70 [ -2.62, 14.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
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Study or subgroup ICS + LABA ICS alone L/min (SE) L/min Weight L/min
N N IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 2499 1435 100.0 % 10.20 [ 8.14, 12.26 ]
Heterogeneity: Chi2 = 13.87, df = 15 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 9.71 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.51, df = 2 (P = 0.47), I2 =0.0%
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Analysis 1.13. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 13
Change in morning PEF (% predicted).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 13 Change in morning PEF (% predicted)
Study or subgroup LABA + ICS ICS alone % (SE) % %
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 61%-79% of predicted
Tal 2002 148 138 3.77 (0.9846) 3.77 [ 1.84, 5.70 ]
-10 -5 0 5 10
Favours treatment Favours control
127Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.14. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 14
Change in evening PEF (L/min) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 14 Change in evening PEF (L/min) at endpoint
Study or subgroup LABA + ICS ICS alone L/min (SE) L/min Weight L/min
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010b 168 84 6.29 (4.2296) 8.0 % 6.29 [ -2.00, 14.58 ]
Eid 2010a 183 84 12.53 (4.1888) 8.2 % 12.53 [ 4.32, 20.74 ]
Morice 2008a 212 104 8.7 (3.376) 12.6 % 8.70 [ 2.08, 15.32 ]
Morice 2008b 207 103 6.4 (3.376) 12.6 % 6.40 [ -0.22, 13.02 ]
Langton Hewer 1995 11 10 90 (25.6) 0.2 % 90.00 [ 39.82, 140.18 ]
SD 039 0718 128 145 15.61 (4.6327) 6.7 % 15.61 [ 6.53, 24.69 ]
Pohunek 2006a 216 106 9.2 (4.3673) 7.5 % 9.20 [ 0.64, 17.76 ]
Malone 2005 101 102 6.4 (3.69) 10.5 % 6.40 [ -0.83, 13.63 ]
Pohunek 2006b 201 107 12 (4.3673) 7.5 % 12.00 [ 3.44, 20.56 ]
Murray 2011 113 118 8.1 (5.1) 5.5 % 8.10 [ -1.90, 18.10 ]
Subtotal (95% CI) 1540 963 79.2 % 9.31 [ 6.67, 11.94 ]
Heterogeneity: Chi2 = 14.72, df = 9 (P = 0.10); I2 =39%
Test for overall effect: Z = 6.92 (P < 0.00001)
2 Mean baseline FEV1 61%-79% of predicted
Tal 2002 148 138 11.7 (3.27) 13.4 % 11.70 [ 5.29, 18.11 ]
Subtotal (95% CI) 148 138 13.4 % 11.70 [ 5.29, 18.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.58 (P = 0.00035)
3 Mean baseline FEV1 not reported
SAM40012a 176 175 5 (4.38) 7.5 % 5.00 [ -3.58, 13.58 ]
Subtotal (95% CI) 176 175 7.5 % 5.00 [ -3.58, 13.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI) 1864 1276 100.0 % 9.30 [ 6.96, 11.65 ]
Heterogeneity: Chi2 = 16.22, df = 11 (P = 0.13); I2 =32%
Test for overall effect: Z = 7.78 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.50, df = 2 (P = 0.47), I2 =0.0%
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Analysis 1.15. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 15
Change in evening PEF (% of predicted).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 15 Change in evening PEF (% of predicted)
Study or subgroup LABA + ICS ICS alone % (SE) % %
N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 61%-79% of predicted
Tal 2002 148 138 3.4 (0.9498) 3.40 [ 1.54, 5.26 ]
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Analysis 1.16. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 16
Change in clinic PEF (L/min).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 16 Change in clinic PEF (L/min)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 not reported
SAM40012a 176 52.7 (53.07) 175 46.2 (54.2) 6.50 [ -4.72, 17.72 ]
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Analysis 1.17. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 17
Change in PEF variability at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 17 Change in PEF variability at endpoint





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 61%-79% of predicted
Russell 1995 75 -4.64 (9.01) 88 -3.35 (7.15) -1.29 [ -3.82, 1.24 ]
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Analysis 1.18. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 18
Mean change in asthma symptom score.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 18 Mean change in asthma symptom score







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Pohunek 2006a 216 -0.07 (0.61) 106 -0.06 (0.61) 18.8 % -0.02 [ -0.25, 0.22 ]
Pohunek 2006b 201 -0.07 (0.61) 107 -0.06 (0.61) 18.5 % -0.02 [ -0.25, 0.22 ]
Tal 2002 148 0.45 (0.52) 138 0.48 (0.52) 18.9 % -0.06 [ -0.29, 0.17 ]
Malone 2005 101 -0.6 (1) 102 -0.5 (1.2) 13.4 % -0.09 [ -0.37, 0.19 ]
Eid 2010a 183 0.03 (0.26) 84 0.06 (0.28) 15.2 % -0.11 [ -0.37, 0.15 ]
Eid 2010b 183 0.03 (0.21) 84 0.06 (0.28) 15.2 % -0.13 [ -0.39, 0.13 ]
Total (95% CI) 1032 621 100.0 % -0.07 [ -0.17, 0.04 ]
Heterogeneity: Chi2 = 0.72, df = 5 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 19
Change in nighttime symptom score.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 19 Change in nighttime symptom score





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010a 183 0.03 (0.24) 84 0.05 (0.26) 46.7 % -0.02 [ -0.09, 0.05 ]
Eid 2010b 183 0.02 (0.18) 84 0.05 (0.26) 53.3 % -0.03 [ -0.09, 0.03 ]
Total (95% CI) 366 168 100.0 % -0.03 [ -0.07, 0.02 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 20
Change in % symptom-free days at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 20 Change in % symptom-free days at endpoint





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010a 168 -0.2 (24.6) 84 -3.7 (27.3) 17.3 % 3.50 [ -3.42, 10.42 ]
Eid 2010b 183 -0.9 (21.3) 84 -3.7 (27.3) 19.0 % 2.80 [ -3.80, 9.40 ]
Malone 2005 101 24.4 (41) 102 21.2 (41) 6.5 % 3.20 [ -8.08, 14.48 ]
Murray 2011 113 10.9 (33.9) 118 18.8 (44.6) 8.0 % -7.90 [ -18.09, 2.29 ]
Pearlman 2009 124 11.5 (32.3) 124 12.2 (31.2) 13.3 % -0.70 [ -8.60, 7.20 ]
Pohunek 2006a 216 33 (29.08) 106 32 (29.08) 18.1 % 1.00 [ -5.76, 7.76 ]
Pohunek 2006b 201 32.9 (29.08) 107 32 (29.08) 17.8 % 0.90 [ -5.92, 7.72 ]
Total (95% CI) 1106 725 100.0 % 0.96 [ -1.91, 3.84 ]
Heterogeneity: Chi2 = 4.04, df = 6 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 1.21. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 21
% symptom-free days.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 21 % symptom-free days







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Murray 2011 113 27.2 (41.4) 118 36.2 (43.5) 38.5 % -0.21 [ -0.47, 0.05 ]
Subtotal (95% CI) 113 118 38.5 % -0.21 [ -0.47, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
2 Mean baseline FEV1 61%-79% of predicted
Tal 2002 148 77.5 (20) 138 75.1 (20) 47.8 % 0.12 [ -0.11, 0.35 ]
Subtotal (95% CI) 148 138 47.8 % 0.12 [ -0.11, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
3 Unclear baseline FEV1
SAM40100 12 0 (0) 12 0 (0) Not estimable
Teper 2005 43 92 (9) 39 93 (7) 13.7 % -0.12 [ -0.56, 0.31 ]
Subtotal (95% CI) 55 51 13.7 % -0.12 [ -0.56, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 316 307 100.0 % -0.04 [ -0.20, 0.12 ]
Heterogeneity: Chi2 = 3.64, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Chi2 = 3.64, df = 2 (P = 0.16), I2 =45%
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Analysis 1.22. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 22
% symptom-free nights at 52 ± 4 weeks.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 22 % symptom-free nights at 52 4 weeks





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 not reported
Teper 2005 43 95 (6) 39 95 (5) 0.0 [ -2.38, 2.38 ]
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Analysis 1.23. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 23
Change in # daytime rescue inhalations (puffs per day) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 23 Change in # daytime rescue inhalations (puffs per day) at endpoint





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 61%-79% of predicted
Malone 2005 101 -0.5 (2.21) 102 -0.4 (1.92) 0.7 % -0.10 [ -0.67, 0.47 ]
Pohunek 2006a 216 -0.59 (0.53) 106 -0.46 (0.53) 14.9 % -0.13 [ -0.25, -0.01 ]
Tal 2002 148 -0.11 (0.7) 138 -0.09 (0.7) 8.6 % -0.02 [ -0.18, 0.14 ]
Pohunek 2006b 201 -0.47 (0.53) 107 -0.46 (0.53) 14.7 % -0.01 [ -0.13, 0.11 ]
Eid 2010a 168 0.08 (0.43) 85 0.1 (0.31) 26.4 % -0.02 [ -0.11, 0.07 ]
Eid 2010b 183 0 (0.33) 84 0.1 (0.31) 33.9 % -0.10 [ -0.18, -0.02 ]
Russell 1995 73 -0.75 (1.78) 86 -0.38 (1.73) 0.8 % -0.37 [ -0.92, 0.18 ]
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(. . . Continued)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 1090 708 100.0 % -0.07 [ -0.11, -0.02 ]
Heterogeneity: Chi2 = 4.93, df = 6 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0072)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 24
Change in # nighttime rescue inhalations at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 24 Change in # nighttime rescue inhalations at endpoint





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean baseline FEV1 61%-79% of predicted
Eid 2010a 168 0.02 (0.3) 84 0.07 (0.29) 48.3 % -0.05 [ -0.13, 0.03 ]
Eid 2010b 183 -0.01 (0.26) 84 0.1 (0.31) 49.0 % -0.11 [ -0.19, -0.03 ]
Russell 1995 70 -0.15 (1.05) 83 -0.11 (0.97) 2.7 % -0.04 [ -0.36, 0.28 ]
Total (95% CI) 421 251 100.0 % -0.08 [ -0.13, -0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.24, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0037)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 25
% days without bronchodilator usage.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 25 % days without bronchodilator usage





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Pohunek 2006a 216 79.4 (20.94) 106 78.2 (20.94) 15.2 % 1.20 [ -3.67, 6.07 ]
Pohunek 2006b 201 77 (20.94) 107 78.2 (20.94) 15.1 % -1.20 [ -6.11, 3.71 ]
Eid 2010a 168 0.3 (0.02) 84 -5.4 (17.5) 18.0 % 5.70 [ 1.96, 9.44 ]
Eid 2010b 183 1.6 (18.6) 84 -5.4 (17.5) 15.8 % 7.00 [ 2.39, 11.61 ]
Pearlman 2009 124 13.2 (31.2) 124 8.3 (26.7) 10.5 % 4.90 [ -2.33, 12.13 ]
Murray 2011 113 53.4 (45) 118 60 (42.5) 5.7 % -6.60 [ -17.90, 4.70 ]
Subtotal (95% CI) 1005 623 80.3 % 2.87 [ -0.44, 6.18 ]
Heterogeneity: Tau2 = 8.85; Chi2 = 11.12, df = 5 (P = 0.05); I2 =55%
Test for overall effect: Z = 1.70 (P = 0.090)
2 Mean baseline FEV1 not reported
Teper 2005 43 92 (8) 39 93 (6) 19.7 % -1.00 [ -4.04, 2.04 ]
Subtotal (95% CI) 43 39 19.7 % -1.00 [ -4.04, 2.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 1048 662 100.0 % 2.07 [ -1.03, 5.16 ]
Heterogeneity: Tau2 = 10.24; Chi2 = 16.58, df = 6 (P = 0.01); I2 =64%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 2.84, df = 1 (P = 0.09), I2 =65%
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Analysis 1.26. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 26
Change in nighttime awakening (number of nights) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 26 Change in nighttime awakening (number of nights) at endpoint





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 61%-79% of predicted
Tal 2002 148 -1.7 (10.4) 138 -1.9 (10.4) 0.20 [ -2.21, 2.61 ]
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Analysis 1.27. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 27
% nights with awakening.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 27 % nights with awakening





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 61%-79% of predicted
Tal 2002 148 5.5 (10.4) 138 6.6 (10.4) -1.10 [ -3.51, 1.31 ]
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Analysis 1.28. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 28
% change in awakening-free nights.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 28 % change in awakening-free nights





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010a 168 -2.4 (8.9) 84 -2.7 (9) 49.5 % 0.30 [ -2.05, 2.65 ]
Eid 2010b 183 -1.8 (9) 84 -2.7 (9) 50.5 % 0.90 [ -1.42, 3.22 ]
Total (95% CI) 351 168 100.0 % 0.60 [ -1.05, 2.26 ]
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 29
Change in rescue-free days (%).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 29 Change in rescue-free days (%)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Murray 2011 113 16.9 (34.3) 118 19.1 (42.6) -2.20 [ -12.15, 7.75 ]
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Analysis 1.30. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 30
Change in % asthma-control days at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 30 Change in % asthma-control days at endpoint





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Eid 2010a 168 -3.9 (23.8) 84 -8 (27.6) 49.4 % 4.10 [ -2.81, 11.01 ]
Eid 2010b 183 -3.5 (23.7) 84 -8 (27.6) 50.6 % 4.50 [ -2.33, 11.33 ]
Total (95% CI) 351 168 100.0 % 4.30 [ -0.56, 9.16 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.74 (P = 0.083)
Test for subgroup differences: Not applicable
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Analysis 1.31. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 31
Change in quality of life (P-AQLQ).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 31 Change in quality of life (P-AQLQ)









units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 108 0.53 (0.83) 55 0.36 (0.97) 16.7 % 0.17 [ -0.13, 0.47 ]
Eid 2010a 151 -0.08 (0.78) 78 -0.03 (0.64) 42.3 % -0.05 [ -0.24, 0.14 ]
Eid 2010b 173 -0.09 (0.9) 78 -0.03 (0.64) 39.5 % -0.06 [ -0.26, 0.14 ]
Lenney 2013 15 1.1 (1.86) 10 1.29 (0.61) 1.5 % -0.19 [ -1.20, 0.82 ]
Total (95% CI) 447 221 100.0 % -0.02 [ -0.14, 0.10 ]
Heterogeneity: Chi2 = 1.90, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
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Analysis 1.32. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 32
Quality of life (P-AQLQ).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 32 Quality of life (P-AQLQ)









units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 108 6.56 (0.5) 55 6.2 (0.92) 7.8 % 0.36 [ 0.10, 0.62 ]
Morice 2008a 185 6.16 (0.87) 91 5.99 (0.94) 10.0 % 0.17 [ -0.06, 0.40 ]
Morice 2008b 172 6.01 (0.95) 90 5.99 (0.94) 9.2 % 0.02 [ -0.22, 0.26 ]
Pohunek 2006a 216 6.2 (0.68) 106 6.2 (0.68) 21.3 % 0.0 [ -0.16, 0.16 ]
Pohunek 2006b 213 6.2 (0.68) 107 6.2 (0.68) 21.3 % 0.0 [ -0.16, 0.16 ]
SD 039 0718 114 6.09 (0.87) 129 5.96 (1.03) 9.3 % 0.13 [ -0.11, 0.37 ]
Subtotal (95% CI) 1008 578 79.0 % 0.07 [ -0.01, 0.16 ]
Heterogeneity: Chi2 = 7.38, df = 5 (P = 0.19); I2 =32%
Test for overall effect: Z = 1.79 (P = 0.074)
2 Mean baseline FEV1 61%-79% of predicted
Eid 2010a 173 6.33 (1) 78 6.42 (0.76) 10.5 % -0.09 [ -0.32, 0.14 ]
Eid 2010b 151 6.26 (0.94) 78 6.42 (0.76) 10.5 % -0.16 [ -0.39, 0.07 ]
Zimmerman 2004a 99 5.8 (0) 43 5.76 (0) Not estimable
Zimmerman 2004b 83 5.72 (0) 42 5.76 (0) Not estimable
Subtotal (95% CI) 506 241 21.0 % -0.12 [ -0.28, 0.03 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 1514 819 100.0 % 0.03 [ -0.04, 0.11 ]
Heterogeneity: Chi2 = 12.34, df = 7 (P = 0.09); I2 =43%
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 4.77, df = 1 (P = 0.03), I2 =79%
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Analysis 1.33. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 33
Change in paediatric asthma caregiver quality of life (P-AQLQ).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 33 Change in paediatric asthma caregiver quality of life (P-AQLQ)









units] IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 108 0.39 (0.83) 55 0.17 (0.69) 23.9 % 0.22 [ -0.02, 0.46 ]
Eid 2010a 151 -0.11 (0.84) 78 -0.15 (0.7) 32.8 % 0.04 [ -0.17, 0.25 ]
Eid 2010b 173 -0.15 (0.64) 78 -0.15 (0.7) 41.6 % 0.0 [ -0.18, 0.18 ]
Lenney 2013 15 1.34 (1.25) 11 1.34 (1.07) 1.7 % 0.0 [ -0.89, 0.89 ]
Total (95% CI) 447 222 100.0 % 0.07 [ -0.05, 0.18 ]
Heterogeneity: Chi2 = 2.16, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.34. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 34
Total # adverse events.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 34 Total # adverse events
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 104/123 54/63 8.4 % 0.99 [ 0.87, 1.12 ]
Eid 2010a 120/184 50/84 8.0 % 1.10 [ 0.89, 1.35 ]
Eid 2010b 104/168 50/85 7.8 % 1.05 [ 0.85, 1.30 ]
Langton Hewer 1995 10/11 9/12 1.0 % 1.21 [ 0.83, 1.77 ]
Malone 2005 60/101 58/102 6.8 % 1.04 [ 0.83, 1.32 ]
Morice 2008a 100/212 41/104 6.4 % 1.20 [ 0.91, 1.58 ]
Morice 2008b 92/203 40/103 6.2 % 1.17 [ 0.88, 1.55 ]
Murray 2011 20/113 25/118 2.9 % 0.84 [ 0.49, 1.42 ]
Pearlman 2009 37/124 35/124 4.1 % 1.06 [ 0.72, 1.56 ]
SD 039 0718 90/128 92/145 10.1 % 1.11 [ 0.94, 1.31 ]
Verberne 1998a 59/60 52/57 6.2 % 1.08 [ 0.99, 1.18 ]
Subtotal (95% CI) 1427 997 67.9 % 1.08 [ 1.00, 1.16 ]
Total events: 796 (LABA + ICS), 506 (ICS alone)
Heterogeneity: Chi2 = 4.25, df = 10 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
2 Mean baseline FEV1 61%-79% of predicted
Russell 1995 84/99 94/105 10.7 % 0.95 [ 0.85, 1.05 ]
SD 039 0714 66/136 65/134 7.7 % 1.00 [ 0.78, 1.28 ]
Subtotal (95% CI) 235 239 18.4 % 0.97 [ 0.86, 1.09 ]
Total events: 150 (LABA + ICS), 159 (ICS alone)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
3 Mean baseline FEV1 not reported
SAM40012a 99/181 111/181 13.0 % 0.89 [ 0.75, 1.06 ]
SAM40100 9/12 6/12 0.7 % 1.50 [ 0.78, 2.88 ]
Subtotal (95% CI) 193 193 13.7 % 0.92 [ 0.78, 1.09 ]
Total events: 108 (LABA + ICS), 117 (ICS alone)
Heterogeneity: Chi2 = 2.27, df = 1 (P = 0.13); I2 =56%
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(. . . Continued)
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 1855 1429 100.0 % 1.04 [ 0.98, 1.10 ]
Total events: 1054 (LABA + ICS), 782 (ICS alone)
Heterogeneity: Chi2 = 12.14, df = 14 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Chi2 = 4.05, df = 2 (P = 0.13), I2 =51%
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Analysis 1.35. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 35
# participants with oral candidiasis.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 35 # participants with oral candidiasis
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 FEV1 ≥ 80% of predicted
Pohunek 2006b 0/201 0/107 Not estimable
Verberne 1998a 0/60 0/56 Not estimable
Pohunek 2006a 0/216 0/106 Not estimable
Malone 2005 4/101 1/102 46.6 % 4.04 [ 0.46, 35.52 ]
Berger 2010 2/123 0/63 30.9 % 2.58 [ 0.13, 52.95 ]
Subtotal (95% CI) 701 434 77.5 % 3.46 [ 0.60, 19.99 ]
Total events: 6 (LABA + ICS), 1 (ICS alone)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
2 Mean baseline FEV1 61%-79% of predicted
Russell 1995 1/99 0/107 22.5 % 3.24 [ 0.13, 78.62 ]
Subtotal (95% CI) 99 107 22.5 % 3.24 [ 0.13, 78.62 ]
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(. . . Continued)
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 800 541 100.0 % 3.41 [ 0.73, 15.87 ]
Total events: 7 (LABA + ICS), 1 (ICS alone)
Heterogeneity: Chi2 = 0.06, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
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Analysis 1.36. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 36
# participants with tremor.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 36 # participants with tremor
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Pohunek 2006a 0/216 0/213 Not estimable
Pohunek 2006b 2/201 0/213 41.9 % 5.30 [ 0.26, 109.66 ]
Verberne 1998a 0/60 0/56 Not estimable
Subtotal (95% CI) 477 482 41.9 % 5.30 [ 0.26, 109.66 ]
Total events: 2 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Mean baseline FEV1 61%-79% of predicted
Russell 1995 0/99 0/107 Not estimable
Zimmerman 2004a 1/106 0/51 58.1 % 1.46 [ 0.06, 35.18 ]
Zimmerman 2004b 0/95 0/50 Not estimable
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(. . . Continued)
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 300 208 58.1 % 1.46 [ 0.06, 35.18 ]
Total events: 1 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 777 690 100.0 % 3.07 [ 0.38, 25.05 ]
Total events: 3 (LABA + ICS), 0 (ICS alone)
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.30)
Test for subgroup differences: Chi2 = 0.33, df = 1 (P = 0.57), I2 =0.0%
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Analysis 1.37. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 37
# participants with tachycardia or palpitations.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 37 # participants with tachycardia or palpitations
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 1/123 1/63 31.6 % 0.51 [ 0.03, 8.05 ]
Pohunek 2006a 0/216 1/213 36.1 % 0.33 [ 0.01, 8.02 ]
Verberne 1998a 0/60 0/56 Not estimable
Subtotal (95% CI) 399 332 67.8 % 0.41 [ 0.05, 3.33 ]
Total events: 1 (LABA + ICS), 2 (ICS alone)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Mean baseline FEV1 61%-79% of predicted
Russell 1995 0/99 0/107 Not estimable
Zimmerman 2004a 1/105 1/51 32.2 % 0.49 [ 0.03, 7.61 ]
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(. . . Continued)
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zimmerman 2004b 0/95 0/50 Not estimable
Subtotal (95% CI) 299 208 32.2 % 0.49 [ 0.03, 7.61 ]
Total events: 1 (LABA + ICS), 1 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Total (95% CI) 698 540 100.0 % 0.44 [ 0.08, 2.31 ]
Total events: 2 (LABA + ICS), 3 (ICS alone)
Heterogeneity: Chi2 = 0.05, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
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Analysis 1.38. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 38
# participants with headache.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 38 # participants with headache
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 26/123 14/63 11.7 % 0.95 [ 0.54, 1.69 ]
Eid 2010a 13/168 9/85 7.6 % 0.73 [ 0.33, 1.64 ]
Eid 2010b 21/184 8/84 7.0 % 1.20 [ 0.55, 2.59 ]
Malone 2005 20/101 20/102 12.6 % 1.01 [ 0.58, 1.76 ]
Murray 2011 6/113 5/118 3.1 % 1.25 [ 0.39, 3.99 ]
Pearlman 2009 4/124 6/124 3.8 % 0.67 [ 0.19, 2.30 ]
SD 039 0718 19/128 20/145 11.9 % 1.08 [ 0.60, 1.92 ]
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(. . . Continued)
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Verberne 1998a 25/60 23/57 14.9 % 1.03 [ 0.67, 1.60 ]
Subtotal (95% CI) 1001 778 72.5 % 1.00 [ 0.79, 1.26 ]
Total events: 134 (LABA + ICS), 105 (ICS alone)
Heterogeneity: Chi2 = 1.46, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
2 Mean baseline FEV1 61%-79% of predicted
Akpinarli 1999 0/16 0/16 Not estimable
Russell 1995 20/99 9/107 5.5 % 2.40 [ 1.15, 5.02 ]
Tal 2002 9/148 6/138 3.9 % 1.40 [ 0.51, 3.83 ]
Zimmerman 2004a 13/105 7/51 6.0 % 0.90 [ 0.38, 2.12 ]
Zimmerman 2004b 10/95 7/50 5.8 % 0.75 [ 0.30, 1.86 ]
Subtotal (95% CI) 463 362 21.2 % 1.34 [ 0.88, 2.04 ]
Total events: 52 (LABA + ICS), 29 (ICS alone)
Heterogeneity: Chi2 = 4.81, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 1.37 (P = 0.17)
3 Mean baseline FEV1 not reported
SAM40012a 14/181 10/181 6.3 % 1.40 [ 0.64, 3.07 ]
Subtotal (95% CI) 181 181 6.3 % 1.40 [ 0.64, 3.07 ]
Total events: 14 (LABA + ICS), 10 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 1645 1321 100.0 % 1.10 [ 0.90, 1.33 ]
Total events: 200 (LABA + ICS), 144 (ICS alone)
Heterogeneity: Chi2 = 7.89, df = 12 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 1.90, df = 2 (P = 0.39), I2 =0.0%
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Analysis 1.39. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 39
# participants with vomiting.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 39 # participants with vomiting
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 6/123 4/63 39.5 % 0.77 [ 0.22, 2.62 ]
Eid 2010a 4/168 3/85 29.7 % 0.67 [ 0.15, 2.95 ]
Eid 2010b 5/184 3/84 30.8 % 0.76 [ 0.19, 3.11 ]
Total (95% CI) 475 232 100.0 % 0.74 [ 0.34, 1.62 ]
Total events: 15 (LABA + ICS), 10 (ICS alone)
Heterogeneity: Chi2 = 0.02, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 1.40. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 40
# participants with otitis media.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 40 # participants with otitis media
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 5/123 4/63 44.0 % 0.64 [ 0.18, 2.30 ]
Eid 2010a 1/168 3/85 33.1 % 0.17 [ 0.02, 1.60 ]
Eid 2010b 7/184 2/84 22.8 % 1.60 [ 0.34, 7.53 ]
Total (95% CI) 475 232 100.0 % 0.70 [ 0.30, 1.63 ]
Total events: 13 (LABA + ICS), 9 (ICS alone)
Heterogeneity: Chi2 = 2.65, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.82 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 1.41. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 41
# participants with upper respiratory tract infection.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 41 # participants with upper respiratory tract infection
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Berger 2010 24/123 15/63 43.7 % 0.82 [ 0.46, 1.45 ]
Eid 2010a 13/168 8/85 23.4 % 0.82 [ 0.35, 1.91 ]
Eid 2010b 11/184 8/84 24.2 % 0.63 [ 0.26, 1.50 ]
Murray 2011 3/113 2/118 4.3 % 1.57 [ 0.27, 9.20 ]
Pearlman 2009 4/124 2/124 4.4 % 2.00 [ 0.37, 10.72 ]
Total (95% CI) 712 474 100.0 % 0.86 [ 0.58, 1.27 ]
Total events: 55 (LABA + ICS), 35 (ICS alone)
Heterogeneity: Chi2 = 1.95, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
Test for subgroup differences: Not applicable
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Analysis 1.42. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 42
# participants with urticaria.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 42 # participants with urticaria
Study or subgroup LABA + ICS ICS alone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Pearlman 2009 0/124 4/124 0.11 [ 0.01, 2.04 ]
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Analysis 1.43. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 43
# participants with adverse cardiovascular events.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 43 # participants with adverse cardiovascular events
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Verberne 1998a 0/60 1/56 100.0 % 0.31 [ 0.01, 7.49 ]
Subtotal (95% CI) 60 56 100.0 % 0.31 [ 0.01, 7.49 ]
Total events: 0 (LABA + ICS), 1 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
2 Mean baseline FEV1 61%-79% of predicted
Akpinarli 1999 0/16 0/16 Not estimable
Subtotal (95% CI) 16 16 Not estimable
Total events: 0 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 76 72 100.0 % 0.31 [ 0.01, 7.49 ]
Total events: 0 (LABA + ICS), 1 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.44. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 44
Deaths.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 44 Deaths





n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Berger 2010 0/123 0/63 24.9 % 0.0 [ -0.02, 0.02 ]
Murray 2011 0/113 0/118 34.5 % 0.0 [ -0.02, 0.02 ]
SD 039 0718 0/128 0/145 40.6 % 0.0 [ -0.01, 0.01 ]
Total (95% CI) 364 326 100.0 % 0.0 [ -0.01, 0.01 ]
Total events: 0 (LABA + ICS), 0 (Increased ICS)
Heterogeneity: Chi2 = 0.0, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.45. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 45
# participants with exacerbations requiring hospitalisation.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 45 # participants with exacerbations requiring hospitalisation
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Langton Hewer 1995 1/11 0/12 3.6 % 3.25 [ 0.15, 72.36 ]
Verberne 1998a 1/60 2/56 15.5 % 0.47 [ 0.04, 5.01 ]
Lenney 2013 2/15 0/11 4.3 % 3.75 [ 0.20, 71.12 ]
Subtotal (95% CI) 86 79 23.4 % 1.50 [ 0.36, 6.14 ]
Total events: 4 (LABA + ICS), 2 (ICS alone)
Heterogeneity: Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
2 Mean baseline FEV1 61%-79% of predicted
SD 039 0714 4/136 1/134 7.6 % 3.94 [ 0.45, 34.80 ]
Tal 2002 5/158 0/138 4.0 % 9.62 [ 0.54, 172.36 ]
Russell 1995 9/99 9/107 65.0 % 1.08 [ 0.45, 2.61 ]
Subtotal (95% CI) 393 379 76.6 % 1.81 [ 0.86, 3.82 ]
Total events: 18 (LABA + ICS), 10 (ICS alone)
Heterogeneity: Chi2 = 3.09, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.56 (P = 0.12)
3 Mean baseline FEV1 not reported
SAM40012a 0/180 0/175 Not estimable
Subtotal (95% CI) 180 175 Not estimable
Total events: 0 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 659 633 100.0 % 1.74 [ 0.90, 3.36 ]
Total events: 22 (LABA + ICS), 12 (ICS alone)
Heterogeneity: Chi2 = 4.60, df = 5 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 1.46. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 46
Change in height (cm) as SD scores at 24 ± 4 weeks.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 46 Change in height (cm) as SD scores at 24 4 weeks





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Verberne 1998a 60 -0.1 (0.31) 57 -0.16 (0.3) 0.06 [ -0.05, 0.17 ]
-0.2 -0.1 0 0.1 0.2
Favours ICS alone Favours LABA + ICS
Analysis 1.47. Comparison 1 LABA versus placebo: both groups receiving similar dose of ICS, Outcome 47
Change in height at 1 year.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 1 LABA versus placebo: both groups receiving similar dose of ICS
Outcome: 47 Change in height at 1 year





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Verberne 1998a 60 5.1 (2.6) 57 4.5 (2.6) 0.60 [ -0.34, 1.54 ]
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Analysis 2.1. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 1 # participants
with exacerbations requiring oral steroids.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 1 # participants with exacerbations requiring oral steroids
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Verberne 1998b 10/60 7/60 58.6 % 1.43 [ 0.58, 3.50 ]
De Blic 2009 2/150 1/153 8.3 % 2.04 [ 0.19, 22.26 ]
Vaessen-Verberne 2010 8/78 4/80 33.1 % 2.05 [ 0.64, 6.54 ]
Total (95% CI) 288 293 100.0 % 1.69 [ 0.85, 3.32 ]
Total events: 20 (LABA + ICS), 12 (Increased ICS)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 2.2. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 2 # participants
with exacerbations requiring hospitalisation.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 2 # participants with exacerbations requiring hospitalisation
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Verberne 1998b 1/60 0/60 9.8 % 3.00 [ 0.12, 72.20 ]
De Blic 2009 1/150 1/153 19.5 % 1.02 [ 0.06, 16.16 ]
Subtotal (95% CI) 210 213 29.3 % 1.68 [ 0.22, 12.66 ]
Total events: 2 (LABA + ICS), 1 (Increased ICS)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Baseline FEV1 61%-79% of predicted
Bisgaard 2006 7/118 2/107 41.2 % 3.17 [ 0.67, 14.95 ]
Subtotal (95% CI) 118 107 41.2 % 3.17 [ 0.67, 14.95 ]
Total events: 7 (LABA + ICS), 2 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
3 Mean baseline FEV1 not reported
SAM40012b 0/180 1/180 29.5 % 0.33 [ 0.01, 8.13 ]
Subtotal (95% CI) 180 180 29.5 % 0.33 [ 0.01, 8.13 ]
Total events: 0 (LABA + ICS), 1 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 508 500 100.0 % 1.90 [ 0.65, 5.54 ]
Total events: 9 (LABA + ICS), 4 (Increased ICS)
Heterogeneity: Chi2 = 1.84, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 1.57, df = 2 (P = 0.46), I2 =0.0%
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Analysis 2.3. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 3 # participants
with exacerbations requiring urgent care visit.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 3 # participants with exacerbations requiring urgent care visit
Study or subgroup LABA + ICS Increased ICS Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Vaessen-Verberne 2010 2/78 0/80 5.13 [ 0.25, 105.10 ]
0.01 0.1 1 10 100
Favours LABA + ICS Favours Higher ICS
Analysis 2.4. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 4 Serious adverse
events.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 4 Serious adverse events








1 Baseline FEV1 ≥ 80% predicted
De Blic 2009 3/150 3/153 16.6 % 1.02 [ 0.21, 4.97 ]
Gappa 2009 2/137 1/145 7.3 % 2.12 [ 0.19, 23.08 ]
Murray 2010 0/12 0/12 Not estimable
Verberne 1998b 3/60 3/60 17.1 % 1.00 [ 0.21, 4.76 ]
Subtotal (95% CI) 359 370 41.0 % 1.15 [ 0.42, 3.16 ]
Total events: 8 (LABA + ICS), 7 (Increased ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 2 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Baseline FEV1 61%-79% of predicted
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(. . . Continued)








Bisgaard 2006 16/117 5/106 44.3 % 2.90 [ 1.10, 7.64 ]
Subtotal (95% CI) 117 106 44.3 % 2.90 [ 1.10, 7.64 ]
Total events: 16 (LABA + ICS), 5 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
3 Mean baseline FEV1 not reported
SAM40012b 2/181 4/186 14.7 % 0.51 [ 0.10, 2.77 ]
SAM40100 0/12 0/12 Not estimable
Subtotal (95% CI) 193 198 14.7 % 0.51 [ 0.10, 2.77 ]
Total events: 2 (LABA + ICS), 4 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.77 (P = 0.44)
Total (95% CI) 669 674 100.0 % 1.54 [ 0.81, 2.94 ]
Total events: 26 (LABA + ICS), 16 (Increased ICS)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.89, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Chi2 = 3.59, df = 2 (P = 0.17), I2 =44%
0.005 0.1 1 10 200
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Analysis 2.5. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 5 Total #
withdrawals.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 5 Total # withdrawals
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Verberne 1998b 5/60 4/60 7.7 % 1.25 [ 0.35, 4.43 ]
Gappa 2009 5/138 3/145 5.6 % 1.75 [ 0.43, 7.19 ]
De Blic 2009 3/150 6/153 11.4 % 0.51 [ 0.13, 2.00 ]
Murray 2010 1/12 1/12 1.9 % 1.00 [ 0.07, 14.21 ]
Vaessen-Verberne 2010 22/78 18/80 34.0 % 1.25 [ 0.73, 2.15 ]
Subtotal (95% CI) 438 450 60.5 % 1.15 [ 0.75, 1.78 ]
Total events: 36 (LABA + ICS), 32 (Increased ICS)
Heterogeneity: Chi2 = 1.82, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Baseline FEV1 61%-79% of predicted
Bisgaard 2006 10/117 14/106 28.1 % 0.65 [ 0.30, 1.39 ]
Subtotal (95% CI) 117 106 28.1 % 0.65 [ 0.30, 1.39 ]
Total events: 10 (LABA + ICS), 14 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
3 Mean baseline FEV1 not reported
SAM40100 1/12 1/12 1.9 % 1.00 [ 0.07, 14.21 ]
SAM40012b 3/176 5/180 9.5 % 0.61 [ 0.15, 2.53 ]
Subtotal (95% CI) 188 192 11.4 % 0.68 [ 0.20, 2.36 ]
Total events: 4 (LABA + ICS), 6 (Increased ICS)
Heterogeneity: Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 743 748 100.0 % 0.96 [ 0.67, 1.37 ]
Total events: 50 (LABA + ICS), 52 (Increased ICS)
Heterogeneity: Chi2 = 4.03, df = 7 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.81)
Test for subgroup differences: Chi2 = 1.98, df = 2 (P = 0.37), I2 =0.0%
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Analysis 2.6. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 6 # withdrawals due
to poor asthma control or exacerbation.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 6 # withdrawals due to poor asthma control or exacerbation
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Verberne 1998b 0/60 1/60 33.6 % 0.33 [ 0.01, 8.02 ]
De Blic 2009 0/150 1/153 33.3 % 0.34 [ 0.01, 8.28 ]
Gappa 2009 0/137 0/144 Not estimable
Vaessen-Verberne 2010 0/78 1/80 33.2 % 0.34 [ 0.01, 8.26 ]
Total (95% CI) 425 437 100.0 % 0.34 [ 0.05, 2.13 ]
Total events: 0 (LABA + ICS), 3 (Increased ICS)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 7 # withdrawals due
to adverse events.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 7 # withdrawals due to adverse events
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Verberne 1998b 2/60 1/60 22.1 % 2.00 [ 0.19, 21.47 ]
De Blic 2009 0/150 2/153 54.7 % 0.20 [ 0.01, 4.21 ]
Gappa 2009 0/137 0/144 Not estimable
Murray 2010 0/12 0/12 Not estimable
Subtotal (95% CI) 359 369 76.8 % 0.72 [ 0.14, 3.63 ]
Total events: 2 (LABA + ICS), 3 (Increased ICS)
Heterogeneity: Chi2 = 1.38, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.40 (P = 0.69)
2 Baseline FEV1 61%-79% of predicted
Bisgaard 2006 1/117 1/106 23.2 % 0.91 [ 0.06, 14.30 ]
Subtotal (95% CI) 117 106 23.2 % 0.91 [ 0.06, 14.30 ]
Total events: 1 (LABA + ICS), 1 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
Total (95% CI) 476 475 100.0 % 0.76 [ 0.19, 3.07 ]
Total events: 3 (LABA + ICS), 4 (Increased ICS)
Heterogeneity: Chi2 = 1.38, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
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Analysis 2.8. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 8 # withdrawals due
to serious non-respiratory event.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 8 # withdrawals due to serious non-respiratory event








1 Mean baseline FEV1 ≥ 80% of predicted
De Blic 2009 0/150 0/153 Not estimable
0.01 0.1 1 10 100
Favours LABA + ICS Favours ICS alone
Analysis 2.9. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 9 Change in FEV1
(L) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 9 Change in FEV1 (L) at endpoint





N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
De Blic 2009 150 153 0 (0.023) 83.1 % 0.0 [ -0.05, 0.05 ]
Subtotal (95% CI) 150 153 83.1 % 0.0 [ -0.05, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Baseline FEV1 61%-79% of predicted
Bisgaard 2006 117 106 0.04 (0.051) 16.9 % 0.04 [ -0.06, 0.14 ]
Subtotal (95% CI) 117 106 16.9 % 0.04 [ -0.06, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
-0.2 -0.1 0 0.1 0.2
Favours increased ICS Favours LABA + ICS
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N N IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 267 259 100.0 % 0.01 [ -0.03, 0.05 ]
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Chi2 = 0.51, df = 1 (P = 0.47), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
Favours increased ICS Favours LABA + ICS
Analysis 2.10. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 10 Change in FEV1
% predicted at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 10 Change in FEV1 % predicted at endpoint
Study or subgroup % (SE) % Weight %
IV,Random,95% CI IV,Random,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Verberne 1998b 0.28 (0.27) 94.0 % 0.28 [ -0.25, 0.81 ]
Gappa 2009 1.94 (1.58) 6.0 % 1.94 [ -1.16, 5.04 ]
Total (95% CI) 100.0 % 0.38 [ -0.39, 1.15 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 1.07, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 11 Change in
morning PEF (L/min) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 11 Change in morning PEF (L/min) at endpoint





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
De Blic 2009 150 26.9 (26.09) 153 19.3 (26.22) 36.9 % 7.60 [ 1.71, 13.49 ]
Gappa 2009 137 30.4 (34.1) 144 16.7 (35.8) 19.2 % 13.70 [ 5.53, 21.87 ]
Verberne 1998b 60 30.92 (33) 60 22.57 (33) 9.2 % 8.35 [ -3.46, 20.16 ]
Subtotal (95% CI) 347 357 65.3 % 9.50 [ 5.07, 13.93 ]
Heterogeneity: Chi2 = 1.45, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.20 (P = 0.000026)
2 Baseline FEV1 61%-79% of predicted
Bisgaard 2006 117 26 (34.51) 106 17 (34.51) 15.6 % 9.00 [ -0.07, 18.07 ]
Subtotal (95% CI) 117 106 15.6 % 9.00 [ -0.07, 18.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
3 Baseline FEV1 not reported
SAM40012b 176 45.1 (39.8) 180 39.2 (38.9) 19.2 % 5.90 [ -2.28, 14.08 ]
Subtotal (95% CI) 176 180 19.2 % 5.90 [ -2.28, 14.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 640 643 100.0 % 8.73 [ 5.15, 12.31 ]
Heterogeneity: Chi2 = 2.03, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 4.78 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.58, df = 2 (P = 0.75), I2 =0.0%
-20 -10 0 10 20
Favours Higher ICS Favours LABA + ICS
166Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.12. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 12 Change in
evening PEF (L/min) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 12 Change in evening PEF (L/min) at endpoint





N N IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 predicted≥ 80%
De Blic 2009 150 153 5.4 (3.04) 42.0 % 5.40 [ -0.56, 11.36 ]
Gappa 2009 137 144 10.8 (4.53) 18.9 % 10.80 [ 1.92, 19.68 ]
Subtotal (95% CI) 287 297 61.0 % 7.08 [ 2.13, 12.02 ]
Heterogeneity: Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
2 Baseline FEV1 61%-79% of predicted
Bisgaard 2006 117 106 7 (4.6276) 18.1 % 7.00 [ -2.07, 16.07 ]
Subtotal (95% CI) 117 106 18.1 % 7.00 [ -2.07, 16.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
3 Baseline FEV1 not reported
SAM40012b 176 180 4.4 (4.3112) 20.9 % 4.40 [ -4.05, 12.85 ]
Subtotal (95% CI) 176 180 20.9 % 4.40 [ -4.05, 12.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 580 583 100.0 % 6.50 [ 2.64, 10.37 ]
Heterogeneity: Chi2 = 1.28, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.30 (P = 0.00097)
Test for subgroup differences: Chi2 = 0.30, df = 2 (P = 0.86), I2 =0.0%
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Analysis 2.13. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 13 Change in clinic
PEF (L/min).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 13 Change in clinic PEF (L/min)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 29.6 (29.4) 144 18.3 (34.3) 69.4 % 11.30 [ 3.84, 18.76 ]
Subtotal (95% CI) 137 144 69.4 % 11.30 [ 3.84, 18.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
2 Baseline FEV1 not reported
SAM40012b 176 52.7 (53.07) 180 51.1 (55.01) 30.6 % 1.60 [ -9.63, 12.83 ]
Subtotal (95% CI) 176 180 30.6 % 1.60 [ -9.63, 12.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Total (95% CI) 313 324 100.0 % 8.33 [ 2.12, 14.54 ]
Heterogeneity: Chi2 = 1.99, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 2.63 (P = 0.0086)
Test for subgroup differences: Chi2 = 1.99, df = 1 (P = 0.16), I2 =50%
-20 -10 0 10 20
Favours LABA + ICS Favours Higher ICS
168Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.14. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 14 Change in
morning PEF (% predicted) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 14 Change in morning PEF (% predicted) at endpoint





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 13.8 (21.8) 144 8.6 (17.5) 5.20 [ 0.56, 9.84 ]
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Analysis 2.15. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 15 Change in
evening PEF (% predicted) at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 15 Change in evening PEF (% predicted) at endpoint





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 9.4 (13.2) 144 5.4 (12.7) 4.00 [ 0.97, 7.03 ]
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Analysis 2.16. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 16 Change in % of
days with a peak flow variability ≥ 20%.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 16 Change in % of days with a peak flow variability≥ 20%





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 -4.7 (12.5) 144 -1.9 (12.5) -2.80 [ -5.72, 0.12 ]
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Analysis 2.17. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 17 Change in
daytime asthma symptom score (mean over study period).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 17 Change in daytime asthma symptom score (mean over study period)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 -0.8 (0.8) 144 -0.8 (0.8) 85.4 % 0.0 [ -0.23, 0.23 ]
Murray 2010 12 -0.35 (0.7) 12 -0.46 (0.56) 7.3 % 0.17 [ -0.63, 0.97 ]
Subtotal (95% CI) 149 156 92.7 % 0.01 [ -0.21, 0.24 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
2 Baseline FEV1 not reported
SAM40100 12 0.46 (0.5) 12 0.44 (0.6) 7.3 % 0.03 [ -0.77, 0.84 ]
Subtotal (95% CI) 12 12 7.3 % 0.03 [ -0.77, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 161 168 100.0 % 0.01 [ -0.20, 0.23 ]
Heterogeneity: Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 2.18. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 18 Change in
nighttime asthma symptom score (mean over study period).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 18 Change in nighttime asthma symptom score (mean over study period)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 -0.5 (0.6) 144 -0.5 (0.6) 85.4 % 0.0 [ -0.23, 0.23 ]
Murray 2010 12 -0.06 (0.31) 12 -0.11 (0.25) 7.3 % 0.17 [ -0.63, 0.97 ]
Subtotal (95% CI) 149 156 92.7 % 0.01 [ -0.21, 0.24 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
2 Baseline FEV1 not reported
SAM40100 12 0.26 (35) 12 0.21 (0.49) 7.3 % 0.00 [ -0.80, 0.80 ]
Subtotal (95% CI) 12 12 7.3 % 0.00 [ -0.80, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.00 (P = 1.0)
Total (95% CI) 161 168 100.0 % 0.01 [ -0.20, 0.23 ]
Heterogeneity: Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.98), I2 =0.0%
-1 -0.5 0 0.5 1
Favours treatment Favours control
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Analysis 2.19. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 19 Change in % of
days without asthma symptoms.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 19 Change in % of days without asthma symptoms





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 41.5 (34.5) 144 33.3 (31.4) 8.20 [ 0.47, 15.93 ]
-20 -10 0 10 20
Favours Higher ICS Favours LABA + ICS
Analysis 2.20. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 20 # daytime
rescue inhalations (puffs per day; mean over study period).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 20 # daytime rescue inhalations (puffs per day; mean over study period)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 not reported
SAM40100 12 0.31 (0.5) 12 0.26 (0.27) 0.05 [ -0.27, 0.37 ]
-1 -0.5 0 0.5 1
Favours ICS alone Favours LABA + ICS
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Analysis 2.21. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 21 # nighttime
rescue inhalations (puffs per day; mean over study period).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 21 # nighttime rescue inhalations (puffs per day; mean over study period)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Baseline FEV1 not reported
SAM40100 12 0.05 (0.06) 12 0.05 (0.16) 0.0 [ -0.10, 0.10 ]
-0.2 -0.1 0 0.1 0.2
Favours ICS alone Favours LABA + ICS
Analysis 2.22. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 22 # daytime
rescue inhalations at endpoint.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 22 # daytime rescue inhalations at endpoint
Study or subgroup puffs/d (SE) puffs/d puffs/d
IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 61%-79% of predicted
Bisgaard 2006 0.02 (0.091) 0.02 [ -0.16, 0.20 ]
-0.2 -0.1 0 0.1 0.2
Favours LABA + ICS Favours Higher ICS
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Analysis 2.23. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 23 Change in
daytime rescue inhalations (puffs per day).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 23 Change in daytime rescue inhalations (puffs per day)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Murray 2010 12 -0.43 (0.82) 12 -0.41 (0.44) -0.02 [ -0.55, 0.51 ]
-1 -0.5 0 0.5 1
Favours ICS alone Favours LABA + ICS
Analysis 2.24. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 24 Change in
nighttime rescue inhalations (puffs per day).
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 24 Change in nighttime rescue inhalations (puffs per day)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Murray 2010 12 0.05 (0.06) 12 0.05 (0.11) 0.0 [ -0.07, 0.07 ]
-0.2 -0.1 0 0.1 0.2
Favours ICS alone Favours LABA + ICS
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Analysis 2.25. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 25 Change in
number of weeks with successful asthma control.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 25 Change in number of weeks with successful asthma control





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 34 (2.7) 144 2.7 (2.7) 31.30 [ 30.67, 31.93 ]
-50 -25 0 25 50
Favours Higher ICS Favours LABA + ICS
Analysis 2.26. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 26 Change in % of
days without salbutamol.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 26 Change in % of days without salbutamol





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 137 39.9 (33.3) 144 32.4 (30.7) 7.50 [ 0.00, 15.00 ]
-50 -25 0 25 50
Favours Higher ICS Favours LABA + ICS
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Analysis 2.27. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 27 Number of
nighttime awakenings.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 27 Number of nighttime awakenings





IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline FEV1 61%-79% of predicted
Bisgaard 2006 -1 (2.69) -1.00 [ -6.27, 4.27 ]
-10 -5 0 5 10
Favours LABA + ICS Favours ICS alone
Analysis 2.28. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 28 Total # adverse
events.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 28 Total # adverse events
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
De Blic 2009 87/150 86/153 23.8 % 1.03 [ 0.85, 1.25 ]
Gappa 2009 43/137 44/145 12.0 % 1.03 [ 0.73, 1.47 ]
Vaessen-Verberne 2010 59/78 62/80 17.1 % 0.98 [ 0.82, 1.16 ]
Verberne 1998b 59/60 52/60 14.5 % 1.13 [ 1.02, 1.26 ]
Subtotal (95% CI) 425 438 67.4 % 1.04 [ 0.94, 1.15 ]
Total events: 248 (LABA + ICS), 244 (Increased ICS)
Heterogeneity: Chi2 = 3.18, df = 3 (P = 0.36); I2 =6%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Mean baseline FEV1 not reported
0.5 0.7 1 1.5 2
Favours LABA + ICS Favours higher ICS
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(. . . Continued)
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SAM40012b 99/181 112/186 30.9 % 0.91 [ 0.76, 1.08 ]
SAM40100 9/12 6/12 1.7 % 1.50 [ 0.78, 2.88 ]
Subtotal (95% CI) 193 198 32.6 % 0.94 [ 0.79, 1.11 ]
Total events: 108 (LABA + ICS), 118 (Increased ICS)
Heterogeneity: Chi2 = 2.11, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 618 636 100.0 % 1.01 [ 0.92, 1.10 ]
Total events: 356 (LABA + ICS), 362 (Increased ICS)
Heterogeneity: Chi2 = 7.93, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Chi2 = 1.01, df = 1 (P = 0.31), I2 =1%
0.5 0.7 1 1.5 2
Favours LABA + ICS Favours higher ICS
Analysis 2.29. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 29 # participants
with oral candidiasis.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 29 # participants with oral candidiasis
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Murray 2010 1/12 1/12 50.3 % 1.00 [ 0.07, 14.21 ]
Vaessen-Verberne 2010 1/78 1/80 49.7 % 1.03 [ 0.07, 16.11 ]
Total (95% CI) 90 92 100.0 % 1.01 [ 0.15, 6.85 ]
Total events: 2 (LABA + ICS), 2 (ICS alone)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LABA + ICS Favours ICS alone
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Analysis 2.30. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 30 # participants
with headache.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 30 # participants with headache
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Verberne 1998b 25/60 16/60 21.8 % 1.56 [ 0.93, 2.62 ]
Gappa 2009 2/137 4/145 5.3 % 0.53 [ 0.10, 2.84 ]
Vaessen-Verberne 2010 14/78 21/80 28.3 % 0.68 [ 0.38, 1.25 ]
De Blic 2009 27/150 23/153 31.1 % 1.20 [ 0.72, 1.99 ]
Subtotal (95% CI) 425 438 86.5 % 1.08 [ 0.80, 1.46 ]
Total events: 68 (LABA + ICS), 64 (Increased ICS)
Heterogeneity: Chi2 = 5.05, df = 3 (P = 0.17); I2 =41%
Test for overall effect: Z = 0.50 (P = 0.61)
2 Mean baseline FEV1 not reported
SAM40012b 14/181 10/186 13.5 % 1.44 [ 0.66, 3.16 ]
Subtotal (95% CI) 181 186 13.5 % 1.44 [ 0.66, 3.16 ]
Total events: 14 (LABA + ICS), 10 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI) 606 624 100.0 % 1.13 [ 0.85, 1.50 ]
Total events: 82 (LABA + ICS), 74 (Increased ICS)
Heterogeneity: Chi2 = 5.41, df = 4 (P = 0.25); I2 =26%
Test for overall effect: Z = 0.84 (P = 0.40)
Test for subgroup differences: Chi2 = 0.44, df = 1 (P = 0.50), I2 =0.0%
0.01 0.1 1 10 100
Favours LABA + ICS Favours Higher ICS
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Analysis 2.31. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 31 # participants
with vomiting.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 31 # participants with vomiting
Study or subgroup LABA + ICS Increased ICS Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 0/137 2/145 0.21 [ 0.01, 4.37 ]
0.01 0.1 1 10 100
Favours LABA + ICS Favours Higher ICS
Analysis 2.32. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 32 # participants
with cold.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 32 # participants with cold
Study or subgroup LABA + ICS ICS alone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mean baseline FEV1 ≥ 80% of predicted
Vaessen-Verberne 2010 28/78 17/80 1.69 [ 1.01, 2.83 ]
0.01 0.1 1 10 100
Favours LABA + ICS Favours ICS alone
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Analysis 2.33. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 33 # participants
with upper respiratory tract infection.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 33 # participants with upper respiratory tract infection
Study or subgroup LABA + ICS Increased ICS Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 3/137 1/145 3.18 [ 0.33, 30.16 ]
0.01 0.1 1 10 100
Favours LABA + ICS Favours Higher ICS
Analysis 2.34. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 34 Linear growth.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 34 Linear growth





IV,Fixed,95% CI IV,Fixed,95% CI
Bisgaard 2006 0.9 (0.357) 49.0 % 0.90 [ 0.20, 1.60 ]
Verberne 1998b 1.5 (0.35) 51.0 % 1.50 [ 0.81, 2.19 ]
Total (95% CI) 100.0 % 1.21 [ 0.72, 1.70 ]
Heterogeneity: Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 4.83 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours Higher ICS Favours LABA+ICS
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Analysis 2.35. Comparison 2 LABA + ICS versus placebo + higher dose of ICS, Outcome 35 Deaths.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 2 LABA + ICS versus placebo + higher dose of ICS
Outcome: 35 Deaths





n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Gappa 2009 0/137 0/145 0.0 [ -0.01, 0.01 ]
-0.02 -0.01 0 0.01 0.02
Favours LABA + ICS Favours Higher ICS
Analysis 3.1. Comparison 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS),
Outcome 1 # participants with exacerbations requiring oral steroids by dose of ICS in both groups.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)
Outcome: 1 # participants with exacerbations requiring oral steroids by dose of ICS in both groups
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low dose of ICS (≤ 400 g/d of BDP-eq)
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
0.01 0.1 1 10 100
Favours LABA + ICS Favours ICS alone
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(. . . Continued)
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 780 596 71.8 % 0.96 [ 0.67, 1.37 ]
Total events: 68 (LABA + ICS), 43 (ICS alone)
Heterogeneity: Chi2 = 6.40, df = 7 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
2 Moderate dose of ICS (401 to 800 g/d of BDP-eq)
Akpinarli 1999 0/16 0/16 Not estimable
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Rutkowski 2009 0/20 0/20 Not estimable
Subtotal (95% CI) 135 135 24.4 % 0.89 [ 0.48, 1.64 ]
Total events: 16 (LABA + ICS), 18 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
3 High dose of ICS (> 800 g/d of BDP-eq)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Unspecified dose of ICS or range of dose only mentioned
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Subtotal (95% CI) 11 12 3.9 % 1.09 [ 0.28, 4.32 ]
Total events: 3 (LABA + ICS), 3 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.09, df = 2 (P = 0.96), I2 =0.0%
0.01 0.1 1 10 100
Favours LABA + ICS Favours ICS alone
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Analysis 3.2. Comparison 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS), Outcome
2 # participants with exacerbations requiring oral steroids by whether LABA dose is usual or higher than usual.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)
Outcome: 2 # participants with exacerbations requiring oral steroids by whether LABA dose is usual or higher than usual
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LABA at usual dose
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
Akpinarli 1999 0/16 0/16 Not estimable
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Rutkowski 2009 0/20 0/20 Not estimable
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Subtotal (95% CI) 915 731 96.1 % 0.94 [ 0.69, 1.28 ]
Total events: 84 (LABA + ICS), 61 (ICS alone)
Heterogeneity: Chi2 = 6.42, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
2 LABA at higher than usual dose
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Subtotal (95% CI) 11 12 3.9 % 1.09 [ 0.28, 4.32 ]
Total events: 3 (LABA + ICS), 3 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.90)
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.02 0.1 1 10 50
Favours LABA + ICS Favours ICS alone
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Analysis 3.3. Comparison 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS),
Outcome 3 # participants with exacerbations requiring oral steroids by type of LABA.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)
Outcome: 3 # participants with exacerbations requiring oral steroids by type of LABA
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol
Akpinarli 1999 0/16 0/16 Not estimable
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Rutkowski 2009 0/20 0/20 Not estimable
Subtotal (95% CI) 387 204 47.6 % 0.89 [ 0.58, 1.39 ]
Total events: 48 (LABA + ICS), 26 (ICS alone)
Heterogeneity: Chi2 = 3.55, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 0.50 (P = 0.62)
2 Salmeterol
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
Subtotal (95% CI) 539 539 52.4 % 1.00 [ 0.66, 1.51 ]
Total events: 39 (LABA + ICS), 38 (ICS alone)
Heterogeneity: Chi2 = 2.82, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.13, df = 1 (P = 0.72), I2 =0.0%
0.02 0.1 1 10 50
Favours LABA + ICS Favours ICS alone
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Analysis 3.4. Comparison 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS),
Outcome 4 # participants with exacerbations requiring oral steroids by single inhaler or separate inhalers for
LABA and ICS.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)
Outcome: 4 # participants with exacerbations requiring oral steroids by single inhaler or separate inhalers for LABA and ICS
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single inhaler
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Subtotal (95% CI) 704 523 55.8 % 0.99 [ 0.66, 1.47 ]
Total events: 58 (LABA + ICS), 32 (ICS alone)
Heterogeneity: Chi2 = 5.99, df = 5 (P = 0.31); I2 =17%
Test for overall effect: Z = 0.07 (P = 0.95)
2 Separate inhaler
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
Akpinarli 1999 0/16 0/16 Not estimable
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Rutkowski 2009 0/20 0/20 Not estimable
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Subtotal (95% CI) 222 220 44.2 % 0.90 [ 0.57, 1.42 ]
Total events: 29 (LABA + ICS), 32 (ICS alone)
Heterogeneity: Chi2 = 0.48, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
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Analysis 3.5. Comparison 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS),
Outcome 5 # participants with exacerbations requiring oral steroids by trial duration.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)
Outcome: 5 # participants with exacerbations requiring oral steroids by trial duration
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≤ 16 weeks
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Akpinarli 1999 0/16 0/16 Not estimable
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Rutkowski 2009 0/20 0/20 Not estimable
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Subtotal (95% CI) 851 675 84.6 % 0.90 [ 0.65, 1.25 ]
Total events: 72 (LABA + ICS), 53 (ICS alone)
Heterogeneity: Chi2 = 4.60, df = 7 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
2≥ 24 weeks
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Subtotal (95% CI) 75 68 15.4 % 1.22 [ 0.59, 2.52 ]
Total events: 15 (LABA + ICS), 11 (ICS alone)
Heterogeneity: Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
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Analysis 3.6. Comparison 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS), Outcome
6 # participants with exacerbations requiring oral steroids by whether funded by producers of LABA.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)
Outcome: 6 # participants with exacerbations requiring oral steroids by whether funded by producers of LABA
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Charity/grant agency funded
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Subtotal (95% CI) 26 23 5.4 % 1.83 [ 0.60, 5.56 ]
Total events: 8 (LABA + ICS), 4 (ICS alone)
Heterogeneity: Chi2 = 1.01, df = 1 (P = 0.32); I2 =1%
Test for overall effect: Z = 1.07 (P = 0.29)
2 Funded by manufacturers of LABA
Akpinarli 1999 0/16 0/16 Not estimable
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
Subtotal (95% CI) 880 700 94.6 % 0.90 [ 0.66, 1.23 ]
Total events: 79 (LABA + ICS), 60 (ICS alone)
Heterogeneity: Chi2 = 4.54, df = 7 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
3 Unknown funding source
Rutkowski 2009 0/20 0/20 Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 1.46, df = 1 (P = 0.23), I2 =32%
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Analysis 3.7. Comparison 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS),
Outcome 7 # participants with exacerbations requiring systemic steroids by publication status.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)
Outcome: 7 # participants with exacerbations requiring systemic steroids by publication status
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Published as full-text papers
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Rutkowski 2009 0/20 0/20 Not estimable
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Subtotal (95% CI) 811 628 75.6 % 0.97 [ 0.69, 1.37 ]
Total events: 71 (LABA + ICS), 46 (ICS alone)
Heterogeneity: Chi2 = 6.44, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
2 Not published as full-text papers
Akpinarli 1999 0/16 0/16 Not estimable
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Subtotal (95% CI) 115 115 24.4 % 0.89 [ 0.48, 1.64 ]
Total events: 16 (LABA + ICS), 18 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
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Analysis 3.8. Comparison 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS),
Outcome 8 # participants with exacerbations requiring systemic steroids by blinding of study.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 3 Subgroup analyses (comparison 01: LABA + ICS vs same dose of ICS)
Outcome: 8 # participants with exacerbations requiring systemic steroids by blinding of study
Study or subgroup LABA + ICS ICS alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Double-blinded studies
Langton Hewer 1995 3/11 3/12 3.9 % 1.09 [ 0.28, 4.32 ]
Simons 1997 0/16 1/16 2.0 % 0.33 [ 0.01, 7.62 ]
Verberne 1998a 10/60 10/57 13.9 % 0.95 [ 0.43, 2.11 ]
Lenney 2013 5/15 1/11 1.6 % 3.67 [ 0.50, 27.12 ]
Rutkowski 2009 0/20 0/20 Not estimable
Akpinarli 1999 0/16 0/16 Not estimable
Russell 1995 16/99 18/99 24.4 % 0.89 [ 0.48, 1.64 ]
Eid 2010a 15/183 13/84 24.1 % 0.53 [ 0.26, 1.06 ]
Eid 2010b 33/168 13/84 23.5 % 1.27 [ 0.71, 2.28 ]
Murray 2011 2/113 1/118 1.3 % 2.09 [ 0.19, 22.71 ]
Pearlman 2009 1/124 1/124 1.4 % 1.00 [ 0.06, 15.81 ]
Malone 2005 2/101 3/102 4.0 % 0.67 [ 0.11, 3.94 ]
Subtotal (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
2 Open-label studies
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA + ICS), 0 (ICS alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 926 743 100.0 % 0.95 [ 0.70, 1.28 ]
Total events: 87 (LABA + ICS), 64 (ICS alone)
Heterogeneity: Chi2 = 6.47, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS),
Outcome 1 # participants with exacerbations requiring oral steroids by dose of ICS in control groups.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS)
Outcome: 1 # participants with exacerbations requiring oral steroids by dose of ICS in control groups
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Low dose of ICS (≤ 400 g/d of BDP-eq)
Verberne 1998b 10/60 7/60 58.6 % 1.43 [ 0.58, 3.50 ]
De Blic 2009 2/150 1/153 8.3 % 2.04 [ 0.19, 22.26 ]
Vaessen-Verberne 2010 8/78 4/80 33.1 % 2.05 [ 0.64, 6.54 ]
Subtotal (95% CI) 288 293 100.0 % 1.69 [ 0.85, 3.32 ]
Total events: 20 (LABA + ICS), 12 (Increased ICS)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Moderate dose of ICS (401 to 800 g/d of BDP-eq)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA + ICS), 0 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
3 High dose of ICS (> 800 g/d of BDP-eq)
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA + ICS), 0 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Unspecified dose of ICS or range of dose only mentioned
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA + ICS), 0 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 288 293 100.0 % 1.69 [ 0.85, 3.32 ]
Total events: 20 (LABA + ICS), 12 (Increased ICS)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS),
Outcome 2 # participants with exacerbations requiring oral steroids by whether LABA dose is usual or higher
than usual.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS)
Outcome: 2 # participants with exacerbations requiring oral steroids by whether LABA dose is usual or higher than usual
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 LABA at usual dose
Verberne 1998b 10/60 7/60 58.6 % 1.43 [ 0.58, 3.50 ]
De Blic 2009 2/150 1/153 8.3 % 2.04 [ 0.19, 22.26 ]
Vaessen-Verberne 2010 8/78 4/80 33.1 % 2.05 [ 0.64, 6.54 ]
Subtotal (95% CI) 288 293 100.0 % 1.69 [ 0.85, 3.32 ]
Total events: 20 (LABA + ICS), 12 (Increased ICS)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 LABA at higher than usual dose
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA + ICS), 0 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 288 293 100.0 % 1.69 [ 0.85, 3.32 ]
Total events: 20 (LABA + ICS), 12 (Increased ICS)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS),
Outcome 3 # participants with exacerbations requiring oral steroids by type of LABA.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS)
Outcome: 3 # participants with exacerbations requiring oral steroids by type of LABA
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Formoterol
De Blic 2009 2/150 1/153 8.3 % 2.04 [ 0.19, 22.26 ]
Vaessen-Verberne 2010 8/78 4/80 33.1 % 2.05 [ 0.64, 6.54 ]
Subtotal (95% CI) 228 233 41.4 % 2.05 [ 0.72, 5.82 ]
Total events: 10 (LABA + ICS), 5 (Increased ICS)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Salmeterol
Verberne 1998b 10/60 7/60 58.6 % 1.43 [ 0.58, 3.50 ]
Subtotal (95% CI) 60 60 58.6 % 1.43 [ 0.58, 3.50 ]
Total events: 10 (LABA + ICS), 7 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 288 293 100.0 % 1.69 [ 0.85, 3.32 ]
Total events: 20 (LABA + ICS), 12 (Increased ICS)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
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Analysis 4.4. Comparison 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS),
Outcome 4 # participants with exacerbations requiring oral steroids by single inhaler or separate inhalers for
LABA and ICS.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS)
Outcome: 4 # participants with exacerbations requiring oral steroids by single inhaler or separate inhalers for LABA and ICS
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Combination inhaler
De Blic 2009 2/150 1/153 8.3 % 2.04 [ 0.19, 22.26 ]
Vaessen-Verberne 2010 8/78 4/80 33.1 % 2.05 [ 0.64, 6.54 ]
Subtotal (95% CI) 228 233 41.4 % 2.05 [ 0.72, 5.82 ]
Total events: 10 (LABA + ICS), 5 (Increased ICS)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Separate inhaler
Verberne 1998b 10/60 7/60 58.6 % 1.43 [ 0.58, 3.50 ]
Subtotal (95% CI) 60 60 58.6 % 1.43 [ 0.58, 3.50 ]
Total events: 10 (LABA + ICS), 7 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
3 Not reported
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (LABA + ICS), 0 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 288 293 100.0 % 1.69 [ 0.85, 3.32 ]
Total events: 20 (LABA + ICS), 12 (Increased ICS)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.26, df = 1 (P = 0.61), I2 =0.0%
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Analysis 4.5. Comparison 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS),
Outcome 5 # participants with exacerbations requiring oral steroids by trial duration.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 4 Subgroup analyses (comparison 02: LABA + ICS vs higher dose of ICS)
Outcome: 5 # participants with exacerbations requiring oral steroids by trial duration
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1≤ 16 weeks
De Blic 2009 2/150 1/153 8.3 % 2.04 [ 0.19, 22.26 ]
Subtotal (95% CI) 150 153 8.3 % 2.04 [ 0.19, 22.26 ]
Total events: 2 (LABA + ICS), 1 (Increased ICS)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2≥ 24 weeks
Verberne 1998b 10/60 7/60 58.6 % 1.43 [ 0.58, 3.50 ]
Vaessen-Verberne 2010 8/78 4/80 33.1 % 2.05 [ 0.64, 6.54 ]
Subtotal (95% CI) 138 140 91.7 % 1.65 [ 0.81, 3.36 ]
Total events: 18 (LABA + ICS), 11 (Increased ICS)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 288 293 100.0 % 1.69 [ 0.85, 3.32 ]
Total events: 20 (LABA + ICS), 12 (Increased ICS)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 5.1. Comparison 5 Sensitivity analysis: LABA + ICS versus placebo + higher dose of ICS, Outcome
1 # participants with exacerbations requiring oral steroids.
Review: Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children
Comparison: 5 Sensitivity analysis: LABA + ICS versus placebo + higher dose of ICS
Outcome: 1 # participants with exacerbations requiring oral steroids
Study or subgroup LABA + ICS Increased ICS Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Baseline FEV1 ≥ 80% of predicted
Verberne 1998b 10/60 7/60 13.7 % 1.43 [ 0.58, 3.50 ]
De Blic 2009 2/150 1/153 1.9 % 2.04 [ 0.19, 22.26 ]
Lemanske 2010 27/157 39/157 76.6 % 0.69 [ 0.45, 1.07 ]
Vaessen-Verberne 2010 8/78 4/80 7.8 % 2.05 [ 0.64, 6.54 ]
Subtotal (95% CI) 445 450 100.0 % 0.93 [ 0.64, 1.33 ]
Total events: 47 (LABA + ICS), 51 (Increased ICS)
Heterogeneity: Chi2 = 4.82, df = 3 (P = 0.19); I2 =38%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (The Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
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Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards









8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
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14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/









11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search methods up to May 2008
Electronic searches
An electronic literature searchwas carried out in the Cochrane Airways Group Specialised Register of asthma trials which is derived from
systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE,
EMBASE and CINAHL and handsearching of respiratory journals and meeting abstracts. This Register also contains a variety of studies
published in foreign languages. We did not exclude trials on the basis of language. The Register was searched using the following terms:
(((beta* and agonist*) and long-acting or “long-acting”) or ((beta* and adrenergic*) and long-acting or “long-acting”) or (bronchodilat*
and long-acting or “long-acting”) or (salmeterol or formoterol or advair or symbicort)) and (((steroid* or glucocorticoid* or corticos-
teroid*) and inhal*) or (budesonide or beclomethasone or fluticasone or triamcinolone or flunisolide)).
This search was then limited with the text word terms (child* or paediat* or pediat* or adolesc* or infan* or toddler* or bab* or young*
or preschool* or “pre school*” or pre-school* or newborn* or “new born*” or new-born* or neo-nat* or neonat*)
Appendix 3. Search strategy to identify relevant trials from the CAGR
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Adrenergic beta-2 Receptor Antagonists
#6 (beta* and agonist*) and (long-acting or “long acting”)
#7 (beta* and adrenergic*) and (long-acting or “long acting”)
#8 bronchodilat* and (long-acting or “long acting”)
#9 salmeterol
#10 *formoterol
#11 #5 or #6 or #7 or #8 or #9 or #10
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#20 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19
#21 #11 and #20
#22 Advair or symbicort or Viani or Seretide or Flutiform
#23 #21 or #22
#24 #4 and #23
#25 child* or paediat* or pediat* or adolesc* or infan* or toddler* or bab* or young* or preschool* or “pre school*” or pre-school* or
newborn* or “new born*” or new-born* or neo-nat* or neonat*
#26 #24 and #25
[In search line #1, MISC1 denotes the field in which the reference has been coded for condition, in this case, asthma]
Appendix 4. Randomisation procedures for GSK-sponsored studies
The procedures for randomising GSK-sponsored studies has been detailed in correspondence between Richard Follows and TL, the
details of which are given below:
The randomisation software is a computer-generated, centralised programme (RandAll). After verification that the randomisation
sequence is suitable for the study design (crossover, block or stratification), Clinical Supplies then package the treatments according
the randomisation list generated. Concealment of allocation is maintained by a third party, since the sites phone in and are allocated
treatments on that basis. Alternatively a third party may dispense the drug at the sites. Unblinding of data for interim analyses can only
be done through RandAll, and are restricted so that only those reviewing the data are unblinded to treatment group allocation.
WH A T ’ S N E W
Last assessed as up-to-date: 23 January 2015.
Date Event Description
23 January 2015 New citation required but conclusions have not changed 8 studies added - conclusions similar
Few new outcomes added - urgent care visits, nighttime
awakenings - new lead author added
Results and discussion redrafted. Summary of findings
tables added
23 January 2015 New search has been performed New literature search run
H I S T O R Y
Review first published: Issue 3, 2009
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Date Event Description
8 December 2009 Amended We have revised the reporting of correspondence in relation to missing data
Correspondence regarding data fromBisgaard 2006 was made directly with study sponsors, not with
Hans Bisgaard. Sponsors were not able to provide data on children in this study with exacerbations
requiring oral corticosteroids
21 April 2008 Amended Converted to new review format
C O N T R I B U T I O N S O F A U T H O R S
BC: update of the review, screening of citations, data extraction, method assessment, write-up and correspondence with the editorial
board of the Cochrane Airways Group.
CC: data extraction and method assessment.
MNC: protocol initiation and write-up, study assessment, characterisation extraction of data and write-up.
SJM: data extraction and proofreading of the manuscript.
FD: protocol development, review development, interpretation of results and review of final manuscript.
D E C L A R A T I O N S O F I N T E R E S T
In the past five years, Francine Ducharme received some research funding from GSK, Merck and AstraZeneca, and gave CME
conferences supported by Merck Frost, GSK and Takeda. Over the past five years, M Ni Chroinin has given CME lectures sponsored
by AstraZeneca. Bhupendrasinh Chauhan, Caroline Chartrand and Stephen J Milan, as well as previous authors, namely, A. Danish,
H. Magalinos, V. Masse, X. Zhang, Toby Lasserson and Ilana Greenstone, report no conflicts of interest.
S O U R C E S O F S U P P O R T
Internal sources
• The authors declare that no such funding was received for this systematic review, Other.
External sources
• The authors declare that no such funding was received for this systematic review, Other.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The principal difference between the protocol for the set of reviews related to long-acting beta-agonists and ICS and this review is the
risk of bias assessment. This has been developed by methodologists and statisticians and aims to provide a transparent mechanism for
reporting the design of clinical trials, and the extent to which review authors judge them to be at risk of bias.
In the current update, we have added two new secondary outcomes, numbers of participants with exacerbations requiring an urgent
care visit and % nights with awakening. We have added a ’Summary of findings’ table.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗administration & dosage; adverse effects]; Adrenergic beta-Agonists [∗administration & dosage; adverse
effects]; Albuterol [administration & dosage; analogs & derivatives]; Anti-Asthmatic Agents [∗administration &dosage; adverse effects];
Asthma [drug therapy]; Beclomethasone [administration & dosage; adverse effects]; Drug Therapy, Combination; Ethanolamines
[administration & dosage]
MeSH check words
Adolescent; Child; Female; Humans; Male
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